var title_f3_50_3872="Precut fistulotomy";
var content_f3_50_3872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Needle-knife fistulotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A fistulotomy is created by puncturing the papilla in its mid or upper part. The needle- knife is then directed downward toward but not into the papillary orifice.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas A Howell, MD and David J Desilets, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3872=[""].join("\n");
var outline_f3_50_3872=null;
var title_f3_50_3873="Left hip involvement in a patient with ankylosing spondylitis";
var content_f3_50_3873=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Left hip involvement in a patient with ankylosing spondylitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are destructive changes in the left hip joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Sheng Guang Li, PLA Hospital, China.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3873=[""].join("\n");
var outline_f3_50_3873=null;
var title_f3_50_3874="General microdermal jewelry design";
var content_f3_50_3874=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    General microdermal jewelry design",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 575px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAI/AcwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiigkAEk4A70AFFeeeL/i/wCE/DUrQSXj392vBhsgJCp92yFH55ryXxF+0Jrl4zx+H9MtbCI8LJOTNJ9eyj6YNS5pFKLZ9O1nanrmk6V/yE9TsbP/AK+J0j/ma+MdY8b+LtcLDUdev3RusccnlJ/3yuBXPi1ZzuclmPUk5qHVLVM+x9S+K/gqwz5mvW0zDtbhpf1UEVzF98fvC0GRa22p3R9olQfqa+ZUtQO1SiADtUOqylSR7td/tFR5/wBC8OSMPWW5A/ktZc37Qussx8jQrFB2DyO38sV5AIgO1L5Ype0Y/Zo9Ul+P/iV1xHpmmRn12uf/AGaqU/x18YSZ8tNPh/3YCf5mvN9goKilzyHyI7ib4zeN5TxqMKD/AGLZB/Q1A3xc8cE/8hlh9IIz/wCy1xhUU0qKOdj5UdrH8YPHMZyNYV/Z7eP/AArVsfjz4vt2H2mLTrpR13QlSfxU15my5600x0c77i5Ee+6H+0PbSMqa3oksI7yWsm8f98nH869L8PfEvwnryqLTWLeKVjgRXLeU+fQbuD+BNfGxiB7UwxEHIqlVZLpo+/AQwBByD0pa+L/CHxF8S+FHjWwv2ltFIzaXOZIiPQA8r/wEivfPAnxp0LxFNFZ6kraTqLcBZmBic+iv/QgfjWsaiZm4NHqlFAIIyORRVkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFNd1jRndgqKMlicACvA/ix8bPs7y6R4KlSSXG2XUV+ZVPpH2J/2unp60nJLcaTZ6X8QPiNofgq2b7fN5+oFcxWUJBkb0z/AHR7n8M180eOPij4m8Y74JZxYacTxa2pKgj/AG26t/L2rkHE97dSXV7NJcXMrF5JZWLMxPUknrVmOADtWEqjZvGCRQhs/WrcdsB2qyFAqRBWdy7EAiC9qcFFSSMOlRFqQC4paZupC1AD6Kj3UbqAHmmmm7qM0ABpKM0maAEooooAAKUikpwNAELpmq7p69KvkA1G8eR0pgekfC/4v6h4XaHTtb33+jZwGJJlgH+yT1X/AGT+Br6i0rUbTVtOgvtOnS4tJ0DxyIeGB/z0r4MkjxXbfCz4iX3gjVUR3kn0aVh9ots5256ug7N/OtYTtozOcL6o+yKKp6PqdnrGmwX+mXEdxaTruSRDkH/6/tVytzAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKRmCqSxAA5JPalrwL9oL4n/Y0ufCmgyKbmVDHfTqf9Up6xr/tEdfTOOvRN2VxpXZzfxv+KzeIJpfD/huVk0pGK3Fypwbkj+Ff9j+f06+SWlvjrUVpCAM1pxrsUeprmlK50RjYeigUrMAcClf5OO+Kr78yipKJieacGwtQqeCTTs/JmkA1myaYxIFJnmg0AIGzS5pjDByKVTkUAOzQTTTR1FADs0ZpgODinUwCijNFIApaSnLQA2inMKbQAo61ZjAYc1AlTJxQMZPB6CqEseM8VsjDDBqrcQ9cUwO1+C3xDfwbq5s9RkdtDuziRevkv2kA/mPT6V9bQSxzwpLC6vE6hlZTkMD0Ir4Emjxk177+zn8QC23wpq8uWGWsJHPUdTF/UfiPStqcujMakeqPoGiiitjEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiignAoA8/+M3jlPBXhZ3t3U6td5itEPVT3kI9F/mRXx0zy3NxJcXMjyzyuXeRzlmYnJJPck12nxq8Uf8JX49u54WzZ2v8Aolv6FVJy34kk/lXIhMBRXPOV2bwjZFm3X7o/GrKHdIPrUEfGT6CpIGzMorM0FuJMM31xVaI5mouj85/3qbGcTA0AWR/q2+tSD/U/jUQP3x+NSRNujZfxpARjrQaGODzTxgo3tQBFTCMHIp9BoAAcimZwaUcGnFdwI70wEIyOKRT60RnnHelYUAKaBQORR0pAOxSDigGloAcDkU1higHFSqNwoAiU81YTmoGXaaliNAyZeKeRuHvTCKkXkAjqKBlG4iI5xVNHms7mK5tZHiljYPHIhwysDkEH1FbskYZeOhrOnhyrKfrTTE0fX/wq8XxeMvCVtel1+3RARXaDqsgHJx6HqK7Gvjr4L+Lm8I+NIBcPt029YW9yCeFyflf/AICT+Wa+xQc9K6YS5kcs42YUUUVZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVynxU1s+HvAGs38bbZlhMcR9Hc7Qf1z+FdXXjn7Ul35Pw+tIA2DPfoCPVQjk/rilJ2Q4q7PlmL5pgTzjmtAjgGs+L26k4rTYYjx7Vys6UKrcEe1Fqf9IWmp978KYjbZlP4Uhi3vEh+tMbgg1NeDepIqvGd8eP4hQBOH+ce4xTrd9sqg9DxUBztyOopGb+IUAWrsFVPsaW2cFip/iFIHE8O0/eAxVaNiF4++hoAskEHntSCpWw+HH3XGfoagTIcqetAxxFC0Dlj7ClT5lb1FIQ2QdHHXvTxhlB/OkXrg9DSR/JKUPQ0wArtb2oNSEbl2nqOlRikAgpwNJilAoAeFyKfGcGkjNKw5oGSSICuRUCnBqeI54Peo3TDZoAsw4kUr/F2pyEqfcdRVaIlTVxhvAYfeH60DJFAI2joeVqvcJn5vzqWI5GB9R7GnuNy59etAHP3sW1iRX1l8BvFp8T+CoobqTdqGnEW02Tyy4+R/xHH1U18uXkWUJxyOK7H4CeIf+Ef+IMEM8my01FfssmTgbicoT+Ix/wACNaU5WZlUjdH13RRRXSc4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4T+1ix/4R/QVzwbpyfwT/69e7V4p+1VaGTwVpl0P+WF8FP0ZG5/NRUz+EqG58xW/MkY981qpHJM6xQo0kjnaqqMkn2FZemRvPfwwxKWkc7FUdyTivp3wB4OsdBgjlEYlv2UeZO3JB7hfQVzM6UeY+G/hXr+qFZLtY9PgPUzHL49lH9cV6BpPwZ0K3KtqN1d3pBztyIkP4Dn9a9MRQop2aQHGf8ACr/CW4H+zGx6faJMf+hVv6V4X0LS7cwWOk2cUbHLfugxb6k5J/GtUU4GmBlXXhXQLsf6RounP7/Z0B/MDNZk3w28ITBt+h24z12M6/yNdWpqQUCOFt/hP4Qgm8waa7+ivcSED9a5bxB8D7S4uWn0PU3tAekM6eYo+jZBx9c17HS0wPjnWNLvPDurXGl6rEY5EbGex9GB7g1RuFKkHuO/qK+t/FXhTSPFFqIdXthIV+5Kh2yJ9D/TpXlPin4Ly29m8vh29kumX/l2uMBiP9lhgZ9iBSsM8cZgGWQdDwaRj5cqt2zzT7u1uNPupbO/glgmU4aORSrD8DUAO5GRvvLSAsuuGOOnUfSmyjhX9KigmLJsb7y/yqxFhlKHoRQA/HII60xxghh0PWi3ORsP3l4qZUDFlPfp9aBkYTNIBT0yPlPUUrLg0gI+hqQcimsOKFODQA9RxkdakOGGexpg+VvrT14JXseRQMj24fB61at87qglGFV+4OKmiOGB7UAOcbH3D7p/Q1Mpz9D/ADprKCxQ9D0psJOCjdRQAyZMgj14NY8u+3uFljJWRGDKw6gjvW9IMrn14rMv4gQTTQmfZ/gTXE8R+EdL1RT808IMg9HHDD8wa3q8U/Ze1j7R4b1PSXbMlncCVAT/AAOP8VP517XXVF3VzkkrOwUUUVQgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuU+KPh4+KPAuq6ZGu64aLzIP+ui/Mv54x+NdXUN3cxWkDTXDFY16kAn9BSYI+J/hHpMt747haSJhHYhpZdw+6wyAD75P6V9T6dFtjFcQbjw5ZeItYvtGGDeziaVQpXcQMErkY5OT1HWuq0fxBpl6ii2uVb5N3PGOuQfcYP6Vyvc61sbR4pDSmm0hjhThTBUGpXqafZyXEgJVQTgewJ/pQBeFEUscm7y3V9rFW2nOD6fWvMfEPiu7ku3jsrmVYU2wkwKMs/Vm68Lhh364560WWva2HW2jlWJYlCiNYVO32ZmwMjpwOxpiPUqK88XX9dhKyebHcxScKFgY9OpB2jP4Zq0fFWowAGWCLryHkQfp8p/Si4WO5orn7LxVZ3MIISd5gPnSGJnwfqK2bS6S6hEkYZQf4XGCPwpiKHiDw5pGvw+Xq9hBc4GFdl+df91uo/A14F4/+FWp6HNJeaIkl/p+SQqDMsQ9GA6j3FfSdNNIZ8OysyybsFWB5FT29wC2DxmvqLxx8PNE8Tq8s0H2W+PIuoAAxP+0Ojfjz714lrnwj8R6dcN9hEGoQZ+Vo3CN+KtjH4E0BZnIyNslWQdOjCrqkEKwOff8ArWVdR3NhcyWl9DJDPGdrI4wQam0+6GfLc49KTQJmi67juX7w5+tAG5f5UsZw2Onoae67W3AfKevsaQyDHamhetTSLzkUzowNAxB80fuKcDlQe4pOj+xoXh/Y0ATAbgV7MOPrTYTlMdxRGccdwaG+S4Po3IoAsk7olYdRTJThklHQ9afDySp70gGVeM9eooESryGA7jIqrOu4H3qa3bhc9QcUyYYZh6GhAdh+z7qp0v4lQ2rvtiv4ntyCeN2Ny/quPxr6vr4a06+bR/Eem6lHnNtcRzfXawJr7jhkWWJJEOUcBgfUGuik9LHPVWo6iiitTMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArmviKl0/hO8FlL5UgKZOM5XcAR+tdLTZY0ljaOVFeNhhlYZBHuKTVxp2Z8+ReF3W32vdBZVbkiL5lI6jOaxpdOuNE1LzoZd0UoxIQpGMnknn/IzXpOuPFBrupQrhQs2QOnUAn9TWVPHHcKQSpz71xNtOx3xSkkzs9N1GDUIRJAwPqPSrdeUQ3dxoOqJIjHyWOGHbFep2kyXNtFNGcq6hhTi7ilG2xKBVPW7Y3mk3UCffZDs/wB4cj9augUPwKog8x8HaJJJpsbX8Lwu8pkYsNrnCrtz3xkv+ldfbwWdlbeRGgZcAHPJPyhf5CoNdvPsoLZ5JwKdpIEkYlk5J55rKTbZtGKSNSKSOWMI8KMg6KygirUbpGAEjVR6AYrLXVbYOUt1e5kBwVhXdg+56Cg3l+TldOZV/wBuQA/pmnqhNJmpItvNGI5oY2QHIVlyKptoOmyL+5jML9njbkfnkfpUMeqKCFu7eSH/AGvvL+YrRglilUPDIrr6qc00yXEh+zanaqxtbuK5UfciuE2n/vtf/iasWV882I7uBrW5/uMdwb/dboasI/HWkdlPXB5zzV3IsOkXIrPuYutXw2aZIuRSHscR4q8I6V4kh2alb5kAwk8fyyJ9D/Q5FeKeM/hlq+gh7rT86hYryWjX94g/2l9PcfpX0tLFkmofLwelGw2kz4/sb7PyS/StiKQMNrcg9/b1rvPjr4Nitoo/EOmQLGNwju0jXA5Pyyce/BPuK8w0243KFPUdKGRtoaZUglD2ppXg+oqXO+MN3X+VIfWkMhYZFNbkAipCMEj8RTPUfjQA4HlW7HipJhuiVu6nFRAZjYelTRHfEw9RQMWNvusKll+VlcVXh6Fe9WQN8JHcUARZ2y8dDzSyHLU1uUHqKRj0NAipqCZhDehxX2N8Mr/+0vh/oFyW3ObONGPqyjaf1Br5AnXdE6/jX0h+zdqH2v4fG1ZstZ3Tx49AcMP5mtqT1Mqq0PVqKKK3MAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiis/ULtoJQjJ+7IyGV1yfYhu30z+FAHlfxL0u1Txstxe3SxWUkCyujPtBfJX8RhaxymhXCn+yru385OhglGQfpWr8WtN025tHvtQjneDy1SUW7KXRVbgLkYHL8+w46Zr5Y0xJ49XURmSN0Y5ZTgj3zXNKF22dcajUUj6A1O4ae3a3ucfaI+Qw6OPWu9+HVy9x4eRZOsMjR59uD/AFryPw/DqOp6Xp8nmefNJK0IY8HqRk+ox/KvcfDumR6VpkdtEc7eWY/xMeprJKzNW7o1OAKgkfrzT5GwDVN25qmxRRyfjYtGsB7GQA1W1DVkt9LSGOTbLJhAwP3Ce59sV0utaYmqWRjPDD5lI7GvOtR0m5N9FDOfmY+Ujeme/wCFRYu4/XfGF/oemQzaJYoYX3AE5IcIPmcADOBxzWT4Y+O4kuVg1zTMIf8AlrbnJ/I1u/Fe0ntfC+kXekyyQwxxPZymI4wjqAQcdjgg14FY6RJbXXnSuhRM7QOpNaxtbUwlzX0PsHRtY0bxHZrPptzHKrDpnBHsRUF9pb2zma0co3fb3+vrXEfCnw0E8FfaL2NoZZ5WngdTtcJgAH6HGa2Y9R1aOeS3hb7dEnU9GX2J6ZqJLqXBtM3bHUpc+XcLhx3HQ1qq5YZHeuXs7uedtsls0ZHdxiuns/mjXNRG/U0lboWI6e3SkHFITWhmMYZphUU8mmk0DSKWr6bBqul3en3a7oLmNon9gR1HuK+QLuyl0jWrywnI861maFiOhKkjI/KvsvNfK/xfhS1+JWqiPgSMkh+pUE/rTRM11KFvKNwz0NSDhip7VQt2yoNXC2Sr+2DUiHH9RUZ4apG9aY+Dg0DEU7Xp9s22XaexpjDp700HDg/hQInI2Te1WYuHI7Gq7Hdg96lU8K34GgBrriQimN9z6VYuB84b6GopBjNAEY5fHrxXsP7L975epeINNJ+8sc6j6Eqf5ivGwfmB9K774EXv2H4pwRZwl5BJCfc43D/0Grg7SInqj6oooorqOYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqtd2cd0pEjSjIx8kjAflnFWaKAOK8dWdha6AbX7MkjTEgCRsAjGGBP0x+OD2r571Lwe0Fw7pcRRQE/xNuYD04619L+OrQXOhs+PmicMPcH5SP1z+FeMaxp6oSWPTmuWtpI7KCvEv/DHSVWdp1d3gtk8mIHhQx5Ygevv/tGvTx8qVieENNOn6PbxMuHI3v8AU8n/AArZnbAxULuW+xBK2ciq79akJyaCuaGUtBYTgVxWsyM+uPEwU45UMM128a81h+JtHa5Zbq2/1ydR6ipa0HF66lWM3Elq8Vxarc27jDqFyGHuOhrMh8M+HVuPN/skiTOdrxFl/wC+SMfpWnpl+8WFcEMOoNdDb3yuooixyiVYoTcYzHcumMBH+RAPTAxx7Vq29vHHEEWKONB0VBgU37SuOtIbjNXcysyRoIc52DNAKoMLxVdpiayo9bgfUlsyD5jFgMEHocHI7dKFrsPbc3t+aQtUQNBai5Vh5NNJpuaKQ7C5r5Y+M8gl+ImpMp4VkX8kFfUtfJPxEnF3401mVTlTdSgH2DED+VOJnU2KFg+VxWgp4x2rG018itdPu0MhE45T3qPPBH406M84pGGHpDFAylMI4P50+LuKCKYCxtlf1qwnKEfjVOM4bFW42wBSAlmOY0NMblaCcoPY0Y4NAFNuGrd8E3f2H4geG7kttUXkSsfZmCn9CawZ+Gpk8zwm3njOHjYMp9CDkU1uJn3aKKq6VeJqGl2d7F/q7iFJl+jKD/WrVdhyBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHLePtTSz0xbYEeZOcn2VSCT+eB+dee6Jp0usamLiYbbKJsgf32B/lV3xvcPqXiaWAEhVcW6+wHX9SxrrdMsltrSJY1CoqgACuKcueZ3wiqcF5lmNQicCqVy/z8VclbahrHuJyrknpTeiCOrJFb58VOOlZP2+3V+ZkDZ6bhWjFPHMgKMD9DUI0ZKrVIGyMGq+acGp3FYq3mmxTNvUbX9qqi0liOByK1t1BIoshpszlEg9anTd3qc4pM0AIB61GlnbJctcLBGJ2+9IFG4/jUm6jdQFiXdRmmCnCgB1FGKXFAijrV8umaRe3r4228Ly898DIFfHd9K0ss0rnc7kkk9ya90+OvigQ2qaBaP+8kxJclT0X+Ffx6/l615F4N0CXxP4ostNjVjCzhp2X+CMH5j+XA9yKpGU3d2GSaFdaTpej3typVNSieaMEYwAxH6jafxqSM16/wDH6yhg8P6G0MaolvOYUVRgKpToP++BXjsZ4FD1Fa2hNuwRSswOajk+7n3piN8wFICxEf3n1qRhjNVozgqferBNMCGThgfWrURylU5TwPY1atz+7pAPVuoqQHIqtuw1PRuKAILr71VJm3WzD+7zVu65qgx5Zf7wIpoTPsD4Jaj/AGn8MNDlY5eKI27f8AYqP0Arua8U/ZX1Dz/CGqWDNlrW83gZ6K6j+qtXtddUXdHLJWYUUUVQgooooAKKKKACiiigAooooAKjnnht4jJcSpFGvVnYKB+JrhvG3xAi0meTT9JRLrUFO12b/Vwn0OOre3bv6V5fqNzqOtTmbU7qW4bOQGPyr9F6CiwHs95468OWrFW1KORh/wA8lZx+YGKpL8SvDZJzczrz3gb/AArx42BA+7UT2Y9Kdh2PeLDxp4evmCwapArnosuYz/49iugR1dQyMGU9CDkGvl2W1xVzRvEer+HpQdPu3SMHJib5oz9VP9OaLAfS9FcV4F8eWniNVtbkLbamBzHn5ZfUp/gefr1rtaQgooooAKKKKACiiigDxfxAxtfE9xK3RLtyfoSefyNd1aXYkt0APauc8dWGNauiB/rAsg/EY/mDWboOseQy2l2dhX5Uc9D7GvPfuyZ6aSnBHcuQwxVaWyhnXEjBR71WvjeG2X7HgOWG49wvtnv0rKvPDzXULNLJNJMR952yavcz2NWXw/atEfK2tXPz20ulTb4yQmeR2qh4XttZ0nXRE7OdPbO8OeB6Ee9dF4huEeMqMFm4A9TUtKxUb3syxbTedErjvUwNN0y222Kg/e60MCjYNBadyTNGaatPAoQMYaaamK0wrTC5GKcBTgtPVaAuIBUiilVakAp2JbGBazfE2sW+gaHdaldH5IVyF7s3ZR9TWtivCP2gvEvm31voNu48u3xNPju5Hyj8Ac/8Cp2IbseWazqFxq2pz3dwTJc3MhY45JJPQV9E/CHwZ/wi+iG4vUH9qXgDy+sa9k/x9/pXO/Bv4dpbQweINciJu2+e1gccRr2cj+96en16exYoFFdWeT/tDSAeH9Li7tdFvyQ/414pGflFepftEXe/UtGsgf8AVxPMR/vEAf8AoJry2EZAFApbjzyh+lRjgg1IRjI+tRUhD34b8al38A1HJ2PrTeiZ96YD5Pun61Ytj8mPaqpOUP1FWbbp/wABpARythqWNqbcfepkR+agCafkVnzcc1em+7VJ+c0wZ7D+yzemHxZrNhn5bi0EwHujgfyc19MV8f8AwC1L7B8UNNVjhblJLY591yP1UV9gV003oc1RahRRRVkBRRRQAUUUUAFFFFABXBfFDxVJpNqmmabKU1G5XLOp5hj6ZHueQPxPpXb3lxFaWk1zO22GFDI7HsAMmvnW81GXXNZu9TnzmdyVU/wp0VfwGKEAun2eWGclicknqa6rT9J3gfL+lZmjoC4zXomhwIQuaoZzc+jbU+7+lc/qFl5ZOBXrV/axrFxjpXB69GoLYpIDi5IwazbyEYPFbE3DNWdefdNMDDimktLpJYnaORGDKynBUjoQexr6G+HHioeI9J23LKNQtwFlHTeOzgfz9/qK+dL7hiRXSfDXXTo/iK3nY/um/dyj/YPX+h/CkB9LUUA5GR0opCCiiigAooooA898azK3ig2/G5LOKT8C8g/9lrldUs1kjJAwxqbxjqiD41JYbs+ZpSx49GDs4/Qmrt7CWCRjq5wPxrhqL32ejSf7tE/hQzWunq9xO5hHQMcgDtj0rp4biOWISRtuQ9DVE2yxacE2jAFRaKhSxYZ48xsU1poS7PUvzRxzDDjNQLp1sJBJ5YZh0zziphUi0x7CD5enSmzwh13DrUxGaQDtRYVzP2lTzUqirDoDTNuKViua43bSFKkFOxTEQhPanqtSBacBQFxgWnBacBTsUyWypqN1Hp+n3N5OcRW8TSufZQSf5V4D8K/DsnjTxfe+IdaiMtlFKZCH5WSUnIX3Cjt9K9c+K1w9t4A1fywS80YgAHfewX+tX/BOhx+HPC9hpqAB448ykfxSHlj+f6UC3NkgDpTTTzVLVL2LTtOur24P7m3iaV8eijP9KCkz5z+M1+L7x/eIpylsiQD8Bk/qxrlLb7wqK+u5NR1S6vJzmWeRpXPuTk1ZtVywpGY2T/WEe9V81PKP3p9M1WB5oAnk+6tNP+r/ABp0n3FqMn92PrQMX+A1atu3+6aq5+Q/WrEB+7/u0AMn6ihBhgKH+ZwKcf8AXN7UgEm6VS9auy89KoscFqYMs+Hb5tJ8TaZfqSDb3Mcuc9gwJr7wjZZI1dDlWGQfUV+f0vUGvtz4ZaoNZ8BaHeZy7Wyo5/2l+U/qK2pPoYVF1OnooorYyCiiigAooooAKKKKAOM+L161n4GvBGcNcMkH4E8/oDXjGlgCBa9Z+OClvB8JGcLeRk/Taw/mRXkmntiMU0M3tOm8txXaaVqYRRzXn6N3Bq5DevH3NMD0W61cNHya5DWLwOW5rOk1F2HU1RmmZzkmiwEchzk1nXjcGrU0mBWXdS5zzQBmXnOai01zHdKfenXDZzUdkCbhcc80gPqrwndm+8OafOxyxiCsfccH+Va1c38PEePwnZhxgkuR9N5rpKQgooooAKKKKAPlX4oawdN+PEl7IfktpYVb/c2KD+hNetapeWumyrPdPwoyqjksT6V4f+0LAYPijqZPSWONx/3wB/Sugt9TbWfDug37SM5SAW0xJziRODn3IwfxrkqaNs7qC5rRZ6YfFdrc2Z3QyxntxnP5VLpuuQ+UIzDJHHnO8jPX1FcRp1xGAAxFdBb3VuIxudAPc1mpXOmVNLQ7CG7hlGY5Uf6GrUZB5BzXAzS2knMc8Yb2YVBBrV5YzZjm81P7rHNPmI9k3selAUlc5pfiuzuQFnIhk9G6VvxzxSqGjkRgfQ1aaZk4uO5JimlRT6SmK5HtpQKfigClYLiYpwFFKBTEGKDS9KaaBHPeNYVuLHT4n5RtRtdw9QJVOP0reJrJ8Ugf2dFK33YbqCZj6Ksqkn8s1pk0DBjXk3x18S/Y9Kj0W2f99dfPNjqsYPA/E/yr03UryGxs5rq5cJDChd2PYAV8oeKdWl13Xbu/mLZnkJVSc7V/hX8BgUmDZnW6E81p2i/N9Bmq0abUFXLcYjc+2KRKK0owM+pqmnLVcvTiJfzqpAN0goAnuOFA+lQk/Ko/GpbzqBUT8H6DFAAxwoFWID86j/Zqq/J/SrVtzK3sKAHKP3g+tNQ5lY+5p5+Ug+nNQwngk0DJjyDWbKfmatBT+7Y1mSH52oQmJIPkBr6f/Zg1QXfga7sWbMlldthfRHAI/XfXzFL/AKnNeq/s0a4NN8ayafK+2HU4TGATx5i/Mv6bh+NaQdmRNXR9VUUUV0HOFFFFABRRRQAUUUUAYHjzSzq/hPUbWMZl8vzIx6sp3AfjjH4189Wr7VxX1JXhPxE8NnQ9aeW3RvsNyTJGccKf4l/D+RHvTQzBjmFTCQGshpChoW696dwNcyCoJZgO9UTdZHWq8txnPNAE89x15rNnmz3qOef3qlLLk9aQD5XyeK1vDVk91qESKuSSOBWTbRGRx1r2P4SeGy139vuEPlw8jPduoH9fy9aAPVtJtRZaZbW3/PKMKfrjn9at0UUhBRRRQAUUUUAfNP7U+kSR+IdK1ZV/cz25tyfRkYn9Q4/KuG+FWsLDc3Wh3Slre9w0Z/uSL3H4Z/IV9PfFfwqvi7wbd2KLm8j/AH9sf+mig4H4jI/GvjOxlm0nWrefaVlt5RlTweDyD+ornqLU6KUtmfQE3hS2eMNDPKjHuGplr4SQNm5upZR2UnAqnaa5K1tDPEfNgkXcjCra67KRwprnuj0uWT2NJPD9hEP9WKQ6HYlgQhH0OKqxahPcHgEV0Ol2M86BtuB/fbp+HrTWuxErx3ZUtfDmnyMNyyg/9dDXR2ehWcSDY1wB/wBdWqe0sY4OT8zep61dBwKtJIwlNsfEixRhFzgDHJyfzNSDmq5eno1O5FiXFLimg5paYhaQmjNNJpiuKTTSaQmmFqAK2rWi6hpl3Zu21Z4miJ9MjGaZZyTGwg+1jbcbAJAOm4DBx7ZqeR8VnX12sUbMzAKoJJPak2Ukeb/HDxD5GnQ6PAxElxiWXH9wHgfiR+leKW6b5c9hWz401l9c8QXV4SfLZtkQ9EHA/wAfxqhBH5cWe5qRPcfjLfSrH3bce5qGJc/jU0/MiRjtxQBT1DhR9AKj09Mybj0UZp+pHLgepzToh5Vmzd24FAiBz5k49OtNbrk+tEYyxNJLwQKYCD7wz65qzZDIdvWqjnDfhir1kMRE0gEujtUj2qFThKddn58e/wDKomOFAoGTLxbk1lk5dj71qP8ALbDPpmspORn1NCEyaYf6PVnRLubTry1vrVtlxbSrLG3oykEfyqCcf6PUlkvygUxH3N4c1WHXNBsNTtxiO6hWUD+6SOR9Qcj8K0q8W/Z08QM+n3Gg3LcxZmt8/wB0/eX8+fxNe011Rd1c5pKzsFFFFMQUUUUAFFFFABVPV9NtdVsZLS9jEkT/AJqfUHsauUUAeC+L/BGp6Q0kkFvNeWgyVkgjLsB7qMkfyrzm8uxbuVlhuEI7OhX+dfYFNkRJFKyKrKexGaYHxuNSDHCRyN9KY2ojOGjcH616b8Wnt5/HkUMdu1slvCsZBhI807mO5cDkc4z7GvMPEywpfyGMyA56eXgf+hUDEa8ifr5g/Af406F7dnAMuCezKa97+C2maZqPgqBr/S9JluI3YBjFHJKy54L8Eg5yB7AV6Ta6bY2hH2WytoCOnlxKuPyFAHhngDwTc6q8Nw8bJaHkysuBj2z1P+TXuthZwWFpHbWqBIkGAPX3PvViikIKKKKACiiigAooooADzXzV+0F4Aaw1U+ItMhP2K6fNyEH+qlJ+8fZv5/WvpWszxNbx3fhzU4Jo1kjktpFKsMg/KamUeZFRdmfMvwxvY9S0ifSJiPPtiZYfUoeoH0PP/Aq72x0KGZRuaUHvhjXhPhO8lsfE+nSwOUbzlQ+6k4I/I19J6ONzH61yNXZ3Qm0ifS9CtbYqwj3MOhbmt1VwuAMUQgACpSKtRsRKV2RYoxUm2jbRYLkZWlUYp+KMUWFccppxNMFGaqxLY4mmE0jNioZJQKBpXJGbFQSSgd6rT3QUdazLu/Cg81DkaRgW7q7Cg81578S9dNpoEsUT4luD5QweQD1P5fzq9rGurHuSM7pPQdq8k8Z6g95qOx3LeUMH6nn/AAqL3HLRGBEvmTAdqvOOiiobNcKXNWI13HJqjImt125c9FH61HF80zP6dPrUtw2yIIOvemL+5gLN1HJ+tAzPucyXe0djtqW+YKFjXovFNslzI0rfw8/jUMzb5DQIfAvyk1ATmb6Vb+5CfYZqlFyzGgBrctWjanES592NZo5fir4OyBz7bRQBVkfdKTSZ3MBTKltF3yjPSgCTUm2WwUdTxWegwoqzqbbpVX8ahA6UxEs4/c1PZL8qmo5RlAKt6cufloQz0P4dTy6fq9pdwEh43BwOMjuPxHFfUVldR3lsk0JyjDP09jXzF4Ii/wBIjBHcV9EeF8pahexFb0zCoblFFFaGYUUUUAFFFFABRRRQAUUUUAeJ/EtAPHZZ5rqH90mC0PmZ6/6s44X8eu6vLPFrK14yrdXsp3dGUKP/AEOvYPi1YXMHiixvYnnaO4j2ALtYqynkDPIHIPXqTXkXiya5+3Mrve/e6NL/APZUxnt/wJtlj8Oyzm3tEdyF82OTfM4BPEgyduOw447dz6bXFfCTSJtL8I27XdtDFc3AEm5Tud0Iyu8+oyeBwB75rtaQgooooAKKKKACiiigAooooAKr6ihksLlFGS0TKB9QasUjDIIPegD4Igl+zahDL/zzlVvyNfUOhToXTnh+V/LNfLeooYruaM/wuR+Rr3L4fasdS8LWkyvm4tf3MnPOV6fmMVxnbHsetxngVIDWdp95Hc26Op5I5HcVdEg9a0TJaJaKj3ikMgpisSUhNQtOB3qvJdAd6XMkNRbLhcConnA71mS3oGfmqhcagoB+as3UNI0ma812B3rNub8DPNYV5qyjIU5NYN7fXM7EJuAPpWfM2aqKib2o6ykIO5ufQVzd5qlxdEiPKL+tRLayO2XySauQ2ZHaiwXMW4UW9vJNKeFUsa8xupGnmeR/vOxY/jXovjucWultGpw8p2fh3rzf+MVaMZ9i5EMRhRVuFcDPpVaAdKtyHZFj1pkkR+eQk8gfzqtqUmAsQ69T9atRkIhc9F/U1l5M91zzk0CLI/dWiju3JqrCN0nPQc1PevyQOg4FRRDCE9zxQA+4bFuT6mqsX3GPvU94cRov41BH/qzQAQj58+nNWLk7YETueTUMC5wP7xp9226bA6DigCCrVkMbm9qrVcT93bk/jQBn3Db7pj+FOUcioQcuTU6D5lpiJ8ZYCr1guJFqrCMua0rKPOOO9AHo3gqP9/ER6ivf/Dwxbp9K8K8Dp+8i/Cvd9BGIE+lbwMZmvRRRWhmFFFFABRRRQAUUUUAFFFFAHKeO/D95ri2EmnywpLauxKy5wwYDofXgV5jrHwo8SalfGXz9PRWbJLSNx+S17zRQBBYW4tLG2tg24QxrGGxjOABmp6KKACiiigAooooAKKKKACiiigAoooNAHwl4sQJ4k1NR0F1KP/HzUnhPxLceG9Q81AZLaUbZov7w9R7iofEEouNavJl6STyOPxYmsmZcrXIdd7Hvvhzxlp99GJbG5Gf4omO11+orpYvFMXRyRXyjFlZG2kg9QRVxNX1S24hv7lR2G8kUcvYr2l90fVY8T25H36afEcB6PXy/F4r1tRt+3MceqKf6U4eMddXOL3BH/TNf8KOVhzx7H0vLr6H7pJ+lVH1WWU/IrV85P4y8QMONSlH+6qj+QrQ8J+Mr221lP7Vu5Z7WYhWaRidh7MP61LgylVR74pup+gxmpV0qeUfOTU3h++PyKwRlPfFdlFEjoGUdaSiU5nGxaFjquakbRsdh+VdkIR6U17cEdKrlJ5zi/wCzdnaq9xAI1PFdlPajB4rm9ZTYGxUtWKUrnjHxFufM1SKAHiNNx+pP/wBauSRcvWx4rmM/iK9PZX2D8OKzY15zTRlLVlqAcgVLcnJC0yHg5prtmSmBBqEu2EIKgsVxlz2pl43mTYqwR5UAHc0CK07bnpy9VFRD5pKlTmQUANv/AL6j0FRJ/qzUl/8A60/QUxP9WaAJrXh8/wB1agY5cmpYztiY+tRL60ACjLAVPdtthI9sUyEZcU2+bjHvQBUi5OasoPmFQQjirSD5qYi7aJmtjTY8yYrPtE4FbumRfvQaEDO/8FR7Jo/TNe4aKMQL9K8e8IxfPH+Fex6OMQr9K3gYTNOiiitCAooooAKKKKACiiigArm/iD4kPhXw3NqKQefNuEcaHpuOeT7AA10lcT8WuPD1oRwReJyP9x6APHLjx94k1EG5k1GaIHokLmNR+C/1q5o3jvUlYLdX1w4B6vcyj/2YVrahoWmz6Yk09nC7tySAUz/3yRmuK1HSLG3LNDbqnsGY/wAyaYz2Lwb45+36vb6dJI0hlO3DHcUOCQQ2AccYw3PPWvSq+c/hMFHieyCgD95xivoykIKKKKACiiigAooooAKKKKACsrxZqA0rwxqt+TtNvaySLzjkKcfritWvLv2h9Y/s/wAC/Y0YiW/mWL/gC/M38gPxpSdlccVd2PlicZdfc1Cy/KfrU8v3k+tNxw1ch1GWy7bj6mpJY8oCBT7tcOpHepkAZKoRmOmDmh06MKutFyRUapwV70XFYolMEjtUZHBHcVbePA+nFQyDBDdu9O4rHtvwY8RjULRNPunzcWuFGTyydj+HT8q95siDEMHivirwtqr6Hr9reKxCI4EmO6HrX1x4X1NLyzjdGDBlBBB61L0ZpF3R1ApcUyNsipBTAhmX5TXJ61HuZhXXTfdNcf4sk+zaVqFx3igkcfgpNTIqJ8338v2jULmb/npKzfmSaIxVePk1ajFBJJ0FV2fBNTyHC1Rc5JpiEt13zZNSXbc4HapLRdoJqtOcsTSAZGOCaki++Kaown1p8fDCgZHe8zGmp9yluzmU0J92gQr8QgVGnSnyngCkQcUwJLYZeobvmQ1atvv1XuBmU0ARRDircK5cVDEvFX7OPLZoEaVpH04rotMhyy8Vk2ceSBXU6RBkjimkJndeEosMn4V6vpYxCteceF4cFK9K08YjFbxMZF2iiirICiiqWuSSQ6NfSQMVlSB2QjqCFOKAM/WfFOm6U7RSO81wv3ooQCV+pJAH0JzXG3HxVgMpS2itBg4y05f8wBj9a4zWLE6npklp5z28rkMd3U/7w7g1jWOg3NmApS3kA7hsf0p2GenR/EG/mXfBFYSL6qGP/s1LJ8S5bQD7baWgz0/flCfoCDmuI0+w+z3DTyMm8rs2IOMZzz61kal4enn1SS8jnWQOc7ZCcqPQH0p2Cx6hF8Uo5SAmnQknoDdkZ/8AIdY/jPxdJrenW9o2nrAPtCvvE+/oG4xtHrXJRadOYjHIkKKRgnO4/lirs9sGgjjRjmPBUtznHrRYLHQXY/4kcX0rhdZ4R/pXWyakraWtu8EiyL3HzKf6/pXM6jbyXSssUbkn1GP50AVvAt5Np+oJdW4jMsbgqJASvXuAR/OvRpviVf20oS4bTA/9wRvu/Lea4PRdGlt4pBPIIywIHlnke+aoW3hu5s52ZJIp1JzuJwT9aQHrmm/ExJXC3FnG47mCX5sf7rf413Gj6tZ6vbedYTCRQcMpGGQ+hHavAFsH3xyXBjjWJg/ynJOPftXVeA75ofGVpBFIB5wZJE7kbSwyO3IGP070NBY9kooopCCiiigAooooAK+bv2ltUNz4osNNVspaW+9h/tOf8AK+ka+OviretqHxE12VmyEuWhXnsny/0rOq9DSktTjpfvrSAZLU5xmVaVR8zVzm5TulzGD6U63HyVJMuYW9qZbjjFMXUSVe9RsuCGHerTLkGoCMqR6UDIHQbj71WkTgj0q63Kg1FMvOfWmhGdIvQ17j8DvEZmsTp87gy23C56lO35cj8q8UkXrWz4E1J9K8S20qEgP+7YeoP/18UPVBF2Z9i2k4ZAc1dVge9cnoWoLcWsbq2QRmugglzjmkmaNFuX7prg/ijN9n8Haq/down/fTBf613LtlK8x+Nkxi8IlP+e1xGn82/wDZaGI8Ji7Grcfaq8fUVaTpSJIpzxVYLzU855qNRxQBMvywmqMlW5G/d4qm/WgB56AUoOCKaOcU/HFAEM/L06McUkgy1PUcUwGMMmnKOKNvNSKvFADrcYamOmXNSxjBp4TLUgIYI85rUso8Gq8EWHIxWvZQHI4qhGjp8GWFdfo8HI4rF0y3JI4rsdHt+nFUkQ2df4ch27K7yzGEFclocWNldhbDCVtEykT0UUVRIVHcRLPbyQyZ2SKUbHoRipKKAPKtS8OPZXZXUofNtv4Lhc7SO2f7p+v4VFfaTbrDvilkIxxgqR/KvWiMjBqhPo+mzkmawtnJ6kxjmncDwfVmltlPl3DgfRf8K5K6jvryUmJbq4x/dDPivqKPQdIjOU0yzB9fJU/0rQjjSJdsaKi+ijAouB8u2NlcLGPNtJQf9qI/4VdS2H8VuPxjr6XoouM+bRbxDrFGPqoqSK3t/MUlIh+AFfRpUHqAfwpDFGeqKfwouFzxSz0+3nT93cSKfRXDfzzVbUrFoFYLcyY+gB/OvbbjT7O4XE9rBIP9uMGqy6FpSnI020z7wqf6UXC585zxapeT/ZtL+1XMxOFEQ3MD9QMj869P+Fnw/utCm/tPW3T7YQfLgQ7vLJ6lj3bqMDj69vS4YIoE2QRpGn91FAH6VJSEFFFFABRRRQAUUUUAMmkWGJ5HOERSxPsK+HNRuGvNQurp/vzytIfqST/Wvsb4g339neCNcus4ZbSRVP8AtMNo/UivjQisar2RtSW7IAMyk+lCD5mqRFxk0kY4JrE1IWGUeooB82Ks7flaoYv9ZTAey1AVwxq2RUTr81ICpjhhTXXMdTlPmamhfkNMRRdcioYyY50YdVYEfnV1k4qsy/MDVIR9E+Fr42rLE5Ox/mU/0rv7OcMoIPFeYaWBJbIG4OBg112jXbqFSQ596yTOho7NJMrXlHx6ugmnaXaDrLM0v/fK4/8AZ69Kt5sgc1438dbgyeINOg7Ja7/++nI/9lqjNnnEfUVaXpVeMVaQcUElWUc03HFWJE5qNhigCFs4qu4q2RULLzQAyMVJilRakA4oAqspzUqLkU5k5qSJeKYEezmnonFTCOpEj4oEQonNWI4+ackfNW4YckUAMhh+cHFb1hb5IOKrW9tkDiui0y2yF4qkiWzQ0y25HFdhpNvjHFZemWvTius0y3xjitEiGzd0iLG2ujhGFrJ06PAFbKDAFaIzY6iiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPM/2gtR+yeBPsqth724SPHqq/Of1UfnXzKVr2P8AaJ1P7V4jsNNRspaQF2H+25/wVfzryMpXNUd5HRTVkVnGFNNVcLU0qdBSsuFNSWVQvytVeMfvavFcRmq0a/vaBEpWmMtWNtNK0DKrJzmowmAauFaYUoAoumBVOVcA1qyJxVG4Tg00Sz2XQZhNYwSKeHRWH5V0thJtYZrz34c3v2jRFjY/PAxjP06j+ePwrvLXnGKza1N07q51NnPkCvIPjKxfxdCfS0Qf+PPXp1o5XAry74tfN4piP/Tqn/oTUyZbHGxjmraCoIxVpBxTIGOtQOKtstRMtAFYrTCnNWSvtSbKAIFWpAtShKeEpgV2jp8aYqyI809IqBEapUqRVMkVWI4vagCCOHnpWhbQZI4p8EGSOK1rS25HFUkJsWyts44rotLtMEcVFYWnTiul060wy8VSRDZc062xjiulsIMAcVTsrfGOK3bSLAHFaJENl+zTAFX1qvAuFFWRVkBRRRQAUUUUAFFFFABRVLWNVsNFsHvdWvILO0QgNNM4VQScDJPvXPf8LL8E/wDQ06P/AOBS/wCNAHXUVyP/AAsvwT/0NOj/APgUv+NH/Cy/BP8A0NOj/wDgUv8AjQB11Fcj/wALL8E/9DTo/wD4FL/jR/wsvwT/ANDTo/8A4FL/AI0AddRXI/8ACy/BP/Q06P8A+BS/40f8LL8E/wDQ06P/AOBS/wCNAHXUVyP/AAsvwT/0NOj/APgUv+NH/Cy/BP8A0NOj/wDgUv8AjQB11Fcj/wALL8E/9DTo/wD4FL/jR/wsvwT/ANDTo/8A4FL/AI0AddRXI/8ACy/BP/Q06P8A+BS/40f8LL8E/wDQ06P/AOBS/wCNAHXUyeRYYXlkICIpZiewHJrlP+Fl+Cf+hp0f/wACl/xrD8a/EnwnJ4ZvYbHxJpcs8yeWFjuVJwevf0zQxpHh3iq9k1nxBf6jKTmeUsB6L2H4DFYrR47Veu9W0fcdmpWhHtIKoSarpmeL62/77FczTOhNEbR5f6UyVOPrR/aenZJ+22//AH2KjfU9PLD/AEy3x/vilZjuh0iYSq6J+8p8mpWB6XkB/wCBioY9Qsd5Ju4cf74osxXRaKU3ZTDqVh/z+Qf99im/2lYf8/cH/fYpWY7okKU0rTDqNh/z9wf99ikOo2GP+PuH/vsUWYXQjpxVG4Tg1bfULE/8vUP/AH0KqzXloc4uYv8AvoU0mJtGz8Prw2us+Qxwlwu3/gQ5H9R+New6ec4rwCwu0jvI5LaVDLGwdcH0Oa970eVJ4YZY/uSKHX6EZpSWpdN6WN6JcYNeafFiE/25Zy44a2C/iGb/ABFeowDKiuH+LNrutdOuQPuu8ZP1AI/kaQ5Hm0a9KtRrxUca1ajWmQRleKjZKubKY0ftQBU2UuyrQjpRHQBWEdPWOrIj9qesZ7CiwECx1KkVWEi9RU6Qk9BTAgjh5q3BBU8MHTitC2t844p2FcitbbJHFbdlacjinWlryOK3rC06cVSRLY7T7TgcV0VlbYxxTLK1wBxW3awcDirSM2yW1hxjitS3jxUMEeKvQpirJZPGMCpBTR0p1MQUUUUAFFFFABRRRQBx/wAUf+QJpX/Yb03/ANK466IVzvxR/wCQJpX/AGG9N/8ASuOugBpNlIkFLmo80bqVwsSZpaj3Uu6gB4pajzS5oCw/NGaZuozTAfRTM0ZoAfRTM0u6gB1FM3UbqAH0UzdRuoAdRTd1GaAHUlN3UbqQWFopuaQmgB1FNzSZouFh1GabmkzRcLHh/wC04N3/AAi4/wBu5/8AQUrP8BObjQLQnrHmI/geP0xWl+0oNz+GB/t3P/oKVkfDDLaTOn9yfP5gVlU1NqR3luvyisX4gWf2rwtcEDLQMso/A4P6E10UKfKKL20W8sbi2fhZo2jPtkYrM1Z4EiVZjSpWt2hleORcOjFWHoR1pjzJFII0R5ZcZ2RjJA9TngfjTsZ3HhKDHT7WXzZGjeJ4pVAba2DkHuCCR2q15NFguURFTxFV0QVIsNAFJYqlSH2q4kHtU6Qe1OwXKaQ1ait+nFW4rfParsNr04p2FcqwW3TitW1tOnFWLa06cVsWln04ppEtkdlZ9OK3rO16cU6ztcY4rYtrfGKtIlsLW3wBxWnBFgCiGLA6VbjTgVZA6JasoMCmItTCmIUUtAooAKKKKACiiigAooooA474pf8AID0v/sNab/6VR1uA1hfFP/kBaZ/2GtO/9Ko62N1TIuK0Jt1G6od1G6pKsT7qN1QhqXd70XFYm3Uu6oN3vRvouFibdS76g30b6dwsT76N9V99G+i4WLG6jd71yfiXxjY6K5gQG6vsf6mM/d/3j2/U+1cBqXirX9TY/wClG0iPSO2+TH/AvvfrTSbE7I9r3Ubq+dp4Z5uZ5pJW9XYsf1qJBc2zbreeWJvVHKn9KfKK59HbqN1eE6d4017S2Gbs3UQ6pcjfn/gX3v1r0Pwv460/W3S3lBtL1uBG5yrn0Vu/0OKTTQ1Y7PdRuqDfRupXHYn3Um6od1G6i4WJt1G6od1G6i4WJd1JuqPdSbqLhYl3Ubqhz70bqQWPH/2hx5lz4YH+1c/+gpWV8LFHk30fG4MrY9sGtr45r5mpeGF97r/0FK5nwhP/AGbrsEj8RSfun9ge/wCBxUyLjoepxR8Cp0j56VaS34HFTLB7VFjS549440o2evyyBcRXP71T7nr+v865Kx2Wkci3YaOTcWeRlO1+eDu6dO3bFe7+L9COq6O3lLm5g/eR+p9V/GvJbuwa4jERbajEBxj7y9x+NOxDOfhu45ZJJIJY/Nl4Bzny4lydxH5n8RWnZTJK2ySRRM3zCI8Mq9QPrjGfrUmp6MLiQTOgdEAOFB3BVydq/wC8eD7ACsWLSZZbyeSb5ZJP3bd98r/MR/uIMZHfBp2uTc6UQe1SLB7VPpiJJDH9n+a227Y2xzheMnPUHsRWhBCkgOxlYA4ODnB9KLDuZ8dv7VZitvatKO1PpVuK09qLCuZ8Nr7VoW1p04rQgtPatK3tOnFUkK5TtbT2rXtbXGOKs21rjtWlBb47VSRNyK2t8Y4rSiiwelLFFjFWkSmSIiYqdVoVakAqhCqKeKQU4UAFFFFABRRRQAUUUUAFFFFAHG/FX/kAab/2GdO/9Ko60t1ZnxW/5AGm/wDYZ07/ANKo6v7qiZpDYlzRuqLdRuqLmliXdRuqEtRuouFiXdRu96hLUhalcLE++k31AXpu+i4WLO+uT8deJX0u3WzsWH2+ccN/zyXpu+vpW/cXMdtbyzzMFiiUu7HsAMk14wbuTVNQuNQnzvncsATnavZfwHFXBXZM9EWNPsTJIWcl3Y5ZmOST6k101pou5AdtV9BiVnXNej6PaRtEM4rUyPPL3SPLU8Vg3FvsYg16vrlrGiNjFedawgWQ49aEBz1zACKxJwYJQyEgg5BFdJP901z+pDrTYHq/w58WSarCbC/fddRLlJD1kUev+0P1H0Ndxvr5t8P38tlqUM0LbZEYFTX0Hp94l7ZQ3MZ+SVQ309qxmrGkdTQ3+4o31X30oapuXYn3Ubqg3e9KGouFibdRuqLdQGouKxLupC1R5pc0XCx5r8Xk83XPC6+11/6Clcz9j56V2HxFj87xR4XXr8t2f/HY6rfYPanuI7fwpKb7QraRzmRR5b/Ucfywa2VgArkvCF0NPnkgnbbBLzk9Fb1/H/Cu5UAgFSCDyCKLBcgWPFcT4v8ACe53vtOQncd0sSjv/eH+Fd9tpdtFgueJpZEqSATjr7VR1jQhqVuyLLJDIEdUZTgZYY59q9g1jw/Ddt59sBDcjnIGA31/xrIXRFuA0e3yL5OTGRhX9x6fyosK547OZrWS6juVxqDGO1toYAceUdpJQnvyRn/ZFXNDja1uhCJ4ra2hdpLnAAT+7yx/2sKOn+rY85Feh3ejrOjW93E3BBxkqVI5BBHIPuK5O88MT2s1tbyxNNpPmSyStBE0krlsYDjrnG5d3PB7dadibnRw2uQMDirsNp7VB4Wa81B764uovItlmMNvBgZULwSx9c8Y7Yrporb2osFzPgtR6VfgtsY4q5Fb47Vajh9qqwrkEMGO1W44qkSPFTKtMQiJUoWlVaUCmIAKeKAKcKAAUtAooAKKKKACiiigAooooAKKKKAOM+K//Ivad/2GdO/9Ko6uA1T+LH/Ivad/2GdO/wDSqOrOeKzma09h+aTNNzSbqg1sOzSFqYWppalcLDy1N3VGWppalcdiUtTS1RFqQtSuOxz3xGvDbeFblFOGuGWEficn9Aa8/wBNAEC12PxPQyeHoSBxHcox+m1h/MiuLsHxGorelsYVNzpNJufKcZrtdO1hUjAzXm6MQcg81ajvZEGM1qZnb6rqyyIea4rUZ/NkODUc147jk1Tlkx1oAjuGwKwb45JrRupuDWRcvkmkBRjOyfIr3D4f3LS+H1Vj9xyB9CAf5k14enzTCvZ/h+hi0Uk92A/Qf41FTY0p7nXh6UNVcPShqwubWLAalDVAGpwai4WJw1LmoQ1ODU7isS5ozTAaXNO4rHI+LI/N8a+Fl/6Z3n/oMdbtjpSXM/lu+zI4OM1l6uvmeP8Awsv/AEyvP/QY67GKDy5VcdjmriroyloyG28O28UivI7SFTkDGBWztqUDIoxVWJuR7aNtSYpcUWC5HtqOW3WXaWHzKcq3cGrGKMUBcy9VsxIFmA+ccN7iqCW3tXRsoZSD0NUfJwSMdKdhXOettFltL95bO7KW0shklt5I967jyShyCpJ57j2rbSHHarKx08JQFyFIsVKqU8LTwKYhgWpFGKWlxQAgpwopcUAApaKUUAFFFFABRRRQAUUUUAFFFFABRRRQBxfxZ/5F3T/+wxp3/pVHU26oPi1x4bsD/wBRjT//AEqjpGlrGo7M3pLQn3Uhaq5lpplrPmNuUsFhTGaoDLTDJSuPlJy1NL1AZKaXFK47E+6k3VDvpN9K4WK+vWf9paPdWvG6RPlz/eHI/UCvKLctHwwKkcEHgivYN9cL4t0doLmS9gGYJTlwP4GPU/Q/zralNJ2MasLq6MWOf3qYTDHWsidjHzUH2sjvXTc5zbeYetUri596oNd5FVprnNICa4n96z5pcnFRSzEmn2kLTSAAZyaAL2jWjXN0igdT+Qr2vQ7cWmnRx4wT8xH8v0xXH+C9E8s+fMvA/wA4/wAfy+ncb656s+h0UodWWN9KHqvvo31jc2sWQ9PD1U30of3p3FYuB6eHqkJKcJKdxcpdD0u6qgkpwkp3DlM24+b4i+Fh/wBMb3/0COu/8r2rz5W3fEjwv/1wvf8A0GOvSsVvDWJzVPiGxj5AKdilXpS1ZmNxRinYoxQA3FGKdijFACYqJ1+fpU2KYRk0AR7acBTsUtADcUYp2KMUAIBS0uKKACiiloAMUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBxHxdOPDFkfTV9P8A/SqOqTS/7L/98GrfxiYp4UtHGMrqtgRn/r5jrGOpyFgQiBfTP9awrbnXhouSdi2ZT/df/vg0nmH+6/8A3wapLfzAsdwO7oMfd+lO/tCbaoyuR1OOtYWZ0+zZaMh/uyf98GkLn+5J/wB8Gq39oTZYjZgjgY6Uhv5tgUMoI/ixyaOVh7ORZ3N/ck/74NJub+5J/wB8Gq5v592cpjpjbxTPtlwAR5vXvgZH0o5R+zZb3t/ck/74NLub+5J/3yap/bbgHPmD6bRik+3XAQr5nfO7AzRyh7ORd3N/ck/75NI43oVeJ2VhggoSCKom+uNxYSYyMYxwPcVH9suMACZuBgUWD2UjNv8AwnbXDk27zQA/wmIsB9OlYl34TgiuFha+YOwzgwYwPxYeldfFfXK7QJchc/eGc/WsO7leXWMSuz4RQCee5ranKTdmzCrQUY8xy174cubcviS2ZQTtPmEZHY9Kpw6PI9wiXDQJGx5ZJdxH4ED+ddRqy4Ridg99pzWAG/0mPnvXScRpWngmK5dgt22VAJxHu4PTp9K3NM8HW9nKHklmkA7CEr+vNPsJHjvnCOyjykbg9/mq/wDap8g+dJwc/e71zTlJNpM7qWHU4qRrx7Y0VI4nVFGABGcD9KXef7kn/ftv8Kxlup16Tyd/4s9aT7VcAACeUADA+asbHR7Fm0HP9yT/AL4b/Cl3H+5J/wB8H/CsUXdz/wA95emPvdv89+tC3dwpGJ5OBgZOaLB7Fm1uP9yT/vg/4Uu8/wByT/vg/wCFYgu7kKoE8mFOR838/WlN7ckk+e/Lbuvf/D2osHsWbe8j+GT/AL4P+FOEh/uSf98H/CsE3lwRjz5Ouev+fyoN7ckufPfLdef5en4UWYexZsXuoQWNrJc3khht4xlpHUgLzjk1kDxv4c/6DNp/31SC/u1ZWS5lVlGAQ2P8n3qZdZ1FQgF5MQmerk5+vrTXmS6MuhnW3jLw/wD8J94fujq9oLaGG6EkpfCoWVNuT74NejJ8QfCLuqr4i00sxwAJhya43w9qt/P8Q9Bt5ryd4Hhu2ZC5wxCpjI6HHb0r1yuqn8JwV4uM2meZfE3xvq/h3xp4Y0TSzbRwarFcyTTvpdxqEiGJVI2RQOrHOTnrjr2pNT+Len6Abq21Wx1a8m06zt7y/u7WyW3jjjmICv5MsvmrgkZTBYfga63xH4O0XxFqVhqGpw3X2+wWRLa4tb6e1kiD4DgNE6nkACuVufhBo1/4tv8AVdXuLq/0+5tLe2GnzXE5B8k5DSyebmcE4OJAenerMSNPixYW+o6nbTJd6hMurRaXY2tnZrHJK8iBwAzzbWGOS7eWB6VyvhP43W+l+GVm8aTXF1qlzqF8kMKC2hZIYW6MzOkeQOB8xLHgbjXpd78OPCt491JNpZWa5vE1B5YrmaKRbhF2rIjq4MZA4+QgVFD8MvCcFvaxW2nT27Ws0s8M8F/cRTxvL/rCJlkEmG7jdj2oAw7X406BfahDa6bpmv3wezjv2nt7MNFFE6s2ZG3fJjaQc8Z6E9arD45aGbM3P9h+INn9ljWVHl2+WtN+wyD992bgqcH0BrtrLwXoVneXt3FazvdXtotjczT3c0zywgEBWZ3Jzyfm6+9Zw+GPhAW4gGkfuhpZ0YD7TN/x6F95j+//AHud33vegDn9V+L+k6NqGsyX7XE+nWsVhJCkFmEb/SVJXMrTbSDjqyxhemWzXe+Ftbg8RaJb6paRGOCfdsBnhm4BIzvhd0PTsx98Hisv/hAPDyTTTW9ve2k80UEMktnqVzbuyQoUjUtHIpwFY8d+CckA1reGtA0vwxo8Ol6FaJaWMRJWNWLHJOSSzEliSepJNAGniilooASilooAMUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHB/Gjjwfb/wDYUsf/AEpjrkt9dd8ZlZ/CNsqjLNqlgAPf7THXLCwu848hs/h/OuavUjFpSdj0cE1ysi8yl8yrH9l3mP8AU/8Ajw/xqvLbzxf6yJ1Hrjj86wVanLRSR2Jp7B5tL5tQZFSwwSzf6qJ2HqBx+dW5KKu2PYd5lHm+9PaxuFHzR4+rD/Gql7Z3W+HMeYd2XCnJI+g/Cs1iKTduZEykopsn8yjzPesy0sW8wma3u8Z7pJWoLSy8s5t5w3+5JW94fzL7zm+tr+VjS9IXFYGr2N0xP2KC8P8Auh6yItP1neA9tf4753UXh/OvvD62v5Wdr5oUZzWSXDauxz/Co/nWemnX+Pmtrsn6NTDp1+H3JZ3efUK1OMoJ35l95FXEKceVRZq6ukixPtYYz64P6Vy7nbcIWIzn1rSmsdTkBDW18R6Yaqg0a+MgJsLogdyhNa+2p/zL7zi5X2Oot2xebvWFf5mrefes7TrOTj7Va3IIGMlH6VenskaM+VBcZ7YV6ylKDd+Zfed1LEKEFFpj6M1zV/YamJV8i3v9uecB+ldTpGlXE0Rcs8acALIpznAyeTnrWNWrTpx5nJG0MRGbtaxHRmtI6PKOkin8MUi6TKSf3sf6/wCFY/XKP8xtzx7mdmitQaO+cNMo+ik1IdGVR80xH4UnjKK6i9pHuY+aTNbB0mEf8tn/ACFRrpQdmCTcDuV/+vSWOovqHtImRMsrxMtu8Ucp+60oJUfUDmqf2bWf+f8A0b/vzNXQvpEq/dkRiemcipE0ZiP3kwB9FXNV9dopb/mTKUXrzHPaDb60vjnR3tr/AEZ75YbgQxNDMFYFV3EntjjFeoJ/wm28b/8AhHNuecefnFcZpFkLT4leGyHLboLwcjH8KV65XfQqRqQUo7HmYj+I9Txz4vaVb3nxR8D3ms6DdavoFtb3y3Yj0uS+jRmRRGGREbkt047Z7Vx9o/xO8N+G9Js9Mt9QstKuLu+kRjC1zcWcJObaKRVguGUdTjyyedpKYzX0nRWxgeJaTe/E3VfE1tHNqktjp1to8N3OyaK3lXlwGIeNDMiOjMACQRkdlFYVnrPxXk0a2kmudeW7m8OXN/IP7HhBivo3by4QPJ4LqF+Q5JzxjIr6KooA+fzqPjoPr+oW9o+k6nd6bpDrdnQZJHaZoibhMxQSOxU5X5lcJ0wM16n8LdQ1fVPCMN14gttUtr5pZAU1IRiUqGwpwkUWARyA0at6+tdbRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHE/F3/kWbH/ALC+n/8ApVHVXeUPyjNWvi7/AMizY/8AYX0//wBKo6qZUV4Wb/HH0OrD7MY9xN2WoWMz55wPyqwTu4AppjryL33OlEaYTG7n6GmyzooIG4fnUgixzjNKH2tkLkimMqxRPK+9w23tmrBQD7oI96e80rDCxj86iMczHJwBQxDWSZiQsn6Ui2pPMjk/Wp1Hlj396V4ywzvApBciKyKOJEP1WomY7v3sgVe5C/1qUwY5L59ulTxiIpgLyKpDK32m1HdKQXCyv/o+1vUYzU0lumdwiRvYimea0fAgIHtiloGhIRJ0/dg+wzSMjqM8Z7kmoHuHcjEbgj2pfKmkGXZlHpRYAZ8ttYj8DUxYhcKKiVBDzHGGb1JyakK3TqSNi/U0ANCNIwMjfJ6KacXjTgOV/GhAYUJc7mPUg0mfNGVXNMBvmNIwCOSO/FSqQmQMlqSNCnJ/IU95SOFT8MUhXEBLHJU4+lLhXyOQfrUZ89+MBB7mnRRmNTlgWPU0ANMCLz/Wn5jjQAqPy4oJAI9T705lLY3YApICB5YG64Bpgdc4RyfarRjjJ5UUoRV6AUBczLFSPiR4YJJOYLz/ANBSvVK8vt/+Sk+GP+uF5/6DHXqFfTZd/u8fn+Zw1vjYUUUV3GQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcT8Xf+RZsf8AsL6f/wClUdVto9Ks/F3/AJFmx/7C+n/+lUdV68LN/jj6HVh9mJUbybe1S00qD1ryDoIC7n2qaOJ8c4H1NMkiB6HFNVHPBdsU1bqMmYbP4gahaYg8AUGDPVjSxoYycDNG4ELu7ZAQ/lUkaM6/M+0frTnMjHjgUJD3c5oWgDNqA8uxp8T4OFGRQ0ajotAJXtgUgJHZz0xTD5nfFPzxnOKQlR1b9aBEJPPJpzTkjHakd0HT+dOhYNyE/HFCYxiLuOXIAqaRFZR+8IoIY8U0QKDzTQEMixIMtIx9qfbyqUOBgZ496kMMQPRTRmNepFDARpQBwMmlTJ5ORTQ4LDYDjue1PZ17mkAjAOufMxUDJjrMac2wk7QxJ9KI4wvLKM+9O4BbxgncdxPYmrBGaaGx2pwbNICJ1K8igOwHNJezNBbPKkE1wyjIihXc7fQVjtrVyf8AmX9d/wDAUf8AxVaQpTnrFXJckty7aNu+JHhj/rhef+gx16jXi9tqtzH420K+Oga55VvFcq4+zDcSyoBgbuenPpXfp4w3Oq/8I74jGTjJseB/49X0mAi4UIqS11/M4qzTm7HU0V5h8W9a8VaZq2mDw6bh9Kjhkn1JNMe1N+q5AVlS4VgUHOcKTx1HWuetvjlHDoV9cx6fJqYstEi1cTyuLV7jfP5RQxhWCEZ6gsD2HNdhme4UV89w/E7U/D/jPx3qt3BLqGipNoyC0e/YG0FxBz5EZUqxJOSMpnGee3ZH4pX03h/xP4gsdAtpNE0OW5gczai0dzK8PX90IWCgnHV8gc47UAepUV4F8R/jHq6eFvEa+G7OPT77T9N07UVvjOsu1blo8qsbRlWI37eeoJPBAB3vGXxhm8JXS299pNhezQC3+3x2N9PK9r5pG0sfswjAOQRudC2eBQB6/RXkb/GGePxCbOTw8v8AZ48S/wDCNNcpfFpPNIysgi8vlTzkbsj3qno/xzOoafdas3hHV10GO1ublL2OOVwPJJ+SQmJY1LbTjbI4HQ4PFAHtFFeK3/xwl0u2uP7T8ORJdpbWV7GlvqPmxNDcuFBaTyhtddwO3BB5w3etO9+LF6j+IY9P8KXN82j6uNMkaKZ3UJtLGeQRxO6qMdFR6APV6K8r8deO9Qf4EXnjDwtPZJdtAJY54JGljjHmBSV8yIFiOmGRec+lVG+IWu6fq19DLo17quoW3h+31L+ztPuEljld5tnyfuFkzj5ickYyAhxkgHr9FeQT/GG6TQo9Rt/D8d0kd1cW1/LBNdtDpvlIrN9o/wBE81G5Ix5RAxkt6V9b+OMemWHiC5i0aC9XSrXTrlWgvzsuRdhT8pMQIVd3Urlu4XpQB7PRXlml/FifVfG02jWHhbU7jT4NTk0qe/jjmbyXTgyOBF5ax545k3AclQK9ToAKKKKACiiigAooooAKKKKACiiigAooooA4n4u/8izY/wDYX0//ANKo6r1Y+Lv/ACLNj/2F9P8A/SqOq9eFm3xx9Dqw+zCmFTnrT6QnFeQdAmKRnC0bqQkelAxPMPpSh88GlH0oIAPSgBrIc5BpoZlOD0qTJNATJyaAEL+gprbm7U8kCjeKAG4O3GKgZeeRVneKQsD2oAhTb/dqZW9qFXnpT8ACgBaazACmsW7UzYzHmgByHeeRkUojTrtX8qcq7RS4oAMcYpCi+lLigUCEGBRkUjDNJsPrQMdxTO/FOC+tOAFAgB4oowKWgDOt/wDkpPhj/rhef+gx16fXmFv/AMlJ8Mf9cLz/ANBjr0+vpsu/3ePz/M4q3xsy9b8O6JrwQa5o+m6kI+UF5apNt+m4HHU/nUOpeE/DmqNC2p6BpF40MXkRG4s45PLj/uLlThfYcVtUV3GRht4Q8NNqqam3h7RzqUZUpdmyi81SoAXD7cjAAA54AFPk8KeHpNTm1GTQdJfUJlZJLprOMyurKVYM+MkEEggnkHFbNFAGDa+DfDFpb3MFr4c0WCC5jEM8cdjEqyxg5CMAuGXPODxUUngXwjKYzJ4W0FzEgjTdp8J2IDkKPl4APIFdHRQBlHw5oZk8w6Nppf7WL/d9lTP2kdJs4/1n+3196ig8J+HINTl1GDQNIi1CUMJLpLONZX3DDZcLk5Bweea2qKAMO28IeG7XTrvT7Xw9o8NhdkG4to7KJYpiOm9QuGx7ioH8C+EZLY27+FtBa33+Z5R0+ErvxjdjbjOOM+ldHRQBT/svT/7LOmfYbX+zTGYjaeSvlFD1XZjGPbFZh8F+Fjam2PhrRDbmIQGI2EWwxh94TG3G0MS2Omeetb9FAHOS+BfCU1rb20vhbQXt7csYYm0+EpEWxu2jbgZwM464FTaj4P8ADOpzrNqXh3RruZY1hD3FjFIwRfurkqflHYdBW7RQBjzeFvD8+spq82haVJqqMHW9e0jM6sOhEmN2R9a2KKKACiiigAooooAKKKKACiiigAooooAKKKKAOJ+Lv/Is2P8A2F9P/wDSqOq9bXj/AEK78Q6Atnp9xDb3cd1BdRvMhdN0UiuAQCDg7fUVy3/CNeO/+gn4a/8AAGf/AOPV5OY4edaUXDodFGaincv0lUf+Ea8d/wDQT8Nf+AM//wAeo/4Rrx3/ANBPw1/4Az//AB6vO+oVu35/5G3tYl7aKMCqP/CNeO/+gn4a/wDAGf8A+PUf8I147/6Cfhr/AMAZ/wD49R/Z9bt+f+Qe1iXqWqH/AAjXjv8A6Cfhr/wBn/8Aj1H/AAjXjv8A6Cfhr/wBn/8Aj1H1Ct2/P/IPaxL9FUP+Ea8d/wDQT8Nf+AM//wAeo/4Rrx3/ANBPw1/4Az//AB6j6hW7fn/kHtYl0qDSbBVP/hGvHf8A0E/DX/gDP/8AHqP+Ea8d/wDQT8Nf+AM//wAeo/s+t2/P/IPaxLuwUoA9Ko/8I147/wCgn4a/8AZ//j1H/CNeO/8AoJ+Gv/AGf/49R9Qrdvz/AMg9rEv0VQ/4Rrx3/wBBPw1/4Az/APx6j/hGvHf/AEE/DX/gDP8A/HqPqFbt+f8AkHtYl+iqH/CNeO/+gn4a/wDAGf8A+PUf8I147/6Cfhr/AMAZ/wD49R9Qrdvz/wAg9rEv0VQ/4Rrx3/0E/DX/AIAz/wDx6j/hGvHf/QT8Nf8AgDP/APHqPqFbt+f+Qe1iX6Kof8I147/6Cfhr/wAAZ/8A49R/wjXjv/oJ+Gv/AABn/wDj1H1Ct2/P/IPaxL9FUP8AhGvHf/QT8Nf+AM//AMeo/wCEa8d/9BPw1/4Az/8Ax6j6hW7fn/kHtYl4jNAGKo/8I147/wCgn4a/8AZ//j1H/CNeO/8AoJ+Gv/AGf/49R9Qrdvz/AMg9rEv0VQ/4Rrx3/wBBPw1/4Az/APx6j/hGvHf/AEE/DX/gDP8A/HqPqFbt+f8AkHtYjbf/AJKT4Y/64Xn/AKDHXp9eeeHvCfiKLxXp+q67f6VLDZxTIkdnbSRsTIAOSzt/dr0OvcwVN06KjLc5arUpXQUUUV1mYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The microdermal jewelry design uses &ldquo;pocketing&rdquo; to insert a dermal anchor in the subcutaneous tissue. The jewelry is screwed into the anchor, appearing to be stuck to the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3874=[""].join("\n");
var outline_f3_50_3874=null;
var title_f3_50_3875="Urethrovaginal sphincter";
var content_f3_50_3875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    Female urethral and urethrovaginal sphincters",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Perineum. External urethral sphincter, urethrovaginal sphincter, and compressor urethrae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Agur A. Essential Clinical Anatomy, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3875=[""].join("\n");
var outline_f3_50_3875=null;
var title_f3_50_3876="How pregnancy happens PI";
var content_f3_50_3876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    How pregnancy happens",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 511px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To get pregnant (in the traditional way), a woman must have sex with a man around the time she ovulates (releases an egg from the ovary). Then the following steps must occur:",
"    <br>",
"     <ol>",
"      <li>",
"       The man's sperm must swim up the vagina, into the uterus, and up the tubes that connect the ovaries to the uterus (called the fallopian tubes).",
"      </li>",
"      <li>",
"       When the sperm reach the woman's egg, at least one sperm must eat through the outer casing of the egg and make it inside. This is called fertilization.",
"      </li>",
"      <li>",
"       The newly fertilized egg must travel down to the uterus.",
"      </li>",
"      <li>",
"       The egg must secure itself to the wall of the uterus. This is called implantation.",
"      </li>",
"     </ol>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3876=[""].join("\n");
var outline_f3_50_3876=null;
var title_f3_50_3877="Intraluminal obstruction after gastric bypass";
var content_f3_50_3877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Intraluminal obstruction after gastric bypass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arrows point to an intraluminal obstruction after gastric bypass. A feces sign is seen in the small bowel and distal bowel is collapsed. The patient presented with abdominal pain and was obstructed by steak. This obstruction resolved spontaneously.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3877=[""].join("\n");
var outline_f3_50_3877=null;
var title_f3_50_3878="Sinus bradycardia";
var content_f3_50_3878=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sinus bradycardia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/50/3878/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3878/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/50/3878/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3878/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/50/3878/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3878/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/50/3878/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus bradycardia is a rhythm in which fewer than the normal number of impulses arise from the sinoatrial (SA) node. The normal heart rate has been considered historically to range from 60 to 100 beats per minute, with sinus bradycardia being defined as a sinus rhythm with a rate below 60 beats per minute. However, a study in 500 normal subjects using an electrocardiographically recorded heart rate found the mean afternoon heart rate for men and women to be about 70 beats per minute with two standard deviation limits of 46 and 93 beats per minute in men and 51 and 95 beats per minute for women; there was no significant age-related effect (",
"    <a class=\"graphic graphic_table graphicRef77746 \" href=\"UTD.htm?37/10/38059\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Sinus arrhythmia often accompanies sinus bradycardia, but the P waves have a normal morphology unless atrial disease is present. A PR interval of up to 0.21 is normal in sinus bradycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2086?source=see_link\">",
"     \"Normal sinus rhythm and sinus arrhythmia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causes, manifestations and management of sinus bradycardia, both in the normal heart and secondary to other conditions, are reviewed here. Primary sinus node dysfunction (sick sinus syndrome) is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=see_link\">",
"     \"Treatment of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SINUS BRADYCARDIA IN THE NORMAL HEART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus bradycardia occurs in normal children and adults, particularly during sleep when rates may transiently drop as low as of 30 beats per minute and pauses of up to 2 seconds are not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. It may also be seen in the absence of heart disease in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At rest, in 25 to 35 percent of asymptomatic individuals under 25 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In well-conditioned athletes [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In some elderly patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As a manifestation of a rare familial syndrome in which asymptomatic sinus bradycardia results from a mutation in HCN4, which is one of a family of pacemaker ion channel genes [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no prognostic significance to sinus bradycardia in otherwise healthy subjects. In subjects over the age of 40, for example, there is no adverse effect on longevity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGIC SINUS BRADYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus bradycardia can be seen in a variety of pathophysiologic settings (",
"    <a class=\"graphic graphic_table graphicRef65521 \" href=\"UTD.htm?11/49/12061\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sick sinus syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus bradycardia may be the first manifestation of SA node dysfunction and the sick sinus syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Primary disease of the SA node is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Exaggerated vagal activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasovagal responses may be associated with a profound bradycardia due to heightened parasympathetic activity and sympathetic withdrawal on the SA node. The combination of the slow heart rate and an associated decline in peripheral vascular resistance is often sufficient to produce presyncope or syncope. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a variety of stimuli for vagal activation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pressure on the carotid sinus, as may occur with a tight collar or with the impact of the stream of water in a shower",
"     </li>",
"     <li>",
"      Vomiting or coughing",
"     </li>",
"     <li>",
"      Valsalva maneuver when straining at stool",
"     </li>",
"     <li>",
"      Sudden exposure of the face to cold water",
"     </li>",
"     <li>",
"      Prolonged standing via a Bezold-Jarisch reflex",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypervagotonia can also result in chronic (ie, nonepisodic) resting sinus bradycardia. This is the primary mechanism of resting bradycardia in well-trained athletes. Junctional bradycardia and Mobitz type I AV block can also be seen in this setting. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Athletes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Increased intracranial pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased intracranial pressure should be excluded when sinus bradycardia occurs in a patient with neurologic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus bradycardia occurs in 15 to 25 percent of patients with acute myocardial infarction, particularly those affecting the inferior wall since the right coronary artery supplies the SA node in approximately 60 percent of people. Increased vagal activity is primarily responsible, and the bradycardia is typically transient. If treatment is necessary because of hemodynamic compromise or ischemia, sinus bradycardia usually responds well to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    (0.6 to 1.0 mg in the majority of cases). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=see_link&amp;anchor=H2#H2\">",
"     \"Supraventricular arrhythmias after myocardial infarction\", section on 'Sinus bradycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Athletes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of well-trained endurance athletes have a sinus bradycardia at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This has traditionally been attributed to increased vagal tone induced by exercise conditioning. However, studies in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    are given to block the parasympathetic and sympathetic pathways suggest that the intrinsic physiology of the sinoatrial node may be altered [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=see_link\">",
"     \"Arrhythmia in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Obstructive sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with obstructive sleep apnea frequently have sinus bradycardia that may be severe (&lt;30 beats per minute) during apneic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Therapies to improve the apnea frequently alleviate the bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/16\">",
"     16",
"    </a>",
"    ]. Although an initial small study suggested that pacing may improve indices of apnea, this finding has not been confirmed in several larger trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link&amp;anchor=H11#H11\">",
"     \"Cardiovascular effects of obstructive sleep apnea\", section on 'Cardiac arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs can depress the SA node and slow the heart rate. These include parasympathomimetic agents, sympatholytic drugs (beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"     reserpine",
"    </a>",
"    , guanethidine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , digitalis, calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and other antiarrhythmic drugs, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of sinus bradycardia include hypothyroidism, hypothermia, and severe prolonged hypoxia (",
"    <a class=\"graphic graphic_table graphicRef65521 \" href=\"UTD.htm?11/49/12061\">",
"     table 2",
"    </a>",
"    ). Infectious agents associated with relative sinus bradycardia include Chagas' disease, legionella, psittacosis, Q fever, typhoid fever, typhus, babesiosis, malaria, leptospirosis, yellow fever, dengue fever, viral hemorrhagic fevers, trichinosis, and Rocky Mountain Spotted fever [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus bradycardia is usually asymptomatic. However, symptoms related to the slow heart rate can occur, including lightheadedness, presyncope or syncope, and worsening of angina pectoris or heart failure. Symptoms may be subtle, with many patients noting only fatigue, which is frequently ascribed to aging rather than bradycardia.",
"   </p>",
"   <p>",
"    The diseased SA node often does not respond appropriately to exercise (chronotropic incompetence), and fatigue or dyspnea on exertion may be the presenting feature. A slow heart rate also may allow the appearance of supraventricular and ventricular extrasystoles or even arrhythmias that would normally be suppressed at a more rapid rate. In the tachycardia-bradycardia syndrome, for example, periods of sinus bradycardia alternate with paroxysms of atrial fibrillation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    flutter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus bradycardia is an electrocardiographic diagnosis (",
"    <a class=\"graphic graphic_waveform graphicRef52675 \" href=\"UTD.htm?25/56/26501\">",
"     waveform 1",
"    </a>",
"    ) that should be distinguished from other bradyarrhythmias (",
"    <a class=\"graphic graphic_table graphicRef50037 \" href=\"UTD.htm?5/12/5323\">",
"     table 3",
"    </a>",
"    ). Ambulatory ECG monitoring is often helpful to correlate symptoms with heart rate or other abnormalities, such as those that occur in the sick sinus syndrome. Noninvasive and invasive tests of autonomic tone are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is",
"    <strong>",
"     not",
"    </strong>",
"    indicated in asymptomatic patients with sinus bradycardia. The following approach should be followed when symptoms occur.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Search for a medication that may be depressing sinus node function. As an example, a beta blocker, nondihydropyridine calcium channel blocker, or sympathetic blocker can be replaced in hypertensive patients with drugs that do not affect SA node function, such as an angiotensin converting enzyme inhibitor. Sympatholytic agents should not be discontinued abruptly, since a withdrawal syndrome may be seen characterized by severe hypertension and, with abrupt beta blocker withdrawal, the precipitation of angina. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1827?source=see_link\">",
"       \"Withdrawal syndromes with antihypertensive therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacologic therapy may be important in an acute myocardial infarction when the SA node is depressed by excessive parasympathomimetic activity or possibly ischemia. In this setting, the SA node rate generally increases after the administration of a vagolytic drug, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/21\">",
"       21",
"      </a>",
"      ]. Temporary pacing is rarely necessary.",
"     </li>",
"     <li>",
"      Long-term pharmacologic therapy is largely ineffective in chronic sinus bradycardia.",
"     </li>",
"     <li>",
"      Temporary or permanent electrical pacing may be required in acute or chronic symptomatic sinus bradycardia. We are generally in agreement with the 2008 American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart",
"      <span class=\"nowrap\">",
"       Association/Heart",
"      </span>",
"      Rhythm Society",
"      <span class=\"nowrap\">",
"       (ACC/AHA/HRS)",
"      </span>",
"      device guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3878/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"       \"Indications for permanent cardiac pacing\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of pacemaker varies with the clinical setting: an atrial pacemaker may be used if there are no other associated supraventricular arrhythmias or AV nodal conduction disturbances; more commonly, however, a dual chamber pacemaker is employed (",
"    <a class=\"graphic graphic_algorithm graphicRef77929 \" href=\"UTD.htm?11/60/12239\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=see_link\">",
"       \"Patient information: Bradycardia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4453165\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus bradycardia, most commonly defined as sinus rhythm with a rate below 60 beats per minute (",
"      <a class=\"graphic graphic_waveform graphicRef52675 \" href=\"UTD.htm?25/56/26501\">",
"       waveform 1",
"      </a>",
"      ), occurs in normal children and adults, particularly during sleep or at rest, in well-conditioned athletes, and in some elderly patients. There is no adverse prognostic significance to asymptomatic sinus bradycardia in otherwise healthy subjects. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sinus bradycardia in the normal heart'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sinus bradycardia can be seen in a variety of pathophysiologic settings (",
"      <a class=\"graphic graphic_table graphicRef65521 \" href=\"UTD.htm?11/49/12061\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sinus bradycardia may be the first manifestation of sinoatrial (SA) node dysfunction and the sick sinus syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"       \"Manifestations and causes of the sick sinus syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vasovagal responses may be associated with a profound bradycardia due to heightened parasympathetic activity and sympathetic withdrawal on the SA node. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Exaggerated vagal activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sinus bradycardia occurs in 15 to 25 percent of patients with acute myocardial infarction, particularly those affecting the inferior wall since the right coronary artery supplies the SA node in approximately 60 percent of people. Increased vagal activity is primarily responsible, and the bradycardia is typically transient. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute myocardial infarction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of drugs can depress the SA node and slow the heart rate. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus bradycardia is usually asymptomatic. However, symptoms related to the slow heart rate can occur, including fatigue, lightheadedness, presyncope or syncope, and worsening of angina pectoris or heart failure. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is",
"      <strong>",
"       not",
"      </strong>",
"      indicated in asymptomatic patients with sinus bradycardia. If symptoms are present that are felt to be related to the bradycardia, any potential offending medications should be withdrawn. If symptoms persist, temporary or permanent electrical pacing may be required. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/1\">",
"      Spodick DH. Normal sinus heart rate: sinus tachycardia and sinus bradycardia redefined. Am Heart J 1992; 124:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/2\">",
"      Spodick DH, Raju P, Bishop RL, Rifkin RD. Operational definition of normal sinus heart rate. Am J Cardiol 1992; 69:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/3\">",
"      Scott O, Williams GJ, Fiddler GI. Results of 24 hour ambulatory monitoring of electrocardiogram in 131 healthy boys aged 10 to 13 years. Br Heart J 1980; 44:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/4\">",
"      Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol 1977; 39:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/5\">",
"      Bjerregaard P. Mean 24 hour heart rate, minimal heart rate and pauses in healthy subjects 40-79 years of age. Eur Heart J 1983; 4:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/6\">",
"      Hilgard J, Ezri MD, Denes P. Significance of ventricular pauses of three seconds or more detected on twenty-four-hour Holter recordings. Am J Cardiol 1985; 55:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/7\">",
"      HISS RG, LAMB LE, ALLEN MF. Electrocardiographic findings in 67,375 asymptomatic subjects. X. Normal values. Am J Cardiol 1960; 6:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/8\">",
"      Talan DA, Bauernfeind RA, Ashley WW, et al. Twenty-four hour continuous ECG recordings in long-distance runners. Chest 1982; 82:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/9\">",
"      Abdon NJ, Landin K, Johansson BW. Athlete's bradycardia as an embolising disorder? Symptomatic arrhythmias in patients aged less than 50 years. Br Heart J 1984; 52:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/10\">",
"      Agruss NS, Rosin EY, Adolph RJ, Fowler NO. Significance of chronic sinus bradycardia in elderly people. Circulation 1972; 46:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/11\">",
"      Milanesi R, Baruscotti M, Gnecchi-Ruscone T, DiFrancesco D. Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel. N Engl J Med 2006; 354:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/12\">",
"      Tresch DD, Fleg JL. Unexplained sinus bradycardia: clinical significance and long-term prognosis in apparently healthy persons older than 40 years. Am J Cardiol 1986; 58:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/13\">",
"      Alpert MA, Flaker GC. Arrhythmias associated with sinus node dysfunction. Pathogenesis, recognition, and management. JAMA 1983; 250:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/14\">",
"      Eraut D, Shaw DB. Sinus bradycardia. Br Heart J 1971; 33:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/15\">",
"      Stein R, Medeiros CM, Rosito GA, et al. Intrinsic sinus and atrioventricular node electrophysiologic adaptations in endurance athletes. J Am Coll Cardiol 2002; 39:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/16\">",
"      Tilkian AG, Guilleminault C, Schroeder JS, et al. Sleep-induced apnea syndrome. Prevalence of cardiac arrhythmias and their reversal after tracheostomy. Am J Med 1977; 63:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/17\">",
"      Miller WP. Cardiac arrhythmias and conduction disturbances in the sleep apnea syndrome. Prevalence and significance. Am J Med 1982; 73:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/18\">",
"      Zwillich C, Devlin T, White D, et al. Bradycardia during sleep apnea. Characteristics and mechanism. J Clin Invest 1982; 69:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/19\">",
"      Cunha BA. The diagnostic significance of relative bradycardia in infectious disease. Clin Microbiol Infect 2000; 6:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/20\">",
"      Puljiz I, Beus A, Kuzman I, Seiwerth S. Electrocardiographic changes and myocarditis in trichinellosis: a retrospective study of 154 patients. Ann Trop Med Parasitol 2005; 99:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/21\">",
"      Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction. N Engl J Med 2003; 348:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3878/abstract/22\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1075 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-42E0F5FCD1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3878=[""].join("\n");
var outline_f3_50_3878=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4453165\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SINUS BRADYCARDIA IN THE NORMAL HEART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGIC SINUS BRADYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Exaggerated vagal activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Increased intracranial pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Athletes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4453165\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1075\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1075|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/60/12239\" title=\"algorithm 1\">",
"      Pacemaker algorithm sinus node dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1075|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/10/38059\" title=\"table 1\">",
"      Normal heart rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/49/12061\" title=\"table 2\">",
"      Causes of bradycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/12/5323\" title=\"table 3\">",
"      Etiologies of bradyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1075|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?25/56/26501\" title=\"waveform 1\">",
"      ECG strip sinus bradycardia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2086?source=related_link\">",
"      Normal sinus rhythm and sinus arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=related_link\">",
"      Patient information: Bradycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=related_link\">",
"      Supraventricular arrhythmias after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=related_link\">",
"      Treatment of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1827?source=related_link\">",
"      Withdrawal syndromes with antihypertensive therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_50_3879="Basic case 3";
var content_f3_50_3879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1121px;\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Basic case 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 90px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3879=[""].join("\n");
var outline_f3_50_3879=null;
var title_f3_50_3880="Causes of secondary and tertiary adrenal insufficiency in adults";
var content_f3_50_3880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of secondary and tertiary adrenal insufficiency in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/50/3880/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3880/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/50/3880/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3880/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/50/3880/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3880/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/50/3880/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal insufficiency can be caused by diseases of the adrenal gland (primary), interference with corticotropin (ACTH) secretion by the pituitary gland (secondary), or interference with corticotropin-releasing hormone (CRH) secretion by the hypothalamus (tertiary). This topic will review the major causes of the latter two disorders; the causes of primary adrenal insufficiency and the clinical manifestations and approach to diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SECONDARY ADRENAL INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any process that involves the pituitary and interferes with ACTH secretion can cause secondary adrenal insufficiency. The ACTH deficiency may be isolated or occur in conjunction with other pituitary hormone deficiencies (panhypopituitarism).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Panhypopituitarism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any disease that affects the pituitary gland can result in diminished secretion of one or more pituitary hormones. Pituitary tissue can be destroyed and hormone secretion reduced by large pituitary tumors or craniopharyngiomas, infectious diseases such as tuberculosis or histoplasmosis, infiltrative diseases, lymphocytic hypophysitis, head trauma, and large intracranial artery aneurysms (",
"    <a class=\"graphic graphic_table graphicRef55951 \" href=\"UTD.htm?18/8/18571\">",
"     table 1",
"    </a>",
"    ). Pituitary infarction can occur at the time of delivery if excessive blood is lost and hypotension occurs (Sheehan's syndrome), and hemorrhage may occur into a pituitary tumor (pituitary apoplexy). Pituitary metastases are frequently (about 5 percent) found in patients with disseminated cancer at autopsy; however, these metastases rarely reduce hormone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"     \"Causes of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ACTH deficiency due to genetic pituitary abnormalities is rare. ACTH and cortisol deficiency have been described in patients with multiple pituitary hormone deficiencies due to mutations in the PROP-1 (Prophet of Pit-1) gene, even though PROP-1 is not expressed in corticotropes. The onset of cortisol deficiency, which may be severe, ranges from childhood to late adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Mutations in other transcription factors involved in early pituitary development (HESX1, LHX4) also can result in variable degrees of hypopituitarism that include ACTH deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link&amp;anchor=H13#H13\">",
"     \"Causes of hypopituitarism\", section on 'Genetic diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Isolated ACTH deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated ACTH deficiency is a rare disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/8\">",
"     8",
"    </a>",
"    ]. The defect is probably at the pituitary level because there is no ACTH secretory response to CRH or vasopressin, as there usually is in hypothalamic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Occasional patients may have hypothyroxinemia and hyperprolactinemia that are corrected with glucocorticoid replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346127370\">",
"    <span class=\"h3\">",
"     Autoimmune",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations suggest that most cases are caused by an autoimmune process:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Frequent association with other autoimmune endocrine disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The presence of lymphocytic hypophysitis with selective corticotroph absence in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The presence of antipituitary antibodies in the serum of 10 of 21 patients in one report [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/15\">",
"       15",
"      </a>",
"      ], and the presence of anticorticotroph antibodies in the serum of at least one patient [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A novel syndrome, referred to as triple H syndrome, of isolated ACTH deficiency and alopecia areata has been described in two women and one man [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. One woman also had vitiligo and anterograde memory loss, and an MR scan revealed hippocampal atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/17\">",
"     17",
"    </a>",
"    ]. A skin biopsy from the male patient showed lymphocytic invasion surrounding the hair follicles [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/18\">",
"     18",
"    </a>",
"    ]. The authors postulated an autoimmune target molecule shared among the hypothalamus (or pituitary corticotrophs), hair follicles, and hippocampus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346127377\">",
"    <span class=\"h3\">",
"     Genetic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three extremely rare genetic conditions can cause isolated ACTH deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346127458\">",
"    <span class=\"h4\">",
"     Mutations in the POMC gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;A syndrome of early onset obesity and secondary adrenal insufficiency has been described in seven patients with homozygous or compound heterozygous loss-of-function mutations in the proopiomelanocortin (POMC) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Their heterozygote relatives were unaffected, indicating a recessive mode of inheritance.",
"   </p>",
"   <p>",
"    This syndrome has been reproduced in homozygous POMC gene knockout mice [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/21\">",
"     21",
"    </a>",
"    ]. Daily intraperitoneal injection of alpha-MSH resulted in decreased food consumption, loss of weight, and darkening of coat color that reversed when the alpha-MSH was stopped. These results suggest that obesity in humans with POMC gene defects and possibly other causes of obesity may be treated with agonists specific for the brain melanocortin-4 receptor.",
"   </p>",
"   <p>",
"    Several POMC mutations and polymorphisms have also been detected in 96 extremely obese children and adolescents, 60 healthy underweight subjects, and 46 patients with anorexia nervosa, none of which was regularly associated with a particular phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346127466\">",
"    <span class=\"h4\">",
"     Cleavage enzyme defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another cause of isolated ACTH deficiency is a congenital defect leading to impaired function of pro-hormone convertase 1 (PC1), which cleaves ACTH from POMC [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346127473\">",
"    <span class=\"h4\">",
"     TPIT gene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;TPIT is a transcription factor necessary for differentiation of the corticotroph cell and POMC production; TPIT gene mutations may be the most common genetic cause of neonatal isolated ACTH deficiency (IAD). In one report of 27 neonates with IAD, homozygous or compound heterozygous mutations in the coding region of the TPIT gene were found in 17 of 27 neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/24\">",
"     24",
"    </a>",
"    ]. All parents of the neonates with TPIT mutations were unaffected carriers, confirming a recessive mode of inheritance. Although IAD due to TPIT mutations is a rare disorder, prenatal diagnosis for families at risk would be beneficial, as neonatal IAD from any cause, if not diagnosed and treated early, can result in death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Familial cortisol-binding globulin (CBG, transcortin) deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;This rare syndrome is caused by point mutations that reduce the affinity of CBG for cortisol (CBG Leuven and CBG Lyon) or null mutations that result in complete CBG deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/25\">",
"     25",
"    </a>",
"    ]. Some patients who are homozygous for these mutations have chronic fatigue and relative hypotension and may meet criteria for chronic fatigue syndrome, and others have chronic pain resembling fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/25\">",
"     25",
"    </a>",
"    ], while others had fatigue but normal blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/26\">",
"     26",
"    </a>",
"    ]. Their morning serum cortisol concentrations are less than 1.8",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    Serum free cortisol, 24-hour urinary free cortisol, and plasma ACTH concentrations are normal. Low serum cortisol and normal plasma ACTH concentrations may lead to misdiagnosis of isolated ACTH deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Traumatic brain injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although traumatic brain injury most often causes growth hormone",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gonadotropin deficiency, ACTH deficiency occurred in 8 percent of 611 patients in one meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/27\">",
"     27",
"    </a>",
"    ]. Although traumatic brain injury is most often suspected after automobile accidents or falls, some studies demonstrate that injuries sustained during boxing and soccer may cause hypopituitarism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This topic is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link&amp;anchor=H20#H20\">",
"     \"Causes of hypopituitarism\", section on 'Traumatic brain injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H290041754\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H290041761\">",
"    <span class=\"h3\">",
"     High dose progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     Megestrol acetate",
"    </a>",
"    is used to treat patients with metastatic breast cancer and to increase appetite in patients with cancer",
"    <span class=\"nowrap\">",
"     anorexia/cachexia,",
"    </span>",
"    and wasting diseases such as AIDS.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     Medroxyprogesterone acetate",
"    </a>",
"    has been administered to sex offenders [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/30\">",
"     30",
"    </a>",
"    ] and for the treatment of breast cancer. These progestins have some glucocorticoid activity via binding to the glucocorticoid receptor. As a result, they may present with Cushingoid features and their withdrawal can occasionally cause secondary adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. This has been reported with doses greater than 300 mg daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=see_link&amp;anchor=H4#H4\">",
"     \"Pharmacologic management of cancer anorexia/cachexia\", section on 'Progesterone analogs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42584?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of tissue wasting in patients with HIV infection\", section on 'Megestrol acetate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"     \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link&amp;anchor=H34056261#H34056261\">",
"     \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\", section on 'Progestins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adrenal insufficiency may also occur",
"    <strong>",
"     during",
"    </strong>",
"    megestrol therapy, presenting with symptoms such as fatigue and weakness, and manifested by a poor response to ACTH stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/35\">",
"     35",
"    </a>",
"    ]. A decreased response to ACTH stimulation in a patient receiving a drug with glucocorticoid activity is to be expected. However, the mechanism of possible adrenal insufficiency is unclear. Possible explanations include: inadvertent or unreported patient discontinuation of megestrol, unmasking of secondary adrenal insufficiency (suppression of the hypothalamic-pituitary-adrenal axis) by intercurrent stress, and mixed agonist-antagonist properties [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the mechanism, clinicians should be alert to the possibility of hypothalamic-pituitary-adrenal suppression or drug-induced Cushing&rsquo;s syndrome in patients who receive chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    or other high dose progestins and of secondary adrenal insufficiency in those who discontinue the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H290041768\">",
"    <span class=\"h3\">",
"     Opiates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic opiate administration is associated with pronounced secondary hypogonadism in both men and women. Opiates may also suppress the hypothalamic-pituitary-adrenal axis, but data are limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link&amp;anchor=H21#H21\">",
"     \"Causes of secondary hypogonadism in males\", section on 'Continuous opiate administration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    decreases afternoon cortisol secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/36\">",
"     36",
"    </a>",
"    ], and the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    anesthesia blocks the usual increase in cortisol levels during surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/37\">",
"     37",
"    </a>",
"    ]. However, the use of epidural morphine did not suppress the increase in cytokines and cortisol seen in the postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic administration of opiates has the potential to cause secondary adrenal insufficiency, as evidenced by case reports involving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Other studies suggest that chronic opiate use disrupts the normal circadian rhythm of cortisol secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/42\">",
"     42",
"    </a>",
"    ], blunts the cortisol response to exogenous ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/43\">",
"     43",
"    </a>",
"    ], and may result in central adrenal insufficiency in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TERTIARY ADRENAL INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of tertiary adrenal insufficiency are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abrupt cessation of high-dose glucocorticoid therapy",
"     </li>",
"     <li>",
"      Correction (cure) of hypercortisolism (Cushing's syndrome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic high-dose glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppression of hypothalamic-pituitary-adrenal function by chronic administration of high doses of glucocorticoids is the most common cause of tertiary adrenal insufficiency. Glucocorticoids may induce adrenal insufficiency, even if given in a dose that normally would not suppress the axis, if their metabolism is reduced by a drug interaction. This can occur, for example, when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    are both given [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High doses of glucocorticoids decrease hypothalamic CRH synthesis and secretion. They also block the trophic and ACTH-secretagogue actions of CRH on the anterior pituitary. This results in decreased synthesis of POMC and decreased secretion of ACTH and other POMC-derived peptides by the pituitary corticotrophs. As a result, pituitary corticotrophs decrease in size, and eventually, the number of identifiable corticotrophs decreases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of ACTH stimulation, the zona fasciculata and zona reticularis of the adrenal atrophy and can no longer produce cortisol. Clinical features of secondary and tertiary adrenal insufficiency that help distinguish them from primary adrenal insufficiency include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cortisol production can be restored by prolonged ACTH administration.",
"     </li>",
"     <li>",
"      Mineralocorticoid secretion is nearly normal because this function depends mostly on the renin-angiotensin system rather than on ACTH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=see_link\">",
"       \"Chapter 6C: Aldosterone\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link\">",
"       \"Evaluation of the response to ACTH in adrenal insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A thorough history regarding medications, creams, and supplements should be obtained in every patient with apparent secondary or tertiary adrenal insufficiency. Glucocorticoids may be taken via the oral, ocular, inhaled, transdermal, rectal or parenteral routes, all of which should be considered. Additionally, these compounds may be present in bleaching creams and herbal preparations and may not be reported as a \"medication\" unless specifically queried [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/47\">",
"     47",
"    </a>",
"    ]. Finally, patients should be asked about any recent therapeutic injections (ie, joint, spine) as many patients are unaware that these contain glucocorticoids. Measurement of exogenous steroids in urine may help to establish the cause and estimate time to recovery if the Cushing&rsquo;s syndrome has occurred as a result of a synthetic glucocorticoid injection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     After the cure of Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tertiary adrenal insufficiency also occurs in patients who are cured of Cushing's syndrome by removal of a pituitary or nonpituitary ACTH-secreting or a cortisol-secreting adrenal tumor. The chronically high serum cortisol concentrations before treatment suppress the hypothalamic-pituitary-adrenal axis in the same manner as chronic administration of high doses of glucocorticoids.",
"   </p>",
"   <p>",
"    For example, patients who achieve remission after transsphenoidal surgery for ACTH-secreting pituitary tumors are typically hypocortisolemic for up to 12 months post-operatively and require glucocorticoid replacement therapy, which must be supplemented during stress. This issue is discussed in detail separately.",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\", section on 'Preoperative glucocorticoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any process that involves the hypothalamus and interferes with CRH secretion will result in tertiary adrenal insufficiency. Such processes include: tumors, infiltrative diseases such as sarcoidosis, and cranial radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link&amp;anchor=H15#H15\">",
"     \"Causes of hypopituitarism\", section on 'Hypothalamic diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rare cause is isolated CRH deficiency in the absence of other apparent disease; the diagnosis is suggested by a poor response of ACTH during an insulin tolerance test but a good response to CRH [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the features of Prader-Willi syndrome is hypothalamic dysfunction, resulting in growth hormone and gonadotropin hormone deficiencies. In addition, some of these patients may also have partial adrenal insufficiency. Because of the high annual death rate in Prader Willi syndrome, and the theoretical possibility of ACTH deficiency, adrenal function was investigated using the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    stimulation test in 25 children with genetically-confirmed Prader-Willi syndrome. Of these, 15 failed to show a normal ACTH response, and 7 of 11 in whom 11-deoxycortisol levels were measured had an abnormal response, suggesting partial adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/51\">",
"     51",
"    </a>",
"    ]. However, one study of 57 patients found normal adrenal function in all 57 patients using the 250 mcg ACTH test",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an insulin tolerance test [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3880/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H290042235\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal insufficiency can be caused by diseases of the adrenal gland (primary), interference with corticotropin (ACTH) secretion by the pituitary gland (secondary), or interference with corticotropin-releasing hormone (CRH) secretion by the hypothalamus (tertiary).",
"   </p>",
"   <p>",
"    <strong>",
"     Secondary adrenal insufficiency",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any process that involves the pituitary and interferes with ACTH secretion can cause secondary adrenal insufficiency. The ACTH deficiency may be isolated or occur in conjunction with other pituitary hormone deficiencies (panhypopituitarism) (",
"      <a class=\"graphic graphic_table graphicRef55951 \" href=\"UTD.htm?18/8/18571\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Secondary adrenal insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated ACTH deficiency is a rare disorder. Some cases are thought to be due to an autoimmune process (see",
"      <a class=\"local\" href=\"#H346127370\">",
"       'Autoimmune'",
"      </a>",
"      above). Genetic causes include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Loss-of-function mutations in the proopiomelanocortin (POMC) gene resulting in a syndrome of early-onset obesity and secondary adrenal insufficiency (see",
"      <a class=\"local\" href=\"#H346127458\">",
"       'Mutations in the POMC gene'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      ACTH deficiency due to a defect in the enzyme that cleaves ACTH from POMC (see",
"      <a class=\"local\" href=\"#H346127466\">",
"       'Cleavage enzyme defect'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      TPIT gene mutations resulting in neonatal isolated ACTH deficiency (see",
"      <a class=\"local\" href=\"#H346127473\">",
"       'TPIT gene mutations'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other causes of secondary adrenal insufficiency include familial cortisol-binding globulin deficiency, traumatic brain injury, and drugs (chronic use of high dose progestins and opiates). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Familial cortisol-binding globulin (CBG, transcortin) deficiency'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Traumatic brain injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H290041754\">",
"       'Drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Tertiary adrenal insufficiency",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suppression of hypothalamic-pituitary-adrenal function by chronic administration of high doses of glucocorticoids is the most common cause of tertiary adrenal insufficiency. Clinical features of secondary and tertiary adrenal insufficiency that help distinguish them from primary adrenal insufficiency include: cortisol production can be restored by prolonged ACTH administration, and mineralocorticoid secretion is nearly normal, because this function depends mostly on the renin-angiotensin system rather than on ACTH.",
"     </li>",
"     <li>",
"      Tertiary adrenal insufficiency also occurs in patients who are cured of Cushing's syndrome by removal of a pituitary or nonpituitary ACTH-secreting or a cortisol-secreting adrenal tumor. The chronically high serum cortisol concentrations before treatment suppress the hypothalamic-pituitary-adrenal axis in the same manner as chronic administration of high doses of glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/1\">",
"      Modhi, G, Bauman, W, Nicolis, G. Adrenal failure associated with hypothalamic and adrenal metastases. Cancer 1981; 47:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/2\">",
"      Pernasetti F, Toledo SP, Vasilyev VV, et al. Impaired adrenocorticotropin-adrenal axis in combined pituitary hormone deficiency caused by a two-base pair deletion (301-302delAG) in the prophet of Pit-1 gene. J Clin Endocrinol Metab 2000; 85:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/3\">",
"      Agarwal G, Bhatia V, Cook S, Thomas PQ. Adrenocorticotropin deficiency in combined pituitary hormone deficiency patients homozygous for a novel PROP1 deletion. J Clin Endocrinol Metab 2000; 85:4556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/4\">",
"      Parks JS, Brown MR, Hurley DL, et al. Heritable disorders of pituitary development. J Clin Endocrinol Metab 1999; 84:4362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/5\">",
"      B&ouml;ttner A, Keller E, Kratzsch J, et al. PROP1 mutations cause progressive deterioration of anterior pituitary function including adrenal insufficiency: a longitudinal analysis. J Clin Endocrinol Metab 2004; 89:5256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/6\">",
"      Machinis K, Pantel J, Netchine I, et al. Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4. Am J Hum Genet 2001; 69:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/7\">",
"      Tajima T, Hattorri T, Nakajima T, et al. Sporadic heterozygous frameshift mutation of HESX1 causing pituitary and optic nerve hypoplasia and combined pituitary hormone deficiency in a Japanese patient. J Clin Endocrinol Metab 2003; 88:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/8\">",
"      Stacpoole PW, Interlandi JW, Nicholson WE, Rabin D. Isolated ACTH deficiency: a heterogeneous disorder. Critical review and report of four new cases. Medicine (Baltimore) 1982; 61:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/9\">",
"      Yoshida T, Arai T, Sugano J, et al. Isolated ACTH deficiency accompanied by 'primary hypothyroidism' and hyperprolactinaemia. Acta Endocrinol (Copenh) 1983; 104:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/10\">",
"      Koide Y, Kimura S, Inoue S, et al. Responsiveness of hypophyseal-adrenocortical axis to repetitive administration of synthetic ovine corticotropin-releasing hormone in patients with isolated adrenocorticotropin deficiency. J Clin Endocrinol Metab 1986; 63:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/11\">",
"      Cantalamessa L, Catania A, Baldini M, et al. CRH and lysine-vasopressin stimulation tests in the diagnosis of hypoadrenalism secondary to hypothalamic or pituitary disorders. Horm Metab Res 1990; 22:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/12\">",
"      Kanemaru Y, Noguchi T, Onaya T. Isolated ACTH deficiency associated with transient thyrotoxicosis and hyperprolactinemia. Endocrinol Jpn 1989; 36:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/13\">",
"      Shigemasa C, Kouchi T, Ueta Y, et al. Evaluation of thyroid function in patients with isolated adrenocorticotropin deficiency. Am J Med Sci 1992; 304:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/14\">",
"      Jensen MD, Handwerger BS, Scheithauer BW, et al. Lymphocytic hypophysitis with isolated corticotropin deficiency. Ann Intern Med 1986; 105:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/15\">",
"      Sugiura M, Hashimoto A, Shizawa M, et al. Heterogeneity of anterior pituitary cell antibodies detected in insulin-dependent diabetes mellitus and adrenocorticotropic hormone deficiency. Diabetes Res 1986; 3:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/16\">",
"      Sauter NP, Toni R, McLaughlin CD, et al. Isolated adrenocorticotropin deficiency associated with an autoantibody to a corticotroph antigen that is not adrenocorticotropin or other proopiomelanocortin-derived peptides. J Clin Endocrinol Metab 1990; 70:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/17\">",
"      Farooqi IS, Jones MK, Evans M, et al. Triple H syndrome: a novel autoimmune endocrinopathy characterized by dysfunction of the hippocampus, hair follicle, and hypothalamic-pituitary adrenal axis. J Clin Endocrinol Metab 2000; 85:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/18\">",
"      Ichiki K, Nakamura T, Fujita N, et al. An endocrinopathy characterized by dysfunction of the pituitary-adrenal axis and alopecia universalis: supporting the entity of a triple H syndrome. Eur J Endocrinol 2002; 147:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/19\">",
"      Krude H, Biebermann H, Luck W, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998; 19:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/20\">",
"      Cl&eacute;ment K, Dubern B, Mencarelli M, et al. Unexpected endocrine features and normal pigmentation in a young adult patient carrying a novel homozygous mutation in the POMC gene. J Clin Endocrinol Metab 2008; 93:4955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/21\">",
"      Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 1999; 5:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/22\">",
"      Hinney A, Becker I, Heib&uuml;lt O, et al. Systematic mutation screening of the pro-opiomelanocortin gene: identification of several genetic variants including three different insertions, one nonsense and two missense point mutations in probands of different weight extremes. J Clin Endocrinol Metab 1998; 83:3737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/23\">",
"      Nussey SS, Soo SC, Gibson S, et al. Isolated congenital ACTH deficiency: a cleavage enzyme defect? Clin Endocrinol (Oxf) 1993; 39:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/24\">",
"      Vallette-Kasic S, Brue T, Pulichino AM, et al. Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations. J Clin Endocrinol Metab 2005; 90:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/25\">",
"      Torpy DJ, Bachmann AW, Grice JE, et al. Familial corticosteroid-binding globulin deficiency due to a novel null mutation: association with fatigue and relative hypotension. J Clin Endocrinol Metab 2001; 86:3692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/26\">",
"      Brunner E, Baima J, Vieira TC, et al. Hereditary corticosteroid-binding globulin deficiency due to a missense mutation (Asp367Asn, CBG Lyon) in a Brazilian kindred. Clin Endocrinol (Oxf) 2003; 58:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/27\">",
"      Bavisetty S, Bavisetty S, McArthur DL, et al. Chronic hypopituitarism after traumatic brain injury: risk assessment and relationship to outcome. Neurosurgery 2008; 62:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/28\">",
"      Tanriverdi F, Unluhizarci K, Kocyigit I, et al. Brief communication: pituitary volume and function in competing and retired male boxers. Ann Intern Med 2008; 148:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/29\">",
"      Ives JC, Alderman M, Stred SE. Hypopituitarism after multiple concussions: a retrospective case study in an adolescent male. J Athl Train 2007; 42:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/30\">",
"      Krueger RB, Hembree W, Hill M. Prescription of medroxyprogesterone acetate to a patient with pedophilia, resulting in Cushing's syndrome and adrenal insufficiency. Sex Abuse 2006; 18:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/31\">",
"      Mann M, Koller E, Murgo A, et al. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997; 157:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/32\">",
"      Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995; 122:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/33\">",
"      Malik KJ, Wakelin K, Dean S, et al. Cushing's syndrome and hypothalamic-pituitary adrenal axis suppression induced by medroxyprogesterone acetate. Ann Clin Biochem 1996; 33 ( Pt 3):187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/34\">",
"      Dux S, Bishara J, Marom D, et al. Medroxyprogesterone acetate-induced secondary adrenal insufficiency. Ann Pharmacother 1998; 32:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/35\">",
"      Subramanian S, Goker H, Kanji A, Sweeney H. Clinical adrenal insufficiency in patients receiving megestrol therapy. Arch Intern Med 1997; 157:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/36\">",
"      Garland EJ, Zis AP. Effect of codeine and oxazepam on afternoon cortisol secretion in men. Psychoneuroendocrinology 1989; 14:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/37\">",
"      George JM, Reier CE, Lanese RR, Rower M. Morphine anesthesia blocks cortisol and growth hormone response to surgical stress in humans. J Clin Endocrinol Metab 1974; 38:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/38\">",
"      Norman JG, Fink GW. The effects of epidural anesthesia on the neuroendocrine response to major surgical stress: a randomized prospective trial. Am Surg 1997; 63:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/39\">",
"      M&uuml;ssig K, Knaus-Dittmann D, Schmidt H, et al. Secondary adrenal failure and secondary amenorrhoea following hydromorphone treatment. Clin Endocrinol (Oxf) 2007; 66:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/40\">",
"      Oltmanns KM, Fehm HL, Peters A. Chronic fentanyl application induces adrenocortical insufficiency. J Intern Med 2005; 257:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/41\">",
"      Schimke KE, Greminger P, Br&auml;ndle M. Secondary adrenal insufficiency due to opiate therapy - another differential diagnosis worth consideration. Exp Clin Endocrinol Diabetes 2009; 117:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/42\">",
"      Facchinetti F, Volpe A, Farci G, et al. Hypothalamus-pituitary-adrenal axis of heroin addicts. Drug Alcohol Depend 1985; 15:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/43\">",
"      Dackis CA, Gurpegui M, Pottash AL, Gold MS. Methadone induced hypoadrenalism. Lancet 1982; 2:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/44\">",
"      Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000; 85:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/45\">",
"      Molimard M, Girodet PO, Pollet C, et al. Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation. Drug Saf 2008; 31:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/46\">",
"      Phifer RF, Spicer SS, Orth DN. Specific demonstration of the human hypophyseal cells which produce adrenocorticotropic hormone. J Clin Endocrinol Metab 1970; 31:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/47\">",
"      Olumide YM, Akinkugbe AO, Altraide D, et al. Complications of chronic use of skin lightening cosmetics. Int J Dermatol 2008; 47:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/48\">",
"      Lansang MC, Farmer T, Kennedy L. Diagnosing the unrecognized systemic absorption of intra-articular and epidural steroid injections. Endocr Pract 2009; 15:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/49\">",
"      Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, et al. Assessment of the hypothalamo-pituitary-adrenal axis in patients treated with radiotherapy and chemotherapy for childhood brain tumor. J Clin Endocrinol Metab 2003; 88:3149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/50\">",
"      Nishihara E, Kimura H, Ishimaru T, et al. A case of adrenal insufficiency due to acquired hypothalamic CRH deficiency. Endocr J 1997; 44:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/51\">",
"      de Lind van Wijngaarden RF, Otten BJ, Festen DA, et al. High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocrinol Metab 2008; 93:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3880/abstract/52\">",
"      Farholt S, Sode-Carlsen R, Christiansen JS, et al. Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2011; 96:E173.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 173 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3880=[""].join("\n");
var outline_f3_50_3880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H290042235\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SECONDARY ADRENAL INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Panhypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Isolated ACTH deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346127370\">",
"      - Autoimmune",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346127377\">",
"      - Genetic causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H346127458\">",
"      Mutations in the POMC gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H346127466\">",
"      Cleavage enzyme defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H346127473\">",
"      TPIT gene mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Familial cortisol-binding globulin (CBG, transcortin) deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H290041754\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H290041761\">",
"      - High dose progestins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H290041768\">",
"      - Opiates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TERTIARY ADRENAL INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic high-dose glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      After the cure of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H290042235\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/173\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/173|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/8/18571\" title=\"table 1\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42584?source=related_link\">",
"      Management of tissue wasting in patients with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=related_link\">",
"      Pharmacologic management of cancer anorexia/cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=related_link\">",
"      Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=related_link\">",
"      Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_50_3881="Protein-losing gastroenteropathy";
var content_f3_50_3881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Protein-losing gastroenteropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/50/3881/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3881/contributors\">",
"     Vladan Milovic, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3881/contributors\">",
"     Richard J Grand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/50/3881/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3881/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/50/3881/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3881/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/50/3881/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein-losing gastroenteropathies are characterized by an excessive loss of serum proteins into the gastrointestinal tract, resulting in hypoproteinemia (detected as hypoalbuminemia), edema, and, in some cases, pleural and pericardial effusions. The diagnosis of protein-losing gastroenteropathy should be considered in patients with hypoproteinemia in whom other causes, such as malnutrition, heavy proteinuria, and impaired protein synthesis due to liver diseases have been excluded.",
"   </p>",
"   <p>",
"    This topic will review the pathogenesis, clinical manifestations, diagnosis and treatment of protein-losing gastroenteropathy. Other causes of hypoalbuminemia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features and diagnosis of malabsorption\", section on 'Protein malabsorption'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41765?source=see_link&amp;anchor=H4#H4\">",
"     \"Mechanisms of nutrient absorption and malabsorption\", section on 'Protein absorption'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=see_link\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=see_link&amp;anchor=H3#H3\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\", section on 'Albumin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal gastrointestinal tract does not contribute significantly to the catabolism of plasma proteins, accounting for only about 10 percent of the normal turnover of albumin and gamma globulin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/1\">",
"     1",
"    </a>",
"    ]. Once plasma proteins pass into the gastrointestinal tract, they are degraded rapidly to amino acids and reabsorbed into the portal circulation.",
"   </p>",
"   <p>",
"    Protein-losing gastroenteropathies can be caused by a diverse group of disorders (",
"    <a class=\"graphic graphic_table graphicRef53419 \" href=\"UTD.htm?39/37/40541\">",
"     table 1",
"    </a>",
"    ). The increase in intestinal leakage of plasma proteins occurs via one of two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mucosal injury with or without",
"      <span class=\"nowrap\">",
"       erosions/ulcerations,",
"      </span>",
"      as in inflammatory bowel disease (IBD) and celiac disease.",
"     </li>",
"     <li>",
"      Increased lymphatic pressure in the gut due to granulomatous or neoplastic involvement of the lymphatic system or after dilated lymph vessels leak protein via the surface epithelium into the gut. The latter mechanism can occur in intestinal lymphangiectasia, congenital abnormalities of the lymphatic system, or disorders of venous stasis such as congestive heart failure or constrictive pericarditis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathophysiology of protein loss in protein-losing gastroenteropathy is different from that in glomerular diseases. In glomerulopathies, protein loss is determined by molecular weight and charge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .) By contrast, the leakage of individual serum proteins in patients with protein-losing gastroenteropathy is independent of molecular weight. Other serum components (eg, iron, lipids, trace elements) also may be lost in the gut.",
"   </p>",
"   <p>",
"    Hypoproteinemia will occur if the extent of net enteral protein loss is greater than the capacity of liver to synthesize particular proteins. Hepatic protein synthesis in patients with protein-losing gastroenteropathy is usually normal or only slightly increased. Thus, gastrointestinal protein loss will reduce the serum concentrations of proteins that have a slow catabolic rate, such as albumin and some immunoglobulins (IgA, IgG, and IgM). By contrast, there is little change in the serum concentrations of proteins with a rapid turnover rate, such as insulin and IgE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of protein-losing gastroenteropathy are highly variable and are determined in part by the underlying cause (",
"    <a class=\"graphic graphic_table graphicRef65661 \" href=\"UTD.htm?23/18/23851\">",
"     table 2",
"    </a>",
"    ). The main findings are reduced serum concentrations of albumin, gamma globulins (IgA, IgG, IgM), fibrinogen, transferrin, and ceruloplasmin. The hypoalbuminemia may lead to edema of the lower extremities due to diminished plasma oncotic pressure. Hypoproteinemia can also be associated with fat and carbohydrate malabsorption and fat-soluble vitamin deficiencies due to small bowel involvement by the primary disease.",
"   </p>",
"   <p>",
"    By comparison, the reductions of other serum proteins rarely cause clinical problems. The changes in clotting factors are not significant and there is",
"    <strong>",
"     not",
"    </strong>",
"    a propensity to recurrent infection due to the hypogammaglobulinemia. However, in patients with lymphatic obstruction and particularly congenital lymphangiectasia, loss of lymphocytes into the gut can produce significant lymphocytopenia with detectable alterations in cellular immunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DISEASES ASSOCIATED WITH MUCOSAL DAMAGE, EROSIONS, AND ULCERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of benign and malignant conditions can be associated with protein-losing gastroenteropathy via inflammatory exudation secondary to erosions and ulcerations (",
"    <a class=\"graphic graphic_table graphicRef53419 \" href=\"UTD.htm?39/37/40541\">",
"     table 1",
"    </a>",
"    ). As an example, enteral protein loss is a relatively common problem in inflammatory bowel disease (ulcerative colitis and Crohn's disease) and gastrointestinal malignancies. In addition to the overt mucosal injury, resulting in absorptive cell loss and ulcerations, both Crohn's disease and malignancy can cause lymphatic obstruction in the mesentery, leading to increased lymphatic pressure and the leakage of lymph into the gut lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protein-losing gastroenteropathy also occurs in a subset of patients with pseudomembranous colitis due to Clostridium difficile infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Such protein loss occurs only in those with diarrhea, not simply colonization with the bacterium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DISEASES ASSOCIATED WITH MUCOSAL DISEASE WITHOUT ULCERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of conditions can alter the integrity of the mucosa of the stomach, small bowel, and colon, resulting in protein leakage into the lumen (",
"    <a class=\"graphic graphic_table graphicRef53419 \" href=\"UTD.htm?39/37/40541\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein-losing gastroenteropathy in celiac disease and tropical sprue is a consequence of the loss of villous structures and surface epithelium that facilitate the diffusion of plasma proteins between the cells. Other intestinal conditions that can be associated with protein-losing gastroenteropathy include allergic gastroenteropathy, eosinophilic gastroenteritis, collagenous colitis, systemic lupus erythematosus, and carbohydrate-deficient glycoprotein syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Treatment of the underlying disease, as with corticosteroids or immunosuppressive drugs in lupus, may lead to resolution of the protein loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27530?source=see_link\">",
"     \"Lymphocytic and collagenous colitis (microscopic colitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Giant hypertrophic gastropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of proliferative, inflammatory, and infiltrative conditions are associated with large or giant mucosal folds in the stomach. One of these, M&eacute;n&eacute;trier's disease, is the most common gastric disorder associated with gastrointestinal protein loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/10\">",
"     10",
"    </a>",
"    ]. However the term M&eacute;n&eacute;trier's disease is often misused to describe any condition associated with giant gastric folds. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2984?source=see_link\">",
"     \"Large gastric folds: Hyperplastic and nonhyperplastic gastropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    M&eacute;n&eacute;trier's disease is characterized by large mucosal folds usually involving the body of the stomach (",
"    <a class=\"graphic graphic_picture graphicRef63252 \" href=\"UTD.htm?39/37/40533\">",
"     picture 1",
"    </a>",
"    ). Hyperplasia of gastric pits and superficial epithelium and replacement of normal gastric glands and parietal cells by hyperplastic glands of mucus-secreting cells are the major pathological features (",
"    <a class=\"graphic graphic_picture graphicRef76093 \" href=\"UTD.htm?38/53/39767\">",
"     picture 2",
"    </a>",
"    ). The result is hypochlorhydria in association with protein loss due to an increase in gastric mucosal permeability. Clinical symptoms include epigastric pain, vomiting, and upper gastrointestinal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2984?source=see_link\">",
"     \"Large gastric folds: Hyperplastic and nonhyperplastic gastropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A childhood form of M&eacute;n&eacute;trier's disease has been associated with cytomegalovirus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/11\">",
"     11",
"    </a>",
"    ]. However, this disorder may be an example of misuse of the term M&eacute;n&eacute;trier's disease for any form of hypertrophic gastropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2984?source=see_link\">",
"     \"Large gastric folds: Hyperplastic and nonhyperplastic gastropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Helicobacter pylori infection also may be a pathogenetically important cause of hypertrophic gastropathy and protein-losing enteropathy. A retrospective analysis found that more than 90 percent of patients with this disorder were infected with H. pylori, and it was postulated that hypertrophic gastropathy might be a form of H. pylori gastritis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/12\">",
"     12",
"    </a>",
"    ]. The observation in case reports that eradication of H. pylori led to complete clinical and morphologic recovery is compatible with this hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30055?source=see_link\">",
"     \"Acute and chronic gastritis due to Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two other disorders are also associated with giant gastric folds and protein-losing gastroenteropathy: lymphocytic gastritis (",
"    <a class=\"graphic graphic_picture graphicRef66689 \" href=\"UTD.htm?13/57/14231\">",
"     picture 3",
"    </a>",
"    ) and secretory hypertrophic gastropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/13,15,16\">",
"     13,15,16",
"    </a>",
"    ]. The latter disorder is characterized by enlarged fundic glands which may contain an increased number of parietal cells, resulting in increased gastric acid secretion.",
"   </p>",
"   <p>",
"    As mentioned above, anti-H. pylori therapy may lead to resolution of the disease in patients infected with this organism. Antacids, H2 blockers, and proton pump inhibitors may be beneficial in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/17\">",
"     17",
"    </a>",
"    ]. When these measures fail, surgical excision of the involved portion of the stomach may be indicated. Anecdotal reports suggest that an alternative to surgery may be the subcutaneous administration of the somatostatin analogue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (100 micrograms twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/18\">",
"     18",
"    </a>",
"    ]. The exact mechanism by which this treatment may act is not known, but it may be that reduced splanchnic blood flow leads to reduced lymphatic pressure. Octreotide has also been used in patients with primary intestinal lymphangiectasia (200 micrograms twice daily). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloidosis is an unusual cause of protein-losing gastroenteropathy due to mucosal infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/19\">",
"     19",
"    </a>",
"    ]. Clinical suspicion is often required to make the diagnosis because the hypoalbuminemia may be ascribed to concurrent nephrotic syndrome due to glomerular involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12280?source=see_link\">",
"     \"Gastrointestinal amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Waldenstrom macroglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Waldenstrom macroglobulinemia can be associated with diarrhea and malabsorption. A series of 15 patients suggested that the underlying cause may be due to intestinal lymphangiectasia resulting in protein-losing enteropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DISEASES ASSOCIATED WITH IMPAIRED LYMPHATIC DRAINAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal lymphangiectasia refers to impaired small intestinal lymph drainage associated with dilated intestinal lymphatic channels. It can be due to primary disorders of intestinal lymphatics or to secondary causes, such as heart failure (",
"    <a class=\"graphic graphic_table graphicRef53419 \" href=\"UTD.htm?39/37/40541\">",
"     table 1",
"    </a>",
"    ). Regardless of the cause, the impaired flow and increased pressure in the intestinal lymphatics has a number of consequences including [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased absorption of chylomicrons and fat-soluble vitamins (A, D, E, K)",
"     </li>",
"     <li>",
"      Reduced recirculation of intestinal lymphocytes into the peripheral circulation",
"     </li>",
"     <li>",
"      Leakage of intestinal lymph into the intestinal lumen",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Primary intestinal lymphangiectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary intestinal lymphangiectasia is characterized by diffuse or localized ectasia of enteric lymphatics, which is often associated with lymphatic abnormalities elsewhere in the body [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/22\">",
"     22",
"    </a>",
"    ]. The ectatic lymphatics may be located in the mucosa, submucosa, or subserosa.",
"   </p>",
"   <p>",
"    The disease primarily affects children and young adults (the mean age of onset is approximately 11 years), but on careful questioning of the parents there is often evidence of symptoms much earlier. There is no gender specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/22\">",
"     22",
"    </a>",
"    ]. Although most cases are sporadic, primary intestinal lymphangiectasia has been reported in multiple siblings of several families, suggesting that at least in certain cases it may have a genetic etiology. Protein-losing gastroenteropathy in association with the yellow-nail syndrome (chronic peripheral lymphedema accompanied by yellowish-colored slow growing nails, recurrent pleural and pericardial effusions, and chylous ascites) has been described in a case report [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/23\">",
"     23",
"    </a>",
"    ]. Turner's syndrome, Noonan's syndrome, and Klippel-Trenaunay syndrome are associated with intestinal lymphangiectasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptoms of patients with primary intestinal lymphangiectasia include intermittent diarrhea, nausea, and vomiting. Some patients develop steatorrhea.",
"   </p>",
"   <p>",
"    Peripheral edema is often present and may be pitting if it results from hypoalbuminemia, or asymmetric and nonpitting if it results from an underlying lymphatic abnormality of the affected extremity. Reversible blindness can rarely occur due to macular edema. Chylothorax or chylous ascites may also be present and should be differentiated from pleural effusions or ascites resulting from hypoproteinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of primary intestinal lymphangiectasia is established based upon the clinical manifestations discussed above, and laboratory and pathologic findings. Laboratory findings are similar to those in other forms of protein-losing enteropathy and include hypoproteinemia with decreased serum levels of albumin, IgA, IgG, IgM, transferrin, and ceruloplasmin. Clotting factors are also frequently decreased, but this rarely leads to clinical consequences. Loss of lymphocytes into the gut can result in significant lymphocytopenia, with detectable alterations in cellular immunity. Patients with steatorrhea may develop fat-soluble vitamin deficiencies.",
"   </p>",
"   <p>",
"    Small bowel contrast studies may show thickened, nodular mucosal folds that simulate stacked coins [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/24\">",
"     24",
"    </a>",
"    ]. On endoscopy, scattered white spots, which have been described as having a snowflake-like appearance, may overly the small intestinal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Consumption of a high-fat meal the evening before endoscopic evaluation may make these findings more apparent.",
"   </p>",
"   <p>",
"    Histopathologic examination reveals markedly dilated lymphatics that are most apparent in the tips of the villi. In addition, electron microscopy reveals dilated lymphatic vessels filled with chylomicrons and precipitated lymph proteins. These findings are also present in the dilated intraepithelial gaps extending from the basolateral membrane to the apical region of the epithelium.",
"   </p>",
"   <p>",
"    The abnormal intestinal lymphatics can also be demonstrated by contrast lymphangiography, nuclear scintigraphy, or magnetic resonance lymphangiography [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. However, their sensitivity and specificity have not been studied in sufficient numbers of patients to justify routine use. Contrast lymphangiography involving injection of contrast material via the pedal vein is painful and of low sensitivity and should not be used. Nuclear scintigraphy has been reported to demonstrate the abnormal intestinal lymphatics by using a technetium labeled tracer (usually albumin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    ) and assessing intestinal leakage [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, it offers little additional information once an alpha-1 antitrypsin clearance test has been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of treatment of primary intestinal lymphangiectasia are similar to the treatment of other forms of protein-losing gastroenteropathy. The mainstay of therapy is a low-fat, high-protein, medium-chain triglyceride supplemented diet [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/24,30,31\">",
"     24,30,31",
"    </a>",
"    ]. Some patients require additional supplementation with calcium salts and water-soluble forms of fat-soluble vitamins. The need for dietary therapy is often permanent, although occasional spontaneous remissions do occur (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Treatment'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Not all patients respond completely to this dietary approach. Intestinal resection or anastomosis of abnormal lymphatics to venous channels may be beneficial for selected patients who have refractory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/24,32\">",
"     24,32",
"    </a>",
"    ]. However, these approaches are not always feasible. Patients with primary intestinal lymphangiectasia often have extensive lymphatic involvement precluding resection. Furthermore, focal lymphatic abnormalities are often difficult to localize. A case report suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (200 micrograms twice daily) was associated with a decrease in enteral protein loss and clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/33\">",
"     33",
"    </a>",
"    ]. The mechanism of action is unclear but likely relates to the reduction in splanchnic blood flow and reduced lymphatic pressure. Octreotide has also been used in patients with giant hypertrophic gastropathy (100 micrograms twice daily). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Giant hypertrophic gastropathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Secondary intestinal lymphangiectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dilated intestinal lymphatics and increased lymph pressure observed in primary intestinal lymphangiectasia may also been seen in patients with secondary causes of impaired lymph flow. The most common causes of secondary intestinal lymphangiectasia are cardiac diseases and retroperitoneal lymph node enlargement due to chemotherapeutic, infectious, or toxic substances (",
"    <a class=\"graphic graphic_table graphicRef53419 \" href=\"UTD.htm?39/37/40541\">",
"     table 1",
"    </a>",
"    ). Secondary intestinal lymphangiectasia has also been described in patients with portal hypertension or hepatic venous outflow obstruction after liver transplantation, and in congenital hepatic fibrosis due to phosphomannose isomerase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/34\">",
"     34",
"    </a>",
"    ]. Secondary intestinal lymphangiectasia due to portal hypertension may be improved by placement of a transjugular intrahepatic portosystemic shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cardiac diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association of protein-losing gastroenteropathy with cardiac disease was first described in 1961 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/37\">",
"     37",
"    </a>",
"    ]. Since then, multiple reports have described this complication in patients with a variety of cardiac diseases including structural heart disease (such as tricuspid insufficiency, congenital pulmonic stenosis, and atrial septal defect), constrictive pericarditis, and cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Surgical repair of complex congenital heart disease (such as the Fontan procedure for a functional single ventricle) has also led to the development of secondary lymphangiectasia, particularly when there is anatomic or functional obstruction to systemic venous drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients can have profound hypoproteinemia with clinically significant nutritional and immunologic consequences. Severe third-spacing of body fluids further compromises the already tenuous hemodynamics and intravascular volume loss. The combination of increased central venous pressures and low cardiac output places the patient at risk for central venous thrombosis and stroke.",
"   </p>",
"   <p>",
"    The standard treatment for these patients has been to use a low-fat, medium-chain triglyceride supplemented diet (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Maintenance of nutrition'",
"    </a>",
"    below) in an attempt to reduce intestinal lymph production. However this approach has not always been effective. Repair of cardiac abnormalities associated with the obstructed venous drainage may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient with suspected protein-losing gastroenteropathy is outlined in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef59916 \" href=\"UTD.htm?42/47/43774\">",
"     algorithm 1",
"    </a>",
"    ). The possible presence of this disorder should be considered in patients with hypoalbuminemia in whom there is no other apparent cause of protein loss or inadequate synthesis or supply (proteinuria, liver diseases, protein malnutrition). Enteral protein loss should be directly demonstrable by measurement of the alpha-1 antitrypsin clearance. The alpha-1 antitrypsin clearance is a nonisotopic alternative to the tests used to detect and quantitate enteric protein loss in the past, such as 51Cr-labeled albumin, 125-I-labeled albumin, and 99mTc-labeled transferrin.",
"   </p>",
"   <p>",
"    Alpha-l antitrypsin has a moderately higher molecular weight than albumin (50,000) and is excreted intact in the stool because it is resistant to proteolysis and degradation in the intestinal lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The normal rate of alpha-1 antitrypsin excretion in the stool is less than 2.6",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    stool, which reflects an intestinal clearance of less than 13",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. There is poor correlation between random stool concentrations of alpha-1 antitrypsin and clearance measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/47\">",
"     47",
"    </a>",
"    ]; as a result a more reliable estimate of protein loss can be obtained by measuring the concentration in stool with simultaneous measurement in plasma from which an estimate of intestinal protein loss can be derived. A 24-hour stool specimen is preferred, since it produces a more reliable estimate of antitrypsin excretion compared with a spot sample. However, many patients will find collecting multiple stools at home to be burdensome.",
"   </p>",
"   <p>",
"    Other possible drawbacks to measuring alpha-1 antitrypsin clearance are that the test does not distinguish between gastric and small intestinal protein loss and that alpha-1 antitrypsin is apparently degraded by the acidic gastric juice below pH 3.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/46\">",
"     46",
"    </a>",
"    ]. To improve the reliability of the test in disorders characterized by gastric acid hypersecretion (eg, secretory gastropathy), an additional refinement has been introduced: measuring alpha-1 antitrypsin clearance during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/48\">",
"     48",
"    </a>",
"    ]; other acid blockade should be equally effective. This modification may be used in patients suspected to have hypertrophic secretory gastropathy or in those with apparent gastrointestinal protein loss but a normal alpha-1 antitrypsin clearance.",
"   </p>",
"   <p>",
"    Increased clearance of alpha-1 antitrypsin from plasma should be interpreted cautiously in patients with diarrhea, since diarrhea itself (without underlying protein-losing gastroenteropathy) can produce this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/47\">",
"     47",
"    </a>",
"    ]. For this reason, values indicative of enhanced enteral protein loss are an alpha-1 antitrypsin clearance greater than 24",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    in patients without diarrhea and greater than 56",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    in patients with diarrhea. Intestinal bleeding also can significantly increase the clearance rates; thus, diet and drug intake should be modified prior to the test in order to reduce the risks of occult gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to documenting the presence of increased enteral protein loss, the diagnostic evaluation must also include identification of the underlying cause. In most patients, the diagnosis can be established from the history, physical examination, clinical manifestations, and laboratory data. As an example, an elevated jugular venous pressure in a patient with relatively normal renal function is usually indicative of right heart failure. In some patients, echocardiography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac catheterization may be necessary to determine the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further studies should be performed as indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of stool fat can indicate small bowel disease.",
"     </li>",
"     <li>",
"      Radiographic studies or magnetic resonance imaging (MRI) of the gastrointestinal tract can help to localize anatomic lesions.",
"     </li>",
"     <li>",
"      Upper and lower gastrointestinal endoscopy with biopsy should be performed if the diagnosis remains uncertain.",
"     </li>",
"     <li>",
"      If all else is normal, consideration should be given to lymphatic disorders and the use of CT scan or MRI. Lymphangiography is not recommended except when specific lymphatic abnormalities are strongly suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of protein-losing gastroenteropathy consists of two components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintenance of nutritional status",
"     </li>",
"     <li>",
"      Treatment of the underlying disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Maintenance of nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be given a diet that is high in protein and low in long-chain fatty acids, generally present as long chain triglycerides (LCTs) in a wide variety of foods. In place of LCTs, medium-chain triglycerides (MCTs) are useful in selected patients to replace lipid calories. MCTs contain saturated fatty acids of 6 to 12 carbon atoms. Various preparations of MCTs are commercially available; many contain caprylic acid (C8), capric acid (C10), and lauric acid (C12), and small amounts of fatty acids shorter than C8 and longer than C10. The efficacy and side effects of these products may also vary. Accordingly, when treating patients, individual responses must be assessed, and products changed as indicated. MCTs are not re-esterified within the intestinal cell. Thus, they bypass the enteric lymphatics and directly enter the portal system. It is believed that the reduction in intake of LCTs reduces lymphatic flow and pressure and decreases the quantity of lymph leakage. This approach is associated with favorable effects on hypoalbuminemia, gastrointestinal symptoms, and growth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/24,30,31\">",
"     24,30,31",
"    </a>",
"    ]. The diet should also provide adequate supplies of essential polyunsaturated fatty acids. These are available in highest concentrations in flax seeds, walnuts, salmon, sardines, and soybeans as well as in corn, canola, and safflower oils.",
"   </p>",
"   <p>",
"    The percentage of patients in whom hypoalbuminemia can be corrected varies considerably and depends upon the type and severity of the underlying disease. Protein balance is generally defined as the difference between protein intake and protein loss (catabolism plus loss from the gut). In normal adults, protein requirements are 0.6 to 0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    ideal body weight per day. In protein-losing enteropathy, this value may increase to 1.5 to 3.0",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day, and protein supplements may be necessary to achieve positive protein balance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Daily protein intake of 150 to 200",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    is easily achieved with a daily diet consisting of 300 to 350 g lean meat, milk, low fat cheese, and egg substitute, together with five or more servings of starch, four or more servings of vegetables, and three or more servings of fruit (one serving equals one-half cup). The diet can be supplemented by commercially available protein formulas. Isolated protein supplements (eg, Casec&reg;, ProMod&reg;) are a reliable source of fat-free dietary protein, but may be expensive for daily use and may be unpalatable. Supplements that provide both protein and nonprotein calories (eg, Ensure&reg;, Isocal&reg;, Peptamen&reg;, and PediaSure&reg;) may be more palatable. Whey protein supplements can be added to skim milk to increase protein intake.",
"   </p>",
"   <p>",
"    In some cases, the gastrointestinal tract is transiently unavailable for enteral feedings because of disturbed gastrointestinal motility, impaired functional intestinal length, or reduced absorptive surface area. Under these circumstances, patients may require parenteral nutrition. Such therapy can lead to improvement in clinical and laboratory status of the disease. When estimated protein requirements can only be partially met by oral feeding and oral supplements, additional calories and protein can be delivered parenterally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment of the underlying disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery for constrictive pericarditis or localized intestinal disease results in remission of the intestinal protein loss in most cases. Miscellaneous other interventions have been described.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcium supplementation in a patient with protein losing enteropathy after Fontan operation attenuated the protein loss with subsequent normalization of serum total protein and albumin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low-dose oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      was found to be an effective therapy for treating protein-losing enteropathy after the Fontan operation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Case reports have suggested that treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      may improve symptoms and protein loss in patients who have undergone the Fontan procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/43,53,54\">",
"       43,53,54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A patient with protein losing gastroenteropathy associated with an autoimmune disease, presumably systemic sclerosis (scleroderma) with CREST syndrome, was treated successfully with long-term low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with protein losing enteropathy due to eosinophilic gastroenteritis responded to an elemental diet in one report [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3881/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62464130\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protein-losing gastroenteropathies are characterized by an excessive loss of serum proteins into the gastrointestinal tract, resulting in hypoproteinemia (detected as hypoalbuminemia), edema, and, in some cases, pleural and pericardial effusions.",
"     </li>",
"     <li>",
"      Protein-losing gastroenteropathies can be caused by a diverse group of disorders (",
"      <a class=\"graphic graphic_table graphicRef53419 \" href=\"UTD.htm?39/37/40541\">",
"       table 1",
"      </a>",
"      ). The increase in intestinal leakage of plasma proteins occurs via one of two mechanisms (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mucosal injury with or without",
"      <span class=\"nowrap\">",
"       erosions/ulcerations,",
"      </span>",
"      as in inflammatory bowel disease (IBD) and celiac disease.",
"     </li>",
"     <li>",
"      Increased lymphatic pressure in the gut due to granulomatous or neoplastic involvement of the lymphatic system or after dilated lymph vessels leak protein via the surface epithelium into the gut.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of protein-losing gastroenteropathy are highly variable and are determined in part by the underlying cause (",
"      <a class=\"graphic graphic_table graphicRef65661 \" href=\"UTD.htm?23/18/23851\">",
"       table 2",
"      </a>",
"      ). The main findings are reduced serum concentrations of albumin, gamma globulins (IgA, IgG, IgM), fibrinogen, transferrin, and ceruloplasmin. The hypoalbuminemia may lead to edema of the lower extremities due to diminished plasma oncotic pressure. Hypoproteinemia can also be associated with fat and carbohydrate malabsorption and fat-soluble vitamin deficiencies due to small bowel involvement by the primary disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to the patient with suspected protein-losing gastroenteropathy is outlined in the figure (",
"      <a class=\"graphic graphic_algorithm graphicRef59916 \" href=\"UTD.htm?42/47/43774\">",
"       algorithm 1",
"      </a>",
"      ). The possible presence of this disorder should be considered in patients with hypoalbuminemia in whom there is no other apparent cause of protein loss or inadequate synthesis or supply (proteinuria, liver diseases, protein malnutrition). Enteral protein loss should be directly demonstrable by measurement of the alpha-1 antitrypsin clearance. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to documenting the presence of increased enteral protein loss, the diagnostic evaluation must also include identification of the underlying cause. In most patients, the diagnosis can be established from the history, physical examination, clinical manifestations, and laboratory data.",
"     </li>",
"     <li>",
"      Treatment of protein-losing gastroenteropathy consists of two components:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Maintenance of nutritional status: Patients should be given a diet that is low in long-chain fatty acids and triglycerides and high in protein.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=see_link\">",
"       Medium chain triglycerides",
"      </a>",
"      are useful in selected patients to replace lipid calories.",
"     </li>",
"     <li>",
"      Treatment of the underlying disease: Surgery for constrictive pericarditis or localized intestinal disease results in remission of the intestinal protein loss in most cases. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/1\">",
"      Schmidt PN, Blirup-Jensen S, Svendsen PJ, Wandall JH. Characterization and quantification of plasma proteins excreted in faeces from healthy humans. Scand J Clin Lab Invest 1995; 55:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/2\">",
"      Acciuffi S, Ghosh S, Ferguson A. Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss. Aliment Pharmacol Ther 1996; 10:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/3\">",
"      Rybolt AH, Bennett RG, Laughon BE, et al. Protein-losing enteropathy associated with Clostridium difficile infection. Lancet 1989; 1:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/4\">",
"      Dansinger ML, Johnson S, Jansen PC, et al. Protein-losing enteropathy is associated with Clostridium difficile diarrhea but not with asymptomatic colonization: a prospective, case-control study. Clin Infect Dis 1996; 22:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/5\">",
"      Stark ME, Batts KP, Alexander GL. Protein-losing enteropathy with collagenous colitis. Am J Gastroenterol 1992; 87:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/6\">",
"      Ebert EC, Hagspiel KD. Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol 2011; 45:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/7\">",
"      Molina JF, Brown RF, Gedalia A, Espinoza LR. Protein losing enteropathy as the initial manifestation of childhood systemic lupus erythematosus. J Rheumatol 1996; 23:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/8\">",
"      Jaeken J, Vanderschueren-Lodeweyckx M, Casaer P. Familial psychomotor retardation with markedly fluctuating serum prolactin, FSH and GH levels, partial TBG-deficiency, increased serum arylsulfatase A and increased CSF protein: a new syndrome. Pediatr Res 1980; 14:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/9\">",
"      Hendriksz CJ, McClean P, Henderson MJ, et al. Successful treatment of carbohydrate deficient glycoprotein syndrome type 1b with oral mannose. Arch Dis Child 2001; 85:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/10\">",
"      Kelly DG, Miller LJ, Malagelada JR, et al. Giant hypertrophic gastropathy (M&eacute;n&eacute;trier's disease): pharmacologic effects on protein leakage and mucosal ultrastructure. Gastroenterology 1982; 83:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/11\">",
"      Sferra TJ, Pawel BR, Qualman SJ, Li BU. M&eacute;n&eacute;trier disease of childhood: role of cytomegalovirus and transforming growth factor alpha. J Pediatr 1996; 128:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/12\">",
"      Bayerd&ouml;rffer E, Ritter MM, Hatz R, et al. Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori--is Helicobacter pylori a pathogenic factor in M&eacute;n&eacute;trier's disease? Gut 1994; 35:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/13\">",
"      Groisman GM, George J, Berman D, Harpaz N. Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori. Am J Gastroenterol 1994; 89:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/14\">",
"      Yamada M, Sumazaki R, Adachi H, et al. Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori. Eur J Pediatr 1997; 156:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/15\">",
"      Farahat K, Hainaut P, Jamar F, et al. Lymphocytic gastritis: an unusual cause of hypoproteinaemia. J Intern Med 1993; 234:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/16\">",
"      Wolber RA, Owen DA, Anderson FH, Freeman HJ. Lymphocytic gastritis and giant gastric folds associated with gastrointestinal protein loss. Mod Pathol 1991; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/17\">",
"      Ladas SD, Tassios PS, Malamou HC, et al. Omeprazole induces a long-term clinical remission of protein-losing gastropathy of M&eacute;n&eacute;trier's disease. Eur J Gastroenterol Hepatol 1997; 9:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/18\">",
"      Yeaton P, Frierson HF Jr. Octreotide reduces enteral protein losses in M&eacute;n&eacute;trier's disease. Am J Gastroenterol 1993; 88:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/19\">",
"      Suzuki C, Higaki S, Nishiaki M, et al. 99mTc-HSA-D scintigraphy in the diagnosis of protein-losing gastroenteropathy due to secondary amyloidosis. J Gastroenterol 1997; 32:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/20\">",
"      Pratz KW, Dingli D, Smyrk TC, Lust JA. Intestinal lymphangiectasia with protein-losing enteropathy in Waldenstrom macroglobulinemia. Medicine (Baltimore) 2007; 86:210.",
"     </a>",
"    </li>",
"    <li>",
"     Davidson NO. Intestinal lipid absorption. In: Textbook of Gastroenterology, Yamada T, Alpers DH, Kaplowitz N (Eds), JB Lippincott, Philadelphia 2003. p.413.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/22\">",
"      Umar SB, DiBaise JK. Protein-losing enteropathy: case illustrations and clinical review. Am J Gastroenterol 2010; 105:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/23\">",
"      Malek NP, Ocran K, Tietge UJ, et al. A case of the yellow nail syndrome associated with massive chylous ascites, pleural and pericardial effusions. Z Gastroenterol 1996; 34:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/24\">",
"      Vardy PA, Lebenthal E, Shwachman H. Intestinal lymphagiectasia: a reappraisal. Pediatrics 1975; 55:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/25\">",
"      Freeman HJ, Nimmo M. Intestinal lymphangiectasia in adults. World J Gastrointest Oncol 2011; 3:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/26\">",
"      Abramowsky C, Hupertz V, Kilbridge P, Czinn S. Intestinal lymphangiectasia in children: a study of upper gastrointestinal endoscopic biopsies. Pediatr Pathol 1989; 9:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/27\">",
"      Laor T, Hoffer FA, Burrows PE, Kozakewich HP. MR lymphangiography in infants, children, and young adults. AJR Am J Roentgenol 1998; 171:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/28\">",
"      Yueh TC, Pui MH, Zeng SQ. Intestinal lymphangiectasia: value of Tc-99m dextran lymphoscintigraphy. Clin Nucl Med 1997; 22:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/29\">",
"      Bhatnagar A, Lahoti D, Singh AK, et al. Scintigraphic diagnosis of protein losing enteropathy using Tc-99m dextran. Clin Nucl Med 1995; 20:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/30\">",
"      JEFFRIES GH, CHAPMAN A, SLEISENGER MH. LOW-FAT DIET IN INTESTINAL LYMPHANGIECTASIA. ITS EFFECT ON ALBUMIN METABOLISM. N Engl J Med 1964; 270:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/31\">",
"      Tift WL, Lloyd JK. Intestinal lymphangiectasia. Long-term results with MCT diet. Arch Dis Child 1975; 50:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/32\">",
"      Mistilis SP, Skyring AP. Intestinal lymphangiectasia: Therapeutic effect of lymph venous anastomosis. Am J Med 1966; 40:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/33\">",
"      Ballinger AB, Farthing MJ. Octreotide in the treatment of intestinal lymphangiectasia. Eur J Gastroenterol Hepatol 1998; 10:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/34\">",
"      de Koning TJ, Dorland L, van Berge Henegouwen GP. Phosphomannose isomerase deficiency as a cause of congenital hepatic fibrosis and protein-losing enteropathy. J Hepatol 1999; 31:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/35\">",
"      Dousset B, Legmann P, Soubrane O, et al. Protein-losing enteropathy secondary to hepatic venous outflow obstruction after liver transplantation. J Hepatol 1997; 27:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/36\">",
"      Stanley AJ, Gilmour HM, Ghosh S, et al. Transjugular intrahepatic portosystemic shunt as a treatment for protein-losing enteropathy caused by portal hypertension. Gastroenterology 1996; 111:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/37\">",
"      DAVIDSON JD, WALDMANN TA, GOODMAN DS, GORDON RS Jr. Protein-losing gastroenteropathy in congestive heart-failure. Lancet 1961; 1:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/38\">",
"      Meadows J, Jenkins K. Protein-losing enteropathy: integrating a new disease paradigm into recommendations for prevention and treatment. Cardiol Young 2011; 21:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/39\">",
"      M&uuml;ller C, Globits S, Glogar D, et al. Constrictive pericarditis without typical haemodynamic changes as a cause of oedema formation due to protein-losing enteropathy. Eur Heart J 1991; 12:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/40\">",
"      Wilkinson P, Pinto B, Senior JR. Reversible protein-losing enteropathy with intestinal lymphangiectasia secondary to chronic constrictive pericarditis. N Engl J Med 1965; 273:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/41\">",
"      Feldt RH, Driscoll DJ, Offord KP, et al. Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 1996; 112:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/42\">",
"      Jacobs ML, Rychik J, Byrum CJ, Norwood WI Jr. Protein-losing enteropathy after Fontan operation: resolution after baffle fenestration. Ann Thorac Surg 1996; 61:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/43\">",
"      Donnelly JP, Rosenthal A, Castle VP, Holmes RD. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr 1997; 130:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/44\">",
"      Masetti P, Marianeschi SM, Cipriani A, et al. Reversal of protein-losing enteropathy after ligation of systemic-pulmonary shunt. Ann Thorac Surg 1999; 67:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/45\">",
"      Bernier JJ, Florent C, Desmazures C, et al. Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin. Lancet 1978; 2:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/46\">",
"      Florent C, L'Hirondel C, Desmazures C, et al. Intestinal clearance of alpha 1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy. Gastroenterology 1981; 81:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/47\">",
"      Strygler B, Nicar MJ, Santangelo WC, et al. Alpha 1-antitrypsin excretion in stool in normal subjects and in patients with gastrointestinal disorders. Gastroenterology 1990; 99:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/48\">",
"      Florent C, Vidon N, Flouri&eacute; B, et al. Gastric clearance of alpha-1-antitrypsin under cimetidine perfusion. New test to detect protein-losing gastropathy? Dig Dis Sci 1986; 31:12.",
"     </a>",
"    </li>",
"    <li>",
"     Heimburger DC, Weinsier RL. Therapeutic diets. In: Handbook of Clinical Nutrition, 3rd ed, Heimburger DC, Weinsier RL (Eds), Mosby, St. Louis 1997. p.235.",
"    </li>",
"    <li>",
"     Alpers DH, Stenson WF, Bier DM. Nutritional planning for patients with protein and calorie deficiency. In: Manual of Nutritional Therapeutics, 3rd ed, Alpers DH, Stenson WF, Bier DM (Eds), Little, Brown, and Co., Boston, MA 1995. p.265.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/51\">",
"      Kim SJ, Park IS, Song JY, et al. Reversal of protein-losing enteropathy with calcium replacement in a patient after Fontan operation. Ann Thorac Surg 2004; 77:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/52\">",
"      Thacker D, Patel A, Dodds K, et al. Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation. Ann Thorac Surg 2010; 89:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/53\">",
"      Kelly AM, Feldt RH, Driscoll DJ, Danielson GK. Use of heparin in the treatment of protein-losing enteropathy after fontan operation for complex congenital heart disease. Mayo Clin Proc 1998; 73:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/54\">",
"      Warnes CA, Feldt RH, Hagler DJ. Protein-losing enteropathy after the Fontan operation: successful treatment by percutaneous fenestration of the atrial septum. Mayo Clin Proc 1996; 71:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/55\">",
"      Sunagawa T, Kinjo F, Gakiya I, et al. Successful long-term treatment with cyclosporin A in protein losing gastroenteropathy. Intern Med 2004; 43:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3881/abstract/56\">",
"      Chehade M, Magid MS, Mofidi S, et al. Allergic eosinophilic gastroenteritis with protein-losing enteropathy: intestinal pathology, clinical course, and long-term follow-up. J Pediatr Gastroenterol Nutr 2006; 42:516.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4769 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3881=[""].join("\n");
var outline_f3_50_3881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H62464130\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DISEASES ASSOCIATED WITH MUCOSAL DAMAGE, EROSIONS, AND ULCERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DISEASES ASSOCIATED WITH MUCOSAL DISEASE WITHOUT ULCERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intestinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Giant hypertrophic gastropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Waldenstrom macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DISEASES ASSOCIATED WITH IMPAIRED LYMPHATIC DRAINAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Primary intestinal lymphangiectasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Secondary intestinal lymphangiectasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cardiac diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Maintenance of nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment of the underlying disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62464130\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4769\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4769|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/47/43774\" title=\"algorithm 1\">",
"      Diagnosis of protein losing enteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4769|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/37/40533\" title=\"picture 1\">",
"      Menetriers disease Gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/53/39767\" title=\"picture 2\">",
"      Menetriers disease Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/57/14231\" title=\"picture 3\">",
"      Lymphocytic gastritis Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4769|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/37/40541\" title=\"table 1\">",
"      Etiology protein losing enterop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/18/23851\" title=\"table 2\">",
"      Lab findings protein losing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30055?source=related_link\">",
"      Acute and chronic gastritis due to Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12280?source=related_link\">",
"      Gastrointestinal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2984?source=related_link\">",
"      Large gastric folds: Hyperplastic and nonhyperplastic gastropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27530?source=related_link\">",
"      Lymphocytic and collagenous colitis (microscopic colitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41765?source=related_link\">",
"      Mechanisms of nutrient absorption and malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=related_link\">",
"      Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_50_3882="Central and branch retinal artery occlusion";
var content_f3_50_3882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Central and branch retinal artery occlusion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/50/3882/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3882/contributors\">",
"     Thomas R Hedges, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/50/3882/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3882/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3882/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/50/3882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/50/3882/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/50/3882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central retinal artery occlusion (CRAO) and branch retinal artery occlusion (BRAO) present with acute, painless loss of monocular vision. These disorders are considered a form of stroke, with a similar clinical approach and management; the clinician attempts to treat the acute event, find the source of the vascular occlusion, and prevent further vascular events from occurring.",
"   </p>",
"   <p>",
"    Issues related to central and branch retinal artery occlusion will be reviewed here. Other ocular ischemic syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10666?source=see_link\">",
"     \"Amaurosis fugax (transient monocular or binocular visual loss)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VASCULAR ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood flowing to the retina travels through blood vessels that are subject to varying environments and external pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/1\">",
"     1",
"    </a>",
"    ]. The central retinal artery arises from the ophthalmic artery, itself a branch of the internal carotid artery. The ophthalmic artery departs from the intracranial portion of the carotid artery at a sharp angle, after which it travels intracranially for a short distance before entering the orbit, usually with the optic nerve. Once entering the orbit, the central retinal artery leaves the ophthalmic artery to enter the cerebral spinal fluid space and then travel within the optic nerve, after which it enters the eye, where it is subjected to intraocular pressure.",
"   </p>",
"   <p>",
"    The central retinal artery supplies the inner retina and the surface of the optic nerve. In about 15 percent of individuals, it is assisted by a branch of the ciliary circulation, the cilioretinal artery, which may supply a portion of the retina, including the macula. This allows for preservation of vision in some patients with central retinal artery occlusion.",
"   </p>",
"   <p>",
"    The physiology of central retinal artery function is poorly understood, but it is primarily autoregulated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/2\">",
"     2",
"    </a>",
"    ]. This means that under a range of systemic mean arterial pressures, ocular blood flow remains constant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link&amp;anchor=H2#H2\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\", section on 'Mechanisms of vascular injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central retinal artery occlusion (CRAO) is a rare event with an incidence of approximately 1 to 10 in 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Symptomatic branch retinal artery occlusion (BRAO) is even less common.",
"   </p>",
"   <p>",
"    Demographic characteristics of patients with CRAO and BRAO are consistent with those seen for other vascular disorders. The mean age of patients is between 60 and 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. More than 90 percent of patients with CRAO and BRAO are over the age of 40 years, although individuals as young as 12 years have been affected [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ]. Men are more commonly affected than women. Hypertension, smoking, and diabetes are more prevalent among patients with retinal artery occlusion compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Patients presenting with CRAO often have a previously undiagnosed vascular risk factor (eg, hyperlipidemia, hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central and branch retinal artery occlusions share a similar list of potential etiologies. Case series that attempt to define a distribution of etiologies are small",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    include a heterogeneous case mix of amaurosis and asymptomatic retinal emboli in addition to CRAO and BRAO. In addition, diagnostic evaluations are not standardized and vary between studies.",
"   </p>",
"   <p>",
"    The distribution of etiologies is also influenced by the patient's age. Carotid artery atherosclerosis is the most common etiology for retinal artery occlusion overall, but is relatively unusual in patients under 40, in whom cardiogenic embolism is the most likely etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In patients over 70 years of age, giant cell arteritis is more likely than in younger patients. Ethnicity may also be relevant; as an example, carotid artery occlusive disease is most prevalent among Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determining the underlying etiology is important to preventing recurrent CRAO and BRAO and other vascular complications. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Diagnosis of etiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Carotid artery atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerotic disease of the ipsilateral carotid artery is the most common cause of retinal artery occlusion. The reported prevalence of significant carotid artery disease among patients with CRAO or BRAO is 10 to 30 percent in most case series but values as high as 70 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/10,14-23\">",
"     10,14-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of high-grade carotid disease in the setting of retinal artery occlusion is important because of the risk for future stroke and other vascular events. Compared with cerebral ischemia, retinal ischemia has been reported to carry a lower risk for stroke in the setting of high-grade carotid disease (&gt;70 percent stenosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/24\">",
"     24",
"    </a>",
"    ]. However, these case series generally also include transient monocular visual loss",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    asymptomatic retinal emboli, which might be expected to have a more benign prognosis than CRAO or BRAO. In one report, three of seven patients with CRAO and high-grade carotid disease had a subsequent stroke over 4.5 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/20\">",
"     20",
"    </a>",
"    ]. This suggests that CRAO may be similar to cerebral infarction in predicting future stroke risk in the setting of high-grade carotid stenosis.",
"   </p>",
"   <p>",
"    Carotid endarterectomy is likely to significantly reduce the risk of future stroke in patients with retinal artery occlusion and high-grade carotid stenosis, although this subgroup has not been specifically studied [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of symptomatic carotid atherosclerotic disease\", section on 'Retinal versus hemispheric ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiogenic embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cardiogenic embolic source (",
"    <a class=\"graphic graphic_table graphicRef60843 \" href=\"UTD.htm?20/43/21181\">",
"     table 1",
"    </a>",
"    ) is second to carotid disease in causing retinal artery occlusion. In some series, this is found in as many as 48 percent of patients (range 2 to 48) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/10,15,23\">",
"     10,15,23",
"    </a>",
"    ]. The prevalence of an underlying cardiac source is influenced by several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiogenic embolism is more likely to underlie retinal artery occlusion in younger patients (&lt;40 years), in whom it may cause up to half of the cases with an identified origin [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The likelihood of a cardiac source for retinal artery occlusion increases significantly if there is a suggestive medical history, such as atrial fibrillation, infectious endocarditis, rheumatic heart disease, cardiac valvular disease, myocardial infarction, congenital heart disease, intravenous drug use, cardiac tumor, or a cardiac murmur [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Visualization of retinal emboli on funduscopic examination is not more frequent among patients with a cardiogenic embolism compared with those with an alternative or unknown etiology [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/16,28\">",
"       16,28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although often considered unlikely, a cardiogenic embolic source is important to identify because chronic anticoagulation may be recommended to prevent more serious events. A detailed review of cardiogenic sources of cerebrovascular emboli is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology and classification of stroke\", section on 'Embolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=see_link\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Small artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to distal emboli, local atheroma within the central retinal artery at the lamina cribrosa may cause arterial occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/29\">",
"     29",
"    </a>",
"    ]. Small artery disease is often the presumptive etiology in older patients with diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension and no other demonstrated cause for retinal artery occlusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=see_link\">",
"     \"Lacunar infarcts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to atherosclerotic carotid artery disease, other vascular disease involving the carotid, ophthalmic, or retinal arteries can lead to symptomatic retinal artery occlusion. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Carotid artery dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fibromuscular dysplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Radiation injury of the carotid or retinal arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/22,32,33\">",
"       22,32,33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Moyamoya disease [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fabry disease [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retinal artery occlusion has also been attributed to vasospasm and migraine, but these are diagnoses of exclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/22,36\">",
"     22,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hematologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of hematologic conditions have been associated with retinal artery occlusion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sickle cell disease can cause arterial occlusion or stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link\">",
"       \"Cerebrovascular complications of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypercoaguable states associated with retinal artery occlusion include antiphospholipid syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/38\">",
"       38",
"      </a>",
"      ], factor V Leiden mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/39-41\">",
"       39-41",
"      </a>",
"      ], protein S deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/42,43\">",
"       42,43",
"      </a>",
"      ], and protein C deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leukemia and lymphoma have been associated with retinal artery occlusion either due to hypercoagulopathy or a hyperviscosity syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/22,45,46\">",
"       22,45,46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of autoimmune diseases can produce a vasculitis that can lead to retinal artery occlusion. The presentation of vision loss is similar to other etiologies; however, retinal emboli are not seen on funduscopic examination in these patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Giant cell arteritis &mdash; About 2 percent of elderly patients with CRAO have underlying giant cell arteritis (GCA). Vision loss in GCA is usually due to ischemic optic neuropathy; however, 10 percent of patients who lose vision from GCA do so on the basis of CRAO [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/15,47,48\">",
"       15,47,48",
"      </a>",
"      ]. While an unusual cause of CRAO, it is important to diagnose GCA because of its implications for prognosis and treatment. GCA should be strongly considered as a potential cause of CRAO in any patient over the age of 50 years who does not have visible retinal emboli. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"       \"Clinical manifestations of giant cell (temporal) arteritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Susac syndrome &mdash; Susac syndrome is a rare vasculitic disorder characterized by vision loss due to branch retinal artery occlusions and accompanied by sensorineural hearing loss and a subacute encephalopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=see_link&amp;anchor=H26#H26\">",
"       \"Primary angiitis of the central nervous system\", section on 'Miscellaneous'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other &mdash; Systemic lupus erythematosus, polyarteritis nodosa, and Wegener's granulomatosis are other disorders that have been associated with retinal artery occlusion [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/22,49-52\">",
"       22,49-52",
"      </a>",
"      ]. In such patients, retinal artery occlusion typically occurs in the setting of an established diagnosis of the underlying autoimmune disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Rare causes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection can cause a secondary vasculitis of the ophthalmic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      retinal artery. These include fungi, particularly mucormycosis, and viruses (cat scratch disease, varicella) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/53-55\">",
"       53-55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CRAO may complicate ocular surgery as well as ocular or retrobulbar injections of steroids or other drugs, presumably by direct injury to the central retinal artery [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cerebral angiography and carotid endarterectomy can lead to thromboembolism and retinal artery occlusion [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/57-62\">",
"       57-62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pressure placed on the eye by a headrest was believed to cause CRAO in two cases after back surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/63,64\">",
"       63,64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One patient developed CRAO following vitrectomy with intraocular gas tamponade and subsequent high-altitude travel [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other rare causes of CRAO include inadvertent injection of talc or other embolic material [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/57,66\">",
"       57,66",
"      </a>",
"      ], fat embolism [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/67\">",
"       67",
"      </a>",
"      ], and amniotic fluid embolism [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Case reports have also described CRAO following intravitreal injections of anti-VEGF agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ) for age-related macular degeneration [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/69,70\">",
"       69,70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ACUTE CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Central retinal artery occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with central retinal artery occlusion (CRAO) develop acute and profound loss of vision in one eye that is usually painless. Occasionally, CRAO is preceded by transient monocular blindness or there is a stuttering or fluctuating course [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/71\">",
"     71",
"    </a>",
"    ]. Rarely, the initial event is heralded by flashing lights. CRAO almost never occurs in both eyes simultaneously, but it may occur sequentially [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vision loss is severe, usually leaving no more than a small temporal island of vision. Most affected patients can see only hand motions and rarely can count fingers.",
"   </p>",
"   <p>",
"    On funduscopic examination, ischemic retinal whitening is seen immediately after an occlusion of the central retinal artery. A \"cherry red spot\" appears in the macula, where the retina is thinner and the retinal pigment epithelium and choroidal vasculature can be seen more easily as the ischemic retina becomes less translucent (",
"    <a class=\"graphic graphic_picture graphicRef51342 \" href=\"UTD.htm?22/41/23187\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, visual acuity may be normal in the approximately 15 percent of patients who have a cilioretinal artery feeding the macular region. These patients have a central area of visual field remaining, usually about 5&ordm; in the vertical dimension and up to 15&ordm; in the horizontal dimension. In one study of 107 CRAOs, 28 (26 percent) showed some degree of macular sparing due to patent cilioretinal arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/72\">",
"     72",
"    </a>",
"    ]. However, only 17 had sparing of the fovea and therefore visual acuity. In these cases, funduscopic examination shows the ischemic retinal whitening clearly surrounding the area of preserved cilioretinal circulation (",
"    <a class=\"graphic graphic_picture graphicRef64725 \" href=\"UTD.htm?11/28/11713\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A complete or relative afferent pupillary defect occurs regardless of the presence of macular sparing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31206?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the patient with anisocoria\", section on 'Examination of the pupil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retinal emboli can be seen in the fundus of 11 to 40 percent of patients with CRAO [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/16,21,73,74\">",
"     16,21,73,74",
"    </a>",
"    ]. The embolic material may appear as iridescent, shiny cholesterol plaques (",
"    <a class=\"graphic graphic_picture graphicRef76602 \" href=\"UTD.htm?34/25/35231\">",
"     picture 3",
"    </a>",
"    );",
"    <span class=\"nowrap\">",
"     gray/white",
"    </span>",
"    platelet plugs (",
"    <a class=\"graphic graphic_picture graphicRef52457 \" href=\"UTD.htm?20/15/20735\">",
"     picture 4",
"    </a>",
"    ); or bright, white calcium fragments. Visible retinal emboli are not more frequent in patients with an identified embolic source in the heart or ipsilateral carotid artery compared with those with another or unidentified etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the acute phase, the blood column in both the arteries and the veins can become segmented with separation of serum from Rouleau stacking of the red corpuscles leading to a \"box carring\" appearance of the blood column.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Branch retinal artery occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with BRAO typically complain of monocular visual loss, which may be restricted to just part of the visual field. At presentation, less than half of patients with BRAO have impaired visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/5\">",
"     5",
"    </a>",
"    ]. The acute funduscopic examination in BRAO demonstrates a sectoral pattern of retinal opacification. Retinal emboli are more frequently seen than with CRAO, being present in up two-thirds of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/21,25,74,75\">",
"     21,25,74,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Associated clinical findings, when present, may suggest a cause. Symptoms and signs of vascular and hematologic disease should be specifically solicited. As examples, contralateral sensory or motor symptoms suggest carotid artery disease, headache may suggest giant cell arteritis in an older person, and neck pain with recent cervical trauma may indicate a carotid artery dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of retinal artery occlusion rarely requires confirmatory testing, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography can be helpful in unusual cases, for example when the acute findings of ischemic retinal whitening or reduced blood flow are not clearly present. In the acute phase, fluorescein angiography shows slowed or absent filling of the central retinal artery with normal filling of the choroid. If the choroid is also affected, giant cell arteritis (GCA) should be considered, especially in an elderly patient [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The erythrocyte sedimentation rate (ESR) and serum C-reactive protein should be measured in all individuals over age 50 with central retinal artery occlusion (CRAO) and no visible retinal emboli to exclude GCA. Although GCA is relatively rare in this setting, acute treatment with corticosteroids improves visual outcomes. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Inflammatory disease'",
"    </a>",
"    above.) If the ESR or serum CRP is elevated or if the clinical setting is very suggestive, the patient should be evaluated for GCA and possible treatment with high-dose corticosteroids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=see_link\">",
"     \"Treatment of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other diagnostic testing in patients with retinal artery occlusion is focused on determining the underlying etiology. These are generally not required for acute management decisions. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Diagnosis of etiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases of central retinal artery occlusion (CRAO), apparently normal perfusion is restored within hours or days, and blood flow may then appear normal on ophthalmoscopy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography.",
"   </p>",
"   <p>",
"    The ischemic retinal whitening can last for days before the retina returns to a normal appearance. If there is concomitant involvement of the choroidal circulation, pigmentary changes under the retina may develop after many weeks or months. Over time, the optic nerve turns pale due to loss of the normal translucent appearance of the axon bundles, which are replaced by more reflective glial tissue. The retinal nerve fiber layer gradually becomes thin. The retinal blood vessels may remain attenuated or return to their normal size.",
"   </p>",
"   <p>",
"    The prognosis varies with the site of retinal artery occlusion. Most patients (80 percent) with BRAO recover normal vision [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/5\">",
"     5",
"    </a>",
"    ], while spontaneous clinical improvement from CRAO is rare. In experimental studies, the retina can survive for only 90 to 100 minutes after ligation of the central retinal artery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/77-79\">",
"     77-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Visual acuity at presentation usually predicts final visual acuity in patients with CRAO. While there are reports of patients who have recovered vision days after apparent CRAO [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/80\">",
"     80",
"    </a>",
"    ], most severely affected patients are left only with a temporal island of vision that allows for hand motions or counting fingers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/81\">",
"     81",
"    </a>",
"    ]. In one series of 34 consecutive cases of CRAO, only 35 percent were left with a visual acuity of better than",
"    <span class=\"nowrap\">",
"     20/100",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/82\">",
"     82",
"    </a>",
"    ]. In another series of 73 CRAOs, only four eyes recovered visual acuity better than counting fingers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ACUTE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central retinal artery occlusion (CRAO) is an ocular emergency. Before any other investigation, attempts to recover vision in the affected eye should be made or at least considered. Animal studies suggest that restoration of blood flow within 90 to 100 minutes leads to no retinal injury, while occlusions persisting for longer than 240 minutes produce massive irreversible damage [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/77-79\">",
"     77-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, there are no clinical trials to determine if any treatment is effective. Some patients do recover spontaneously, and apparently successful maneuvers to recover vision may reflect this phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/82\">",
"     82",
"    </a>",
"    ]. A 2009 review concluded that among patients with nonarteritic CRAO, there was not enough evidence to decide if any interventions reportedly used in the treatment of CRAO result in any beneficial or harmful effect on visual outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/83\">",
"     83",
"    </a>",
"    ]. A 2010 retrospective analysis of CRAO patients showed there was no difference in clinical outcome between standard of care (paracentesis, ocular massage, intraocular hypotensive agents) versus observation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonetheless, given the poor prognosis of visual recovery after CRAO, some attempt at treatment is usually made if the patient presents early, within the first 24 hours.",
"   </p>",
"   <p>",
"    Given the less-dire prognosis, acute treatments with uncertain efficacy are generally not provided for branch retinal artery occlusion (BRAO). Clinical efforts instead focus on determining the underlying etiology and preventing future vascular events. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Long-term prognosis and management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An important exception is the use of corticosteroids in the rare patient with CRAO secondary to giant cell arteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/85\">",
"     85",
"    </a>",
"    ]. In these patients, prompt initiation of corticosteroids improves the prognosis for vision in both the affected and unaffected eye. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=see_link\">",
"     \"Treatment of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Revascularization techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;While intraarterial thrombolytic therapy is increasingly used to treat CRAO [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/86-89\">",
"     86-89",
"    </a>",
"    ], more clinical trial results are awaited to determine whether intraarterial thrombolysis should be a recommended treatment for CRAO [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/83,90,91\">",
"     83,90,91",
"    </a>",
"    ] A meta-analysis of retrospective, nonrandomized studies published in 2000 reported a potential benefit for this treatment when compared with the natural history of CRAO, with 15 percent of patients achieving normal vision and 27 percent achieving",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    visual acuity or better [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/89\">",
"     89",
"    </a>",
"    ]. While serious complications are a concern with this treatment, only 6 of the 100 cases reviewed had a complication, none with permanent morbidity. Subsequent reports have largely echoed this experience [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/92-95\">",
"     92-95",
"    </a>",
"    ]. However, a randomized controlled trial compared intra-arterial thrombolysis with rtPA to conservative therapy in 84 patients with CRAO within 20 hours (mean 12 hours) of symptom onset and found no difference in visual outcomes between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/96\">",
"     96",
"    </a>",
"    ]. Intracerebral hemorrhage occurred in two of the treated patients. The long time-to-treatment in this study may have contributed to the findings.",
"   </p>",
"   <p>",
"    There is little information regarding the use of systemic administration of thrombolytic therapy for CRAO. Local (intraarterial) administration has the advantage of providing the thrombolytic agent in close proximity to the occlusion and allowing titration of the dose to achieve revascularization, thus optimizing efficacy and minimizing complications. At present, the risks associated with systemic thrombolysis (intracerebral and systemic hemorrhage) are felt to be unfavorable compared with potential benefit for CRAO. A phase II study of intravenous tPA CRAO is ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical revascularization techniques are also under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/98\">",
"     98",
"    </a>",
"    ]. In two case reports, patients with CRAO underwent central retinal arteriotomy with a stylet during vitreous surgery or with laser therapy, disrupting the obstruction and producing a good visual outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/99-101\">",
"     99-101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Conservative therapies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ocular massage, whereby intermittent pressure is applied to the eye. Aqueous outflow is increased with pressure, and retinal perfusion should improve once the digital pressure is relieved [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/102\">",
"       102",
"      </a>",
"      ]. These maneuvers may also dislodge the embolism.",
"     </li>",
"     <li>",
"      Anterior chamber paracentesis, using either a Graefe knife or a syringe, causes a sudden drop in intraocular pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/81,103\">",
"       81,103",
"      </a>",
"      ]. This may dislodge an embolus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increase ocular perfusion.",
"     </li>",
"     <li>",
"      Reduction of intraocular pressure may also be accomplished by intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      , intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      , or topical pressure lowering drops.",
"     </li>",
"     <li>",
"      Vasodilator medications used to improve ocular blood flow have included",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"       isosorbide dinitrate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/3,104,105\">",
"       3,104,105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A mixture of 95 percent oxygen and 5 percent carbon dioxide (Carbogen) can be provided in an attempt to induce vasodilation and improve oxygenation. However, this is difficult to obtain in most hospitals on an urgent basis, and published reports are not supportive of its efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/82,103\">",
"       82,103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperbaric oxygen therapy, to maintain oxygenation of the retina pending reperfusion, has been used to preserve vision with mixed results in small series of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/106-109\">",
"       106-109",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In individuals who are not candidates for intraarterial thrombolysis and present with a CRAO less than 24 hours old, we usually perform anterior chamber paracentesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     LATE OCULAR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A neovascular response may occur in patients with central retinal artery occlusion (CRAO) when enough retina survives under hypoxic conditions. Neovascularization typically becomes apparent after two or three months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/77,110,111\">",
"     77,110,111",
"    </a>",
"    ]. It may involve the retina, or worse, the iris and anterior chamber angle [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent complications include vitreous hemorrhage and neovascular glaucoma. Vitreous hemorrhage is unusual, occurring in less than 2 percent of patients. Neovascular glaucoma has been reported to occur in up to 18 percent of cases and can be severe and refractory to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/10,110,113,114\">",
"     10,110,113,114",
"    </a>",
"    ]. Enucleation may be required if glaucoma causes unbearable pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=see_link\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     LONG-TERM PROGNOSIS AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older case series report that patients with retinal artery occlusion, particularly CRAO, are at risk of cardiovascular as well as cerebrovascular events and have reduced life expectancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/15,73,115,116\">",
"     15,73,115,116",
"    </a>",
"    ]. Risks and modification of risks are etiology-specific.",
"   </p>",
"   <p>",
"    A significant number of cases (up to 20 percent in older and 50 to 67 percent in younger patients) have no identified etiology after extensive diagnostic work-up [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/6,15,23\">",
"     6,15,23",
"    </a>",
"    ]. In general, these patients have a good prognosis with regard to future vascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/15,117\">",
"     15,117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnosis of etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A suggestive medical history may tailor the diagnostic work-up to the most likely etiology. In most cases, testing will include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carotid artery imaging &mdash; A carotid duplex ultrasound, cervical magnetic resonance imaging, or computed tomographic angiography will, in most cases, be the first test ordered, as carotid atherosclerosis is the most common cause of CRAO and BRAO. The presence of visible emboli on funduscopic examination is not predictive of a hemodynamically significant carotid artery stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"       \"Evaluation of carotid artery stenosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exclusion of giant cell arteritis &mdash; Giant cell arteritis (GCA) should be excluded in all patients with CRAO who are over 50 years in age and have no visible retinal embolus. This should be done emergently on presentation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac evaluation &mdash; Cardiogenic embolism should be ruled out in patients in whom carotid disease has been excluded (",
"      <a class=\"graphic graphic_table graphicRef60843 \" href=\"UTD.htm?20/43/21181\">",
"       table 1",
"      </a>",
"      ). Testing may include Holter monitoring and echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/118\">",
"       118",
"      </a>",
"      ]. The details of this evaluation are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link&amp;anchor=H35#H35\">",
"       \"Overview of the evaluation of stroke\", section on 'Cardiac evaluation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The yield of cardiac testing is low in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/6,27\">",
"       6,27",
"      </a>",
"      ]. In one case series, while 48 of 104 individuals with either CRAO or BRAO had abnormalities on transthoracic echocardiography, in only 12 were the findings felt to warrant long-term anticoagulation, suggesting that in the other 36, the findings may not have been clinically relevant [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/28\">",
"       28",
"      </a>",
"      ]. Similar results are reported in other case series [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/26,27,119\">",
"       26,27,119",
"      </a>",
"      ]. A higher rate of abnormalities (72 percent) is reported in patients who undergo transesophageal echography [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/118,120\">",
"       118,120",
"      </a>",
"      ]. However, most of these additional findings represent entities in which the association with embolism and indications for anticoagulation are uncertain (eg, mitral valve prolapse, aortic arch atheroma). In most cases of isolated retinal artery occlusion, a transthoracic echocardiogram is sufficient to screen for structural cardiac disease that requires anticoagulation",
"      <br/>",
"      <br/>",
"      A baseline electrocardiogram (ECG) should also be included in the evaluation of these patients, as cardiac morbidity and mortality in patients with retinal artery occlusion is significant [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/15,73,115,116\">",
"       15,73,115,116",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypercoagulable testing &mdash; Hypercoagulable testing should be performed in individuals who have suggestive histories (prior thrombosis, miscarriage, or family history), as well as in individuals with an otherwise negative work-up [",
"      <a class=\"abstract\" href=\"UTD.htm?3/50/3882/abstract/121\">",
"       121",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H25#H25\">",
"       \"Evaluation of the patient with established venous thrombosis\", section on 'Choice of coagulation tests'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term management of these patients focuses on preventing recurrent vascular events and is cause specific. Patients with a cardiac source of emboli will often be managed with chronic anticoagulation, and patients with high-grade carotid disease will likely undergo carotid endarterectomy. Patients with an uncertain etiology should be treated with antiplatelet therapy and atherosclerosis risk factor modification, if applicable.",
"   </p>",
"   <p>",
"    Secondary prevention of vascular events in these conditions is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link\">",
"     \"Management of symptomatic carotid atherosclerotic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=see_link\">",
"     \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic retinal artery occlusion is a rare clinical event defined by acute painless monocular visual loss with retinal ischemia visualized on funduscopic examination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retinal artery occlusions share a list of etiologies with ischemic cerebrovascular disease. Carotid artery atherosclerosis is the most common etiology and carries a high risk of future cerebral infarction. Cardiogenic embolism is the most likely etiology in young patients. Other causes include clotting disorders, vasculitis, and other vascular diseases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Giant cell arteritis is an infrequent cause of central retinal artery occlusion (CRAO) in older patients, but is important to diagnose because prompt treatment can improve visual outcome. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CRAO usually presents with severe, profound vision loss in one eye, while branch retinal artery occlusion (BRAO) presents with monocular vision loss, in which visual acuity is not usually severely affected, if at all. Funduscopic examination reveals ischemic retina. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Acute clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CRAO has a poor prognosis for spontaneous recovery of vision. Efforts to restore vision should begin emergently, as irreversible retinal injury occurs within 100 minutes of arterial occlusion. However, no treatments currently available have been proven to improve visual outcomes. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Acute treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intraarterial thrombolysis is increasingly performed, however, preliminary reports provide conflicting results. We suggest that the use of thrombolysis for CRAO be limited to centers participating in clinical trials of this therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For other patients presenting within 24 hours of onset, we suggest emergent ophthalmology consultation and interventions to lower intraocular pressure and restore blood flow (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BRAO has a much better prognosis, with 80 percent of patients recovering normal vision. Acute treatments are generally not offered. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Branch retinal artery occlusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic work-up in CRAO and BRAO focuses on identifying the underlying etiology, in order to institute appropriate secondary prevention measures to reduce the risk of future vascular events. Unless the etiology is known at presentation, we recommend performing a carotid imaging study and an ECG. Other tests (sedimentation rate, echocardiography, coagulation tests) are often performed. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term management to prevent vascular events is cause specific. For patients with an uncertain etiology of retinal artery occlusion, we recommend atherosclerosis risk factor modification and treatment with an antiplatelet agent if there are no contraindications (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Long-term prognosis and management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/1\">",
"      Hayreh SS. Orbital vascular anatomy. Eye (Lond) 2006; 20:1130.",
"     </a>",
"    </li>",
"    <li>",
"     Hedges TR. Ocular ischemia. In: Brain Ischemia: Basic Concepts and Clinical Relevance, Caplan LR.  (Ed), Springer Verlag, London 1995. p.61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/3\">",
"      Rumelt S, Dorenboim Y, Rehany U. Aggressive systematic treatment for central retinal artery occlusion. Am J Ophthalmol 1999; 128:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/4\">",
"      Leavitt JA, Larson TA, Hodge DO, Gullerud RE. The incidence of central retinal artery occlusion in Olmsted County, Minnesota. Am J Ophthalmol 2011; 152:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/5\">",
"      Yuzurihara D, Iijima H. Visual outcome in central retinal and branch retinal artery occlusion. Jpn J Ophthalmol 2004; 48:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/6\">",
"      Smit RL, Baarsma GS, Koudstaal PJ. The source of embolism in amaurosis fugax and retinal artery occlusion. Int Ophthalmol 1994; 18:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/7\">",
"      Karjalainen K. Occlusion of the central retinal artery and retinal branch arterioles. A clinical, tonographic and fluorescein angiographic study of 175 patients. Acta Ophthalmol Suppl 1971; 109:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/8\">",
"      Warrasak S, Tapaneya-Olarn W, Euswas A, et al. Fibromuscular dysplasia: a rare cause of cilioretinal artery occlusion in childhood. Ophthalmology 2000; 107:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/9\">",
"      Wong TY, Klein R. Retinal arteriolar emboli: epidemiology and risk of stroke. Curr Opin Ophthalmol 2002; 13:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/10\">",
"      Hayreh SS, Podhajsky PA, Zimmerman MB. Retinal artery occlusion: associated systemic and ophthalmic abnormalities. Ophthalmology 2009; 116:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/11\">",
"      Rudkin AK, Lee AW, Chen CS. Vascular risk factors for central retinal artery occlusion. Eye (Lond) 2010; 24:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/12\">",
"      Greven CM, Slusher MM, Weaver RG. Retinal arterial occlusions in young adults. Am J Ophthalmol 1995; 120:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/13\">",
"      Brown GC, Magargal LE, Shields JA, et al. Retinal arterial obstruction in children and young adults. Ophthalmology 1981; 88:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/14\">",
"      Ahuja RM, Chaturvedi S, Eliott D, et al. Mechanisms of retinal arterial occlusive disease in African American and Caucasian patients. Stroke 1999; 30:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/15\">",
"      Appen RE, Wray SH, Cogan DG. Central retinal artery occlusion. Am J Ophthalmol 1975; 79:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/16\">",
"      Sharma S, Brown GC, Pater JL, Cruess AF. Does a visible retinal embolus increase the likelihood of hemodynamically significant carotid artery stenosis in patients with acute retinal arterial occlusion? Arch Ophthalmol 1998; 116:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/17\">",
"      Tomsak RL, Hanson M, Gutman FA. Carotid artery disease and central retinal artery occlusion. Cleve Clin Q 1979; 46:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/18\">",
"      Shah HG, Brown GC, Goldberg RE. Digital subtraction carotid angiography and retinal arterial obstruction. Ophthalmology 1985; 92:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/19\">",
"      Sheng FC, Quinones-Baldrich W, Machleder HI, et al. Relationship of extracranial carotid occlusive disease and central retinal artery occlusion. Am J Surg 1986; 152:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/20\">",
"      Douglas DJ, Schuler JJ, Buchbinder D, et al. The association of central retinal artery occlusion and extracranial carotid artery disease. Ann Surg 1988; 208:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/21\">",
"      Brown GC, Magargal LE. Central retinal artery obstruction and visual acuity. Ophthalmology 1982; 89:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/22\">",
"      Merchut MP, Gupta SR, Naheedy MH. The relation of retinal artery occlusion and carotid artery stenosis. Stroke 1988; 19:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/23\">",
"      Babikian V, Wijman CA, Koleini B, et al. Retinal ischemia and embolism. Etiologies and outcomes based on a prospective study. Cerebrovasc Dis 2001; 12:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/24\">",
"      Wolintz RJ. Carotid endarterectomy for ophthalmic manifestations: is it ever indicated? J Neuroophthalmol 2005; 25:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/25\">",
"      Recchia FM, Brown GC. Systemic disorders associated with retinal vascular occlusion. Curr Opin Ophthalmol 2000; 11:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/26\">",
"      Sharma S, Sharma SM, Cruess AF, Brown GC. Transthoracic echocardiography in young patients with acute retinal arterial obstruction. RECO Study Group. Retinal Emboli of Cardiac Origin Group. Can J Ophthalmol 1997; 32:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/27\">",
"      Sharma S, Naqvi A, Sharma SM, et al. Transthoracic echocardiographic findings in patients with acute retinal arterial obstruction. A retrospective review. Retinal Emboli of Cardiac Origin Group. Arch Ophthalmol 1996; 114:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/28\">",
"      Sharma S, Brown GC, Cruess AF. Accuracy of visible retinal emboli for the detection of cardioembolic lesions requiring anticoagulation or cardiac surgery. Retinal Emboli of Cardiac Origin Study Group. Br J Ophthalmol 1998; 82:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/29\">",
"      Hayreh SS. Pathogenesis of occlusion of the central retinal vessels. Am J Ophthalmol 1971; 72:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/30\">",
"      Mokhtari F, Massin P, Paques M, et al. Central retinal artery occlusion associated with head or neck pain revealing spontaneous internal carotid artery dissection. Am J Ophthalmol 2000; 129:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/31\">",
"      McDonough RL, Forteza AM, Flynn HW Jr. Internal carotid artery dissection causing a branch retinal artery occlusion in a young adult. Am J Ophthalmol 1998; 125:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/32\">",
"      Evans LS, Van de Graaff WB, Baker WH, Trimble SN. Central retinal artery occlusion after neck irradiation. Am J Ophthalmol 1992; 114:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/33\">",
"      Noble KG. Central retinal artery occlusion: the presenting sign in radiation retinopathy. Arch Ophthalmol 1994; 112:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/34\">",
"      Chace R, Hedges TR 3rd. Retinal artery occlusion due to moyamoya disease. J Clin Neuroophthalmol 1984; 4:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/35\">",
"      Sher NA, Reiff W, Letson RD, Desnick RJ. Central retinal artery occlusion complicating Fabry's disease. Arch Ophthalmol 1978; 96:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/36\">",
"      Katz B. Migrainous central retinal artery occlusion. J Clin Neuroophthalmol 1986; 6:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/37\">",
"      Mansi IA, Alkhunaizi AM, Al-Khatti AA. Bilateral central retinal artery occlusion secondary to sickle cell disease. Am J Hematol 2000; 64:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/38\">",
"      Rumelt S, Rehany U. Central retinal artery occlusion associated with primary antiphospholipid syndrome. Eye (Lond) 1999; 13 ( Pt 5):699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/39\">",
"      Dori D, Beiran I, Gelfand Y, et al. Multiple retinal arteriolar occlusions associated with coexisting primary antiphospholipid syndrome and factor V Leiden mutation. Am J Ophthalmol 2000; 129:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/40\">",
"      Talmon T, Scharf J, Mayer E, et al. Retinal arterial occlusion in a child with factor V Leiden and thermolabile methylene tetrahydrofolate reductase mutations. Am J Ophthalmol 1997; 124:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/41\">",
"      Dhar-Munshi S, Ayliffe WH, Jayne D. Branch retinal arteriolar occlusion associated with familial factor V Leiden polymorphism and positive rheumatoid factor. Arch Ophthalmol 1999; 117:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/42\">",
"      Golub BM, Sibony PA, Coller BS. Protein S deficiency associated with central retinal artery occlusion. Arch Ophthalmol 1990; 108:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/43\">",
"      Greven CM, Weaver RG, Owen J, Slusher MM. Protein S deficiency and bilateral branch retinal artery occlusion. Ophthalmology 1991; 98:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/44\">",
"      Nelson ME, Talbot JF, Preston FE. Recurrent multiple-branch retinal arteriolar occlusions in a patient with protein C deficiency. Graefes Arch Clin Exp Ophthalmol 1989; 227:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/45\">",
"      Cohen RG, Hedges TR 3rd, Duker JS. Central retinal artery occlusion in a child with T-cell lymphoma. Am J Ophthalmol 1995; 120:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/46\">",
"      Goodman GK, Winkler CF, Eiferman RA, Yam LT. Bilateral occlusion of the central retinal artery associated with hyperglobulinemia in hairy cell leukemia. Can J Ophthalmol 1982; 17:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/47\">",
"      Mohan K, Gupta A, Jain IS, Banerjee CK. Bilateral central retinal artery occlusion in occult temporal arteritis. J Clin Neuroophthalmol 1989; 9:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/48\">",
"      Eagling EM, Sanders MD, Miller SJ. Ischaemic papillopathy. Clinical and fluorescein aniographic review of forty cases. Br J Ophthalmol 1974; 58:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/49\">",
"      Read RW, Chong LP, Rao NA. Occlusive retinal vasculitis associated with systemic lupus erythematosus. Arch Ophthalmol 2000; 118:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/50\">",
"      Dougal MA, Evans LS, McClellan KR, Robinson J. Central retinal artery occlusion in systemic lupus erythematosus. Ann Ophthalmol 1983; 15:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/51\">",
"      Mirza S, Raghu Ram AR, Bowling BS, Nessim M. Central retinal artery occlusion and bilateral choroidal infarcts in Wegener's granulomatosis. Eye (Lond) 1999; 13 ( Pt 3a):374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/52\">",
"      Solomon SM, Solomon JH. Bilateral central retinal artery occlusions in polyarteritis nodosa. Ann Ophthalmol 1978; 10:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/53\">",
"      Galetta SL, Wulc AE, Goldberg HI, et al. Rhinocerebral mucormycosis: management and survival after carotid occlusion. Ann Neurol 1990; 28:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/54\">",
"      Solley WA, Martin DF, Newman NJ, et al. Cat scratch disease: posterior segment manifestations. Ophthalmology 1999; 106:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/55\">",
"      Cho NC, Han HJ. Central retinal artery occlusion after varicella. Am J Ophthalmol 1992; 114:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/56\">",
"      Sullivan KL, Brown GC, Forman AR, et al. Retrobulbar anesthesia and retinal vascular obstruction. Ophthalmology 1983; 90:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/57\">",
"      Devenyi P, Schneiderman JF, Devenyi RG, Lawby L. Cocaine-induced central retinal artery occlusion. CMAJ 1988; 138:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/58\">",
"      Yamamoto S, Takatsuna Y, Sato E, Mizunoya S. Central retinal artery occlusion after radial optic neurotomy in a patient with central retinal vein occlusion. Am J Ophthalmol 2005; 139:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/59\">",
"      Egbert JE, Schwartz GS, Walsh AW. Diagnosis and treatment of an ophthalmic artery occlusion during an intralesional injection of corticosteroid into an eyelid capillary hemangioma. Am J Ophthalmol 1996; 121:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/60\">",
"      Johnson LN, Krohel GB, Hong YK, Wood G. Central retinal artery occlusion following transfemoral cerebral angiography. Ann Ophthalmol 1985; 17:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/61\">",
"      Treiman RL, Bloemendal LC, Foran RF, et al. Ipsilateral blindness: a complication of carotid endarterectomy. Arch Surg 1977; 112:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/62\">",
"      Jumper JM, Horton JC. Central retinal artery occlusion after manipulation of the neck by a chiropractor. Am J Ophthalmol 1996; 121:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/63\">",
"      Locastro A, Novak KD, Biglan AW. Central retinal artery occlusion in a child after general anesthesia. Am J Ophthalmol 1991; 112:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/64\">",
"      Grossman W, Ward WT. Central retinal artery occlusion after scoliosis surgery with a horseshoe headrest. Case report and literature review. Spine (Phila Pa 1976) 1993; 18:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/65\">",
"      Fang IM, Huang JS. Central retinal artery occlusion caused by expansion of intraocular gas at high altitude. Am J Ophthalmol 2002; 134:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/66\">",
"      Mames RN, Snady-McCoy L, Guy J. Central retinal and posterior ciliary artery occlusion after particle embolization of the external carotid artery system. Ophthalmology 1991; 98:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/67\">",
"      COGAN DG, KUWABARA T, MOSER H. FAT EMBOLI IN THE RETINA FOLLOWING ANGIOGRAPHY. Arch Ophthalmol 1964; 71:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/68\">",
"      Kim IT, Choi JB. Occlusions of branch retinal arterioles following amniotic fluid embolism. Ophthalmologica 2000; 214:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/69\">",
"      von Hanno T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol 2010; 88:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/70\">",
"      Mansour AM, Bynoe LA, Welch JC, et al. Retinal vascular events after intravitreal bevacizumab. Acta Ophthalmol 2010; 88:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/71\">",
"      Werner MS, Latchaw R, Baker L, Wirtschafter JD. Relapsing and remitting central retinal artery occlusion. Am J Ophthalmol 1994; 118:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/72\">",
"      Brown GC, Shields JA. Cilioretinal arteries and retinal arterial occlusion. Arch Ophthalmol 1979; 97:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/73\">",
"      Savino PJ, Glaser JS, Cassady J. Retinal stroke. Is the patient at risk? Arch Ophthalmol 1977; 95:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/74\">",
"      Wilson LA, Warlow CP, Russell RW. Cardiovascular disease in patients with retinal arterial occlusion. Lancet 1979; 1:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/75\">",
"      Russell RW. The source of retinal emboli. Lancet 1968; 2:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/76\">",
"      David NJ, Norton EW, Gass JD, Beauchamp J. Fluorescein angiography in central retinal artery occlusion. Arch Ophthalmol 1967; 77:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/77\">",
"      Hayreh SS, Kolder HE, Weingeist TA. Central retinal artery occlusion and retinal tolerance time. Ophthalmology 1980; 87:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/78\">",
"      Hayreh SS, Zimmerman MB, Kimura A, Sanon A. Central retinal artery occlusion. Retinal survival time. Exp Eye Res 2004; 78:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/79\">",
"      Hayreh SS, Weingeist TA. Experimental occlusion of the central artery of the retina. IV: Retinal tolerance time to acute ischaemia. Br J Ophthalmol 1980; 64:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/80\">",
"      Duker JS, Brown GC. Recovery following acute obstruction of the retinal and choroidal circulations. A case history. Retina 1988; 8:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/81\">",
"      Augsburger JJ, Magargal LE. Visual prognosis following treatment of acute central retinal artery obstruction. Br J Ophthalmol 1980; 64:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/82\">",
"      Stone R, Zink H, Klingele T, Burde RM. Visual recovery after central retinal artery occlusion: two cases. Ann Ophthalmol 1977; 9:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/83\">",
"      Fraser SG, Adams W. Interventions for acute non-arteritic central retinal artery occlusion. Cochrane Database Syst Rev 2009; :CD001989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/84\">",
"      Rudkin AK, Lee AW, Aldrich E, et al. Clinical characteristics and outcome of current standard management of central retinal artery occlusion. Clin Experiment Ophthalmol 2010; 38:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/85\">",
"      Matzkin DC, Slamovits TL, Sachs R, Burde RM. Visual recovery in two patients after intravenous methylprednisolone treatment of central retinal artery occlusion secondary to giant-cell arteritis. Ophthalmology 1992; 99:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/86\">",
"      Richard G, Lerche RC, Knospe V, Zeumer H. Treatment of retinal arterial occlusion with local fibrinolysis using recombinant tissue plasminogen activator. Ophthalmology 1999; 106:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/87\">",
"      Schmidt D, Schumacher M, Wakhloo AK. Microcatheter urokinase infusion in central retinal artery occlusion. Am J Ophthalmol 1992; 113:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/88\">",
"      Weber J, Remonda L, Mattle HP, et al. Selective intra-arterial fibrinolysis of acute central retinal artery occlusion. Stroke 1998; 29:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/89\">",
"      Beatty S, Au Eong KG. Local intra-arterial fibrinolysis for acute occlusion of the central retinal artery: a meta-analysis of the published data. Br J Ophthalmol 2000; 84:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/90\">",
"      Plant GT, Landau K. Thrombolysis for central retinal artery occlusion. J Neurol Neurosurg Psychiatry 2005; 76:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/91\">",
"      Hazin R, Dixon JA, Bhatti MT. Thrombolytic therapy in central retinal artery occlusion: cutting edge therapy, standard of care therapy, or impractical therapy? Curr Opin Ophthalmol 2009; 20:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/92\">",
"      Schmidt DP, Schulte-M&ouml;nting J, Schumacher M. Prognosis of central retinal artery occlusion: local intraarterial fibrinolysis versus conservative treatment. AJNR Am J Neuroradiol 2002; 23:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/93\">",
"      Arnold M, Koerner U, Remonda L, et al. Comparison of intra-arterial thrombolysis with conventional treatment in patients with acute central retinal artery occlusion. J Neurol Neurosurg Psychiatry 2005; 76:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/94\">",
"      Butz B, Strotzer M, Manke C, et al. Selective intraarterial fibrinolysis of acute central retinal artery occlusion. Acta Radiol 2003; 44:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/95\">",
"      Aldrich EM, Lee AW, Chen CS, et al. Local intraarterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion: the Johns Hopkins Hospital experience. Stroke 2008; 39:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/96\">",
"      Schumacher M, Schmidt D, Jurklies B, et al. Central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial. Ophthalmology 2010; 117:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/97\">",
"      Chen CS, Lee AW, Campbell B, et al. Study of the efficacy of intravenous tissue plasminogen activator in central retinal artery occlusion. Int J Stroke 2011; 6:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/98\">",
"      Tang WM, Han DP. A study of surgical approaches to retinal vascular occlusions. Arch Ophthalmol 2000; 118:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/99\">",
"      Tang WM, Topping TM. Vitreous surgery for central retinal artery occlusion. Arch Ophthalmol 2000; 118:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/100\">",
"      Reynard M, Hanscom TA. Neodymium:yttrium-aluminum-garnet laser arteriotomy with embolectomy for central retinal artery occlusion. Am J Ophthalmol 2004; 137:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/101\">",
"      Shalchi MH, Daneshvar R. Transluminal Nd:YAG laser embolysis in a case of hemiretinal arterial occlusion. East Mediterr Health J 2009; 15:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/102\">",
"      Nielsen NV. Treatment of acute occlusion of the retinal arteries. Acta Ophthalmol (Copenh) 1979; 57:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/103\">",
"      Atebara NH, Brown GC, Cater J. Efficacy of anterior chamber paracentesis and Carbogen in treating acute nonarteritic central retinal artery occlusion. Ophthalmology 1995; 102:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/104\">",
"      Incandela L, Cesarone MR, Belcaro G, et al. Treatment of vascular retinal disease with pentoxifylline: a controlled, randomized trial. Angiology 2002; 53 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/105\">",
"      Kuritzky S. Nitroglycerin to treat acute loss of vision. N Engl J Med 1990; 323:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/106\">",
"      Herzog, LM, Meyer, GW, Carson, S, et al. Central retinal artery occlusion treated with hyperbaric oxygen. J Med 1992; 7:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/107\">",
"      Beiran I, Goldenberg I, Adir Y, et al. Early hyperbaric oxygen therapy for retinal artery occlusion. Eur J Ophthalmol 2001; 11:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/108\">",
"      Rumelt S, Brown GC. Update on treatment of retinal arterial occlusions. Curr Opin Ophthalmol 2003; 14:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/109\">",
"      Menzel-Severing J, Siekmann U, Weinberger A, et al. Early hyperbaric oxygen treatment for nonarteritic central retinal artery obstruction. Am J Ophthalmol 2012; 153:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/110\">",
"      Duker JS, Brown GC. Iris neovascularization associated with obstruction of the central retinal artery. Ophthalmology 1988; 95:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/111\">",
"      Duker JS, Sivalingam A, Brown GC, Reber R. A prospective study of acute central retinal artery obstruction. The incidence of secondary ocular neovascularization. Arch Ophthalmol 1991; 109:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/112\">",
"      Duker JS, Brown GC. Neovascularization of the optic disc associated with obstruction of the central retinal artery. Ophthalmology 1989; 96:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/113\">",
"      Henkind P, Wise GN. Retinal neovascularization, collaterals, and vascular shunts. Br J Ophthalmol 1974; 58:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/114\">",
"      Hayreh SS, Podhajsky P. Ocular neovascularization with retinal vascular occlusion. II. Occurrence in central and branch retinal artery occlusion. Arch Ophthalmol 1982; 100:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/115\">",
"      Lorentzen SE. Occlusion of the central retinal artery. A follow-up. Acta Ophthalmol (Copenh) 1969; 47:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/116\">",
"      Hankey GJ, Slattery JM, Warlow CP. Prognosis and prognostic factors of retinal infarction: a prospective cohort study. BMJ 1991; 302:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/117\">",
"      Gass JD, Tiedeman J, Thomas MA. Idiopathic recurrent branch retinal arterial occlusion. Ophthalmology 1986; 93:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/118\">",
"      Kramer M, Goldenberg-Cohen N, Shapira Y, et al. Role of transesophageal echocardiography in the evaluation of patients with retinal artery occlusion. Ophthalmology 2001; 108:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/119\">",
"      Mouradian M, Wijman CA, Tomasian D, et al. Echocardiographic findings of patients with retinal ischemia or embolism. J Neuroimaging 2002; 12:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/120\">",
"      Greven CM, Weaver RG, Harris WR, et al. Transesophageal echocardiography for detecting mitral valve prolapse with retinal artery occlusions. Am J Ophthalmol 1991; 111:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/50/3882/abstract/121\">",
"      Salomon O, Huna-Baron R, Moisseiev J, et al. Thrombophilia as a cause for central and branch retinal artery occlusion in patients without an apparent embolic source. Eye (Lond) 2001; 15:511.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5236 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3882=[""].join("\n");
var outline_f3_50_3882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VASCULAR ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Carotid artery atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiogenic embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Small artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hematologic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Rare causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ACUTE CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Central retinal artery occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Branch retinal artery occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ACUTE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Revascularization techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Conservative therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      LATE OCULAR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      LONG-TERM PROGNOSIS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnosis of etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5236\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5236|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/41/23187\" title=\"picture 1\">",
"      Fundus after CRAO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/28/11713\" title=\"picture 2\">",
"      CRAO with macular sparing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/25/35231\" title=\"picture 3\">",
"      BRAO cholesterol plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/15/20735\" title=\"picture 4\">",
"      BRAO platelet fibrin embolu",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5236|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/43/21181\" title=\"table 1\">",
"      Cardioaortic sources embolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10666?source=related_link\">",
"      Amaurosis fugax (transient monocular or binocular visual loss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31206?source=related_link\">",
"      Approach to the patient with anisocoria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=related_link\">",
"      Cerebrovascular complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=related_link\">",
"      Etiology and classification of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=related_link\">",
"      Evaluation of carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=related_link\">",
"      Lacunar infarcts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=related_link\">",
"      Management of symptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=related_link\">",
"      Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=related_link\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=related_link\">",
"      Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=related_link\">",
"      Treatment of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_50_3883="Current pregnancy history";
var content_f3_50_3883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Current pregnancy history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Medications taken",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cigarette use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recreational drug use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exposure to radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaginal bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea, vomiting, weight loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exposure to toxic substances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Restricted diet",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3883=[""].join("\n");
var outline_f3_50_3883=null;
var title_f3_50_3884="BCR breakpoints in leukemia";
var content_f3_50_3884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Phenotypes and frequencies of leukemias in the presence of various BCR breakpoint sites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Leukemia",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Breakpoints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        M-BCR",
"       </td>",
"       <td class=\"subtitle2\">",
"        m-BCR",
"       </td>",
"       <td class=\"subtitle2\">",
"        &micro;-BCR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        CML",
"       </td>",
"       <td>",
"        P: classic",
"       </td>",
"       <td>",
"        P: classic",
"       </td>",
"       <td>",
"        P: CNL1; CML2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        f: &gt;90 percent",
"       </td>",
"       <td>",
"        f: &lt;9 percent",
"       </td>",
"       <td>",
"        f: +1 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        AML",
"       </td>",
"       <td>",
"        P: AML",
"       </td>",
"       <td>",
"        P: M4/M5a AML",
"       </td>",
"       <td>",
"        P: AML",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        f: majority of 1 percent",
"       </td>",
"       <td>",
"        f: rare",
"       </td>",
"       <td>",
"        f: very rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Adult ALL",
"       </td>",
"       <td>",
"        P: classic",
"       </td>",
"       <td>",
"        P: classic",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        f: 10 percent",
"       </td>",
"       <td>",
"        f: 20 percent",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Childhood ALL",
"       </td>",
"       <td>",
"        P: hyperleukocytic",
"       </td>",
"       <td>",
"        P: classic",
"       </td>",
"       <td>",
"        -",
"        <br/>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        f: 0.75 percent",
"       </td>",
"       <td>",
"        f: 4.25 percent",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     P: leukemia phenotype; f: frequency, expressed in percentage of total number of patients diagnosed with specific neoplasm; 1: predominantly; 2: occasional; -: absent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3884=[""].join("\n");
var outline_f3_50_3884=null;
var title_f3_50_3885="IBD nutr monitor";
var content_f3_50_3885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Monitoring of nutritional status in children with inflammatory bowel disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Measurement",
"       </td>",
"       <td class=\"subtitle1\">",
"        At diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Every 3 to 6 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Growth failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight (plot on growth chart to track percentile)",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Height (plot on growth chart to track percentile and/or calculate height velocity)",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BMI (calculate from weight and height, and plot on growth chart to track percentile)*",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mid-arm circumference*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triceps skinfold*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pubertal status",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biological parents' height",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24-hour diet recall, or 3 to 5 day diet record",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutritional supplement intake",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticipatory guidance for diet and feeding behavior",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laboratory testing for micronutrient deficiencies",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone age",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X (annual)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone densitometry (DXA)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X (annual)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This chart depicts the author's approach to monitoring nutritional issues in children with inflammatory bowel disease, and is consistent with expert panels (Kleinman et al. J Pediatr Gastroenterol Nutr 2004; 39:15; Heuschkel et al. Inflamm Bowel Dis 2008; 14:839). We generally define growth failure as a persistent decline in height percentiles or height velocity less than 10th percentile for age.",
"    <div class=\"footnotes\">",
"     BMI: body mass index; DXA: dual energy x-ray absorptiometry.",
"     <br>",
"      * In children 2 to 18 years.",
"      <br>",
"       &bull; In girls starting at age 9 years, and boys starting at age 10 years.",
"       <br>",
"        &Delta; A review of vitamins, minerals, oral or enteral formulas, herbal/botanical or other complimentary and alternative medicine produces.",
"        <br>",
"         &loz; In older children and adolescents (optimal age for starting monitoring not defined)",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3885=[""].join("\n");
var outline_f3_50_3885=null;
var title_f3_50_3886="Effect of PGI2 and NO on PaO2";
var content_f3_50_3886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effects of inhaled prostacyclin and inhaled nitric oxide on oxygenation and shunt fraction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 233px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Both inhaled prostacyclin (PGI2) and inhaled nitric oxide (NO) improved arterial oxygenation and shunt fraction (QsQt) in patients with severe ARDS who were treated sequentially with both agents.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Zwissler, B, Kemming, G, Habler, O, et al, Am J Respir Crit Care Med 1996; 154:1671.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3886=[""].join("\n");
var outline_f3_50_3886=null;
var title_f3_50_3887="Lower vaginal atresia";
var content_f3_50_3887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Agenesis (atresia) of the lower vagina, or thick transverse vaginal septum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_50_3887=[""].join("\n");
var outline_f3_50_3887=null;
